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Results presented in the first part of the thesis demonstrate that hamsters, 12 h 
after lipopolysaccharide (LPS, acute systemic infection), or 24 h after zymosan (acute 
noninfectious systemic inflammation), or turpentine (acute localized sterile 
inflammation) administration, which are well characterized inducers of acute phase 
response (APR), became substantially hyperlipidemic. This hyperlipidemia in 3 distinct 
models of stressed hamsters was associated with significant increases in plasma total 
lipid, TG, FFA, TC, VLDL-C and LDL-C, with a minimum decrease (3 % to 17 %) in 
HDL-C. The resuhs show that relative to esterified cholesterol, the increase in free 
cholesterol was substantially higher in L-C (151 %), T-C (53 %) and Z-C (94 %) 
hamsters, indicating a reduction in the esterification of free cholesterol, which is 
consistent with a reduced plasma LCAT activity. Feeding of dietary tocotrienols 
(Tocomin) for 10 days before and 12 h after LPS, or 24 h after turpentine or zymosan 
administration, significantly ameliorated all the above parameters. Consistent with 
plasma, liver and kidney TG, FFA and TC levels, which were increased in stressed 
hamsters, were significantly reduced to near normal value in Tocomin pretreated groups. 
Concordant with published reports that relative to large buoyant (lb-) LDL, the 
concentration of small dense (sd-) LDL was substantially increased in patients with 
hyperLDLchoIesterolemia, hypertriglyceridemia, combined hyperlipidemia, and 
hyperlipidemia with CHD; our results demonstrate a substanfial increase in more 
atherogenic sd-LDL. An average increase >59 %, >38 % or >48 % of LDL-C and 
LDL-apoB were recognized in sd-LDL subpopulation of L-C, T-C or Z-C stressed 
hamsters, respectively. Pretreatment of these hamsters with Tocomin significantly 
reduced the cholesterol and apoB content of sd-LDL as well as their percent share of 
LDL close to normal values. It is interesting to mention that Tocomin mediated reduction 
in sd-LDL-C levels was proportionally and preferentially greater than that of LDL-C 
levels. In addition, both cholesterol and apoB content of LDL density subfractions have 
always increased or decreased in tandem, indicating that each particle is homogeneous. 
Consistent with the known similarities of lipoprotein metabolism in hamsters 
with humans, a LDL-C/HDL-C ratio of 2.49 in normal hamsters was obtained, which is 
lower than the normal range of 3.2-3.6 or preferably lower reported for humans. This 
normal ratio of 2.49 was increased to a ratio value of 4.53, 3.56 or 4.33 in L-C, T-C or Z-
C hamsters, respectively. Similarly, in normal hamsters, HDL-C/TC ratio of 0. 220 was 
observed, which is similar to a reported ratio of 0.20 or preferably higher in humans. 
This ratio of 0.220 in N-C was significantly reduced to a ratio value of 0.135 in L-C, 
0.166 in T-C or 0.138 in Z-C hamsters. In addition, we have initially included sd-LDL-
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C/HDL-C ratio, which was substantially increased from a normal ratio value of 0.751 to 
2.69, 1.43 or 2.16 in 3 groups of stressed hamsters. Pretreatment of stressed hamsters 
with dietary Tocomin reversed all the above ratios to near normal levels. These results, 
which represent an initial demonstration, indicate that treatment of stressed hamsters 
with tocotrienols effectively ameliorated all the lipid parameters including highly 
atherogenic sd-LDL. 
The significant increase in plasma and lipoprotein lipid levels in 3 models of 
infection and inflammation is consistent with a significant increase of 55 %, 41 % or 
47 % in hepatic HMG-CoA reductase activity of L-C, T-C or Z-C hamsters, respectively. 
Pretreatment of stressed hamsters with dietary Tocomin was associated with a significant 
reduction of 67 % to 72 %, in hepatic HMG-CoA reductase activity, which is apparently 
responsible for the reduction in lipid levels. Based on these resuhs, it can be concluded 
that cholesterol lowering property of Tocomin in stressed hamsters is due to the 
suppression of enzymatic activity of HMG-CoA reductase, the rate limiting enzyme in 
the biosynthetic pathway of cholesterol. 
As a part of host response to infection and inflammation, plasma, erythrocytes, 
liver and kidney lipid peroxidation products, namely, conjugated diene, lipid 
hydroperoxide and malondialdehyde (MDA), as well as in vitro MDA release from intact 
erythrocytes subjected to hydrogen peroxide-induced lipid peroxidation were 
significantly increased (+54 % to +109 % vs. N-C), while plasma total antioxidants was 
significantly reduced (-33 % to -61 % vs. N-C) in L-C, T-C or Z-C hamsters. Tocomin 
administration to stressed hamsters for 10 days before and 12 h after LPS (L-Tj), or 24 h 
after turpentine or zymosan administration, significantly decreased the plasma, liver and 
kidney lipid peroxidation products including the in vitro MDA release from intact 
erythrocytes, with a concomitant and significant increase in plasma total antioxidants. 
However, simultaneous administration of LPS and 5 mg Tocomin to hamsters (L-T2), 12 
h prior to killing, the increase in plasma total antioxidants was significantly lower (18 % 
in L-T2 vs. 106 % in L-Ti) with no decrease in the levels of conjugated diene and lipid 
hydroperoxide except a decline of only 11 % in MDA, indicating that pretreatment of 
hamsters with dietary tocotrienols, 10 days prior to LPS administration is essential. Our 
results show that during acute infection and inflammation in L-C, T-C or Z-C hamsters, 
due to exaggerated oxidative stress and depletion of plasma antioxidants, the ex vivo base 
line diene conjugation (BDC) levels of sd-LDL and Ib-LDL including LDL were 
increased. However, in comparison to Ib-LDL BDC level, sd-LDL BDC value was 
higher by an average value of ~1.9-fold, indicating a markedly enhanced oxidative 
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susceptibility of sd-LDL in vivo. Consistent with ex vivo BDC levels of LDL, sd-LDL, 
and Ib-LDL, susceptibility of these particles to Cu'^ '^ -induced oxidation, as measured by 
their lag time, was decreased in stressed hamsters. It is important to mention that in 
comparison to a lag phase value of 90 min for LDL and 60 min for Ib-LDL, in N-C, the 
lag phase of sd-LDL was only 18.0 min, indicating a substantially increased in vitro 
susceptibility of sd-LDL to oxidation. The Cu'^ '^ -catalyzed oxidizability of sd-LDL from 
stressed hamsters was further reduced from a lag time of 18 min in N-C to 8 min, 14 min 
and 12 min in L-C, T-C and Z-C, while the lag time of Ib-LDL was reduced to 30 min in 
L-C and 40 min in both T-C and Z-C from a N-C lag time value of 60 min. Tocomin 
supplementation partially blocked the in vivo and in vitro LDL, sd-LDL and Ib-LDL 
oxidizability as seen by a decrease in ex vivo BDC levels and an increase in their lag 
phase values. Similarly, Cu^^-induced maximal formation of lipid hydroperoxide and 
MDA in LDL and Ib-LDL was achieved after 12 h of oxidation, while for sd-LDL only 
30 min was required. These maximal lipid hydroperoxide and MDA levels were 
significantly decreased in Tocomin pretreated groups. Our results demonstrate that 
plasma and LDL associated phospholipids were also increased during APR, which were 
significantly decreased in Tocomin fed hamsters. In comparison to plasma and LDL 
phospholipids, lysophosphatidylcholine content (LPC) of LDL, which is known to exert 
several proatherogenic effect and is a marker for LDL oxidation, was substantially 
increased (4- to 8-fold) in circulating LDL after LPS, turpentine or zymosan treatment, 
which indicates that lipoprotein phospholipids are oxidized in vivo during APR. 
Pretreatment with dietary tocotrienols significantly blocked the increase in LPC levels of 
LDL and reduced them by 1.3- to 1.6-fold, indicating a potent antioxidant property of 
Tocomin. 
Acute infection and inflammation may enhance oxidative stress not only through 
the increased production of ROS but also through weakening the antioxidant defense 
system. In this context, antioxidant role of serum HDL-complexed paraoxonase 
(PON)/aryIesterase enzyme in the protection of LDL as well as HDL from oxidative 
modification is noteworthy. Our results demonstrate that plasma and HDL arylesterase 
activity was significantly decreased (22 % to 38 %), while LDL-C/arylesterase ratio was 
significantly increased following LPS, turpentine or zymosan administration. Tocomin 
pretreatment significantly blocked the reduction in arylesterase activity and decreased the 
LDLC: arylesterase activity ratio, indicating an enhanced capacity to protect LDL from 
oxidation. 
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In contrast to PON/arylesterase enzyme, xanthine oxidase (XO) is known to be an 
important biological source of free radicals. Xanttiine oxidase activity in plasma, liver 
and kidney has been reported to be increased during acute infection and inflammation 
stressed rodents with dyslipidemia and that free radicals generated in the enzymatic 
processes are involved in oxidative damage. Our resuhs show that increased XO activity 
in plasma, liver and kidney of L-C, T-C or Z-C stressed hamsters was significantly 
blocked by Tocomin and reduced to a level close to normal values. These results show 
that dietary tocotrienols, in addition to their potent hypolipidemic and antioxidant 
activity, has the ability to reduce XO activity, indicating its additional therapeutic benefit 
in the prevention and treatment of infection and inflammation induced atherosclerosis. 
It is well known that during acute infection and inflammation in rodents, oxidant 
stress may be increased owing to a higher production of ROS, which are controlled by 
antioxidant enzymes, SOD, catalase, Gpx, Gred and GSH. An impaired radical 
scavenger function has been linked to decreased activity of enzymatic and nonenzymatic 
antioxidants. Our results show a significant decrease in the activities of antiperoxidative 
enzymes, CAT, SOD, Gred, GST as well as GSH, in erythrocytes, liver and kidney of 
LPS, turpentine or zymosan stressed hamsters, except Gpx activity which was 
significantly increased in erythrocytes but decreased in liver and kidney. Feeding of 
10 mg Tocomin to stressed hamsters, for 10 days before and 12 h after LPS or 24 h after 
turpentine or zymosan administration was quite effective in reversing/normalizing the 
altered levels of enzymatic and nonenzymatic antioxidants in erythrocytes, liver and 
kidney. 
The combined results, which represent an initial demonstration, strongly suggest 
that dietary tocotrienols, because of their potent hypolipidemic/antiatherogenic and 
antioxidant actions, were able to substantially ameliorate/normalize all the altered 
parameters described in this part of the thesis, and thus, can be useful in the therapy of 
systemic inflammatory process which might induce atherosclerosis. In conclusion, based 
on Tocomin mediated multiple therapeutic benefits, described in the present study, daily 
intake of tocotrienols as a dietary supplement may be useful in the prevention and 
treatment of infection/inflammation induced dyslipidemia/hyperlipidemia as well as 
atherosclerosis in dyslipidemic patients with chronic infection and inflammatory 
diseases. 
Results presented in the second part of the thesis demonstrate a close association 
between the distribution of cholesterol and apoB concentrations in sd-LDL and Ib-LDL 
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as well as their percent share of LDL in five groups of type 2 diabetic subjects with 
varying degree of hypercholesterolemia. In addition, we examined the differential in vivo 
as well as in vitro Cu"^ "^ -catalyzed oxidizability of more atherogenic sd-LDL, less 
atherogenic Ib-LDL as well as LDL from normolipidemic and five groups of type 2 
diabetic-hypercholesterolemic subjects. Thus, our data exhibited a strong corelationship 
between several indices of oxidation, i.e. conjugated diene, lipid hydroperoxide, MDA, 
and lag time, as well as electrophoretic mobility of in vivo and in vitro oxidized LDL, sd-
LDL and Ib-LDL, with their concentrations in plasma and severity of 
hypercholesterolemia in five groups of type 2 diabefic subjects. 
Due to prior treatment of diabetic subjects in group A and B with atorvastatin and 
fenofibrate for 98 and 47.3 weeks, their lipid parameters were normalized to a level 
similar to normal control values. However, since diabetic subjects in group C, D and E 
were on lipid lowering drugs for 39.3, 15 and 5.3 weeks, respectively, their degree of 
hypercholesterolemia, particularly increased LDL particles, in each group was higher in 
the order C<D<E. Consistent with published reports that relative to Ib-LDL, the 
concentration of more atherogenic sd-LDL was significantly increased in subjects with 
various types of hyperlipidemia, hyperlipidemia with CHD and type 2 diabetic-
hyperlipidemic patients with CHD, sd-LDL-C levels of diabetic-hypercholesterolemic 
subjects in group C, D and E were increased by 101 %, 317 % and 539 %, respectively, 
in comparison to corresponding values in N-C, while a little increase (18 % to 30 %) in 
Ib-LDL-C levels had occurred. Thus, a majority of LDL-C (36 %, 103 % or 128 %) was 
recovered in more atherogenic sd-LDL subpopulation of diabetic subjects in group C, D 
and E, while a decrease of 19 %, 43 % or 54 % of LDL-C was recognized in less 
atherogenic Ib-LDL, indicating a shift of cholesterol from Ib-LDL to more atherogenic 
sd-LDL subspecies. Our resuhs show that both cholesterol and apoB content of sd-LDL 
and its percent share of LDL-C and LDL-apoB always increased in tandem, indicafing 
that each particle in LDL density subfractions is homogeneous. 
During prolonged diabetes coupled with hypercholesterolemia/hyperLDL 
cholesterolemia, due to sustained oxidative stress and increasing depletion of serum 
endogenous antioxidants in group A-E (-70 % to -88 % vs. N-C value; Table 29), the 
oxidizability of sd-LDL was further increased and its lag phase value of 12.0 min in N-C 
was reduced to 6.8 min in group A, 6.0 min in group B, 4.0 min in Group C, 2.0 min in 
group D and E, which is 6- to 15-fold or 12- to 20-fold lower than corresponding lag 
phase values in Ib-LDL or LDL. In contrast, considering a significantly increased 
buoyancy in Ib-LDL particles, its lag phase value of 40 min in N-C was not further 
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reduced in group A, B and C, while it was reduced to 30 min in group D and 12 min in 
group E, indicating a substantially lower susceptibility of Ib-LDL to Cu"^ "^ -catalyzed 
oxidation than sd-LDL. Maximal formation of conjugated diene and MDA during in 
vitro Cu'^ '^ -catalyzed oxidation of LDL and Ib-LDL was achieved after 12 h of 
incubation, whereas, for sd-LDL, these maximal values were obtained after only 30 min 
of oxidation, indicating an accelerated in vitro oxidizability of sd-LDL. 
Our results demonstrate that consistent with the preferentially enhanced ex vivo 
oxidizability of sd-LDL subspecies in normal subjects, its electrophoretic mobility of 1.4 
mm was also higher than 1.1 mm for Ib-LDL or 1.0 mm for LDL. As expected, in each 
group of diabetic-hypercholesterolemic subjects, the electrophoretic mobility of native 
sd-LDL, Ib-LDL and LDL was increased to a maximal value of 1.6 mm, 1.3 mm and 1.1 
mm respectively, indicating a further differential increase in the in vivo oxidative 
modification of the LDL density subfractions. In addition, in vitro Cu'^ '^ -catalyzed 
oxidation of LDL, sd-LDL and Ib-LDL in each group for indicated time periods, 
revealed a close association between progressive increase in the levels of three lipid 
peroxidation products and their electrophoretic mobility. Consistent with increasing 
hypersd-LDLcholesterolemia in diabetic subjects of group C, D and E, the 
electrophoretic mobility of sd-LDL after only 4 min of oxidation was increased to a 
common mobility value of 2.3 mm from their corresponding native sd-LDL mobility 
value of 1.5 mm, 1.5 mm or 1.6 mm, respectively. In contrast, for less atherogenic Ib-
LDL, the electrophoretic mobility was increased from native Ib-LDL value of 1.2 mm 
and 1.3 mm to 1.9 mm and 1.8 mm in group C and D, respectively, after 120 min of 
oxidation, while in group E its electrophoretic mobility was increased to 1.9 mm from a 
native value of 1.3 mm, after 30 min of oxidation. Consistent with above results 
describing a significantly enhanced in vivo and in vitro oxidizability of more atherogenic 
sd-LDL, its electrophoretic mobility was also substantially increased than less 
atherogenic Ib-LDL, indicating an enormous acceleration in the Cu'^ '^ -catalyzed oxidation 
of sd-LDL subpopulation. 
It is well known that diabetes may enhance oxidative stress not only through the 
increased production of ROS but also through weakening the antioxidant defense system. 
In this context, the antioxidant role of serum HDL-complexed arylesterase/ paraoxonase 
(PON) enzyme in the protection of LDL as well as HDL from oxidative modification is 
important. Our results show an increasing reduction in serum arylesterase activity and 
increasing elevation in LDL-C: arylesterase activity ratio in diabetic subjects of group 
A-E with increasing hyperLDLcholesterolemia, indicating a reduced capacity of HDL in 
ZUi^^--^ 
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the protection of LDL oxidation. Together, these results indicating an enhanced ex vivo 
and in vitro oxidizability of LDL and more atherogenic sd-LDL in conjunction with a 
decreased serum arylesterase activity and increased LDL-C: arylesterase activity ratio in 
diabetic subjects with varying degree of hyperLDLcholesterolemia is likely to be a 
potential mechanism for the increased oxidation of circulating LDL density subfractions. 
Based on our combined results presented in this section of the thesis, it can be 
concluded that increasing severity of oxidative stress evoked in diabetic subjects is 
closely related to increasing degree of hypercholesterolemia, particularly 
hyperLDLcholesterolemia and hypersd-LDLcholesterolemia, in the order C<D<E. This 
differential effect was fully reflected in decreasing levels of serum total antioxidants and 
arylesterase activity as well as in several indices of oxidative stress, such as substantial 
shift from less atherogenic Ib-LDL to more atherogenic sd-LDL, and differential in vivo 
and in vitro oxidizability of LDL, sd-LDL and Ib-LDL. In addition, in vivo and Cu^^-
catalyzed in vitro oxidation of LDL, sd-LDL and Ib-LDL in each group for indicated 
time periods, revealed a close association between progressive increase in the levels of 
conjugated diene, lipid hydroperoxide and MDA and their electrophoretic mobility, 
which in turn fully correlated with increasing degree of hypercholesterolemia. 
It is interesting to mention that similar to diabetic-hypercholesterolemic patients 
in group C, D and E, different degree of hypercholesterolemia and oxidative stress 
induced in lipopolysaccharide (non-HDL-C +71 %, sd-LDL-C +238 % vs. N-C), 
turpentine (non-HDL-C +39 %, sd-LDL-C +84 %) and zymosan (non-HDL-C + 47 %, 
sd-LDL-C +140 %) stressed hamsters also exhibited a similar correlationship between 
various parameters. These parameters include hypercholesterolemia, particularly 
hyperLDLcholesterolemia and hypersd-LDLcholesterolemia, in the order 
LPS<zymosan<turpentine stressed hamsters. This differential effect was fully reflected 
in decreasing levels of serum total antioxidants and arylesterase activity as well as in 
several indices of oxidative stress, such as substantial shift from less atherogenic Ib-LDL 
to more atherogenic sd-LDL, and differential in vivo and in vitro oxidizability of LDL, 
sd-LDL and Ib-LDL. 
Based on the combined results presented in the thesis, it can be concluded that the 
increased prevalence and concentration of sd-LDL in dyslipidemic patients with either 
chronic infection and inflammation or diabetes might contribute to their increased CHD 
risk. Quantification of sd-LDL-C by a simple and rapid precipitation method involving 
fractionation of purified precipitated LDL is useful to evaluate atherogenic risks in 
various types of hyperlipidemia/hypercholesterolemias, including diabetic linked 
Abstract 
dyslipidemia as well as infection and inflammation induced dyslipidemia. Thus, sd-LDL, 
being a better and integral marker for CHD risks, than LDL, is applicable to routine 
clinical use and allows the rapid analysis of large number of samples. Finally, 
considering the strong hypolipidemic/antiatherogenic and antioxidant actions of 
Tocomin, daily supplementation of dietary tocotrienols may be useful in the prevention 
and treatment of infection/inflammation and diabetes induced 
dyslipidemia/hyperlipidemia and atherosclerosis. Therefore, daily use of dietary 
tocotrienols will be highly efficacious, cost effective as well as good source of vitamin E. 
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Cardiovascular disease (CVD) is the main cause of disability and premature death 
worldwide, and is projected to remain the leading cause of death. An estimated 17.5 
million people died from this disease in 2005, representing 30 % of all global deaths. Of 
these deaths, 7.6 million were due to coronary heart disease (CHD) and 5.7 million 
because of stroke. If immediate and proper attention is not paid, by 2015 an estimated 20 
million people will die from CVD, including stroke (WHO, 2005). Between 1990 and 
2020 these diseases are expected to increase by 120 % for women and 137 % for men in 
developing countries as compared with 30-60 % in developed countries (Murray, 1997). 
Hence, this disease greatly contributes to the rising costs of health care in the world. It is 
a major public-health challenge, especially in low and middle income countries, where 
80 % of these deaths occur. South Asian (people who originate from India, Srilanka, 
Bangladesh and Pakistan) migrants to the United Kingdom, South Africa, Singapore and 
North America experience 1.5-4.0 times higher CHD mortality compared with 
indigenous populations (Enas et al, 1992). It has been projected that by the year 2010, 
60% of the world's patients with heart disease will be in India (Gaziano et al, 2006). 
Epidemiological studies show that there are at present 29.8 million patients with CHD in 
this country (Indrayan, 2004). Age standardized CVD death rates (per 100, 000) in 
middle-aged subjects (30-69 years) are low in developed countries such as Canada (120) 
and Britain (180) and high in developing countries Brazil (320), China (280), Pakistan 
(400), Nigeria (410), Russia (680) and India (405) (WHO, 2005). Moreover, in India 
about 50 % of CHD-related deaths occur in people younger than 70 years compared with 
only 22% in the West. In developing countries 94 % of deaths from stroke occur in 
people aged, 70 years in contrast to 6 % in developed countries (Gaziano et al, 2006). In 
the Indian urban population, the prevalence of hypertension and CVD is 3-4 times higher 
than in rural subjects. Coronary risk factors such as hypertension and high cholesterol 
levels were more prevalent in the urban subjects (Padmavati, 1962; Gupta and Malhotra, 
1975; Chadha et al, 1990; Reddy et al, 2002). The WHO estimates that, over the next 
10 years, India will lose 237 billion USD due to heart disease, stroke, and diabetes 
(WHO, 2005). 
In diabetes mellitus (DM), altered cellular metabolism caused by hyperglycemia 
has been suggested to play an important role in increasing the risk of cardiovascular, 
renal, ophthalmic and neurological disorders (Brownlee et al, 1988; Nathan, 1993). 
Although diabetes control complication trials (DCCT) indicated that blood glucose is 
highly predictive microvascular disease (DCCTRG, 1993), the contribution of all the 
commonly measured risk factors can explain no more than 25 % of the excess 
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macrovascular CAD associated with diabetes (Pyorola et al, 1987). The increased 
propensity to accelerated atherosclerosis is due to abnormalities in lipid profile which are 
one of the major contributing causes of vascular complications in diabetic patients (Ono 
et al, 1998; Giugliano et al, 1996). Several clinical and epidemiological studies indicate 
that diabetes mellitus (DM) is an independent risk factor for CVD in both men and 
women, which increases the CVD risk by two-to six-fold relative to non diabetic subjects 
(Grundy et al, 1999; Assmann et al, 1999). The total number of subjects worldwide 
with diabetes is projected to increase from 171 million in 2000 to 366 million in 2030 
(WHO, 2006). The results of prevalence studies of diabetes mellitus in India were 
systematically reviewed with emphasis on those utilizing the standard WHO criteria for 
diabetes diagnosis. In the year 2000 an estimated 31.7 million individuals in India were 
reported to be diabetics and it is projected that by the year 2030 this number will be 
increased to 79.4 million (Wild et al, 2004). According to WHO report (2006), it was 
estimated that during 2000 about 171 million persons worldwide were affected by DM 
out of which, 5 to 10 % were designated as type 1 and 90 to 95 % were type 2 DM. 
Moreover, 80 % of all type 2 DM patients will die of an atherosclerotic event (Garber, 
1995). 
It is widely recognized that atherosclerosis is an inflammatory disorder (Ross, 
1999). Moreover, recent epidemiological studies have strongly suggested that disorders 
that lead to systemic inflammation increases the risk of developing CVD. For example, 
studies have shown that patients with autoimmune diseases such as systemic lupus 
erythematosus, rheumatoid arthritis, or psoriasis have an increased risk of coronary 
artery disease (CAD) (Roman et al, 2003; Asanuma et al, 2003; Solomon et al, 2003; 
Gelfand et al, 2006). Moreover, an increased incidence of CAD exists in patients with 
local inflammatory diseases such as rheumatoid arthritis and psoriasis (Myllykangas-
luosujarvi et al, 1995; McDonald and Calabresi, 1978). Similarly, a higher incidence of 
CAD occurs inpatients with Chlamydia pneumoniae and cytomegalovirus infections, and 
these microorganisms have been detected in atherosclerotic plaques (Mendall et al, 
1995; Melnick et al, 1993; Chiu et al, 1997). However, an increased incidence of CAD 
also occurs in patients with Helicobacter pylori infections, HIV infections, chronic dental 
infections, and chronic bronchitis, infections in which microorganisms are not localized 
to the vessel wall (Mendall et al, 1994; Mattila et al, 1993; Jousilahti et al, 1996; 
Destefano et al, 1993; Hsue et al, 2004). The Bruneck study provided the first 
epidemiological evidence that subclinical endotoxemia constitutes a strong risk factor for 
the development of early atherogenesis in subjects with chronic or recurrent bacterial 
infections and a link between smoking atherosclerosis. Moreover, chronic infections 
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conferred an increased risk of atherosclerosis development even in low-risk subjects, 
who lack conventional vascular risk factors (Wiedermann et al, 1999). Davi et al. 
(2005), provides evidence of enhanced in vivo lipid peroxidation and platelet activation 
in dyspeptic individuals with H. pylori infection and identifies a novel mechanism 
through which an infectious agent could contribute to development of atherothrombosis. 
Furthermore, a number of clinical disorders that are well recognized to increase the risk 
of CVD, such as diabetes, chronic renal failure and obesity, are now recognized to 
induce systemic inflammation (Wellen et ah, 2005; Zoccali, 2006). In humans, no single 
factor can account for all the causes of CAD, and a substantial proportion of patients 
have none of the traditional risk factors, such as hypertension, obesity, smoking, 
hypercholesterolemia or genetic predisposition. Both infection and inflammation induce 
the systemic host response known as acute phase response (APR), and produce many 
abnormalities that could increase the risk of developing atherosclerosis including 
alterations in lipid and lipoprotein metabolism, which are often mediated by cytokines, 
particularly highly sensitive C-reactive protein, TNF-a, IL-1 and IL-6 (Khovidhunkit et 
al, 2004). 
1.1 Pathogenesis of Infection and Inflammation 
Epidemiological studies have suggested a link between atherosclerosis and 
infection and inflammation. Atherosclerosis is a multifaceted disease process with 
several different well defined risks factors, such as hypercholesterolemia, smoking, 
hypertension and diabetes. An infectious etiology of atherosclerosis has received 
considerable attention (Buja, 1996). This theory was initially formulated in the first two 
decades of 20 century (Frotingham, 1911; Ophuls, 1921), but did not receive much 
attenfion until the late 1970s when Fabricant et al. (1978) showed that chickens infected 
with avian herpes virus developed vascular lesions similar to those found in human 
atherosclerosis. Since then a number of infectious agents have been implicated in human 
atherosclerosis and include Chlamydia pneumoniae, helicobacter pylori, herpes simplex 
virus and cytomegalovirus (CMV) (Mattila et al, 1989; Kuo et al, 1995), on the basis of 
finding these infectious agents in the atherosclerotic segments and by positive serology. 
Saikku et al. (1988) provided the first serologic evidence of an association of C. 
pneumoniae with CAD. Since the initial report by this Finnish group, several studies 
have demonstrated this associafion in a variety of patients with CAD using 
seroepidemiologic evidence (Dahlen et al, 1995; Spodick et al, 1984). In 1992, Shor et 
al. detected C. pneumoniae in fatty streaks and atheromatous lesions in seven autopsy 
cases. One potentially important source of inflammation is endotoxin (lipopolysaccharide 
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[LPS]), a unique glycolipid that comprises most of the outer leaflet of the outer wall of 
Gram-negative bacteria (GNB) (Stoll et al, 2004). Even in apparently healthy 
individuals, endotoxin can be detected in human plasma. The Bruneck study provided the 
first epidemiological evidence that subclinical endotoxemia constitutes a strong risk 
factor for the development of carotid atherosclerosis (Wiedermann et al, 1999). 
Bacterial lipopolysaccharide is a potent stimulus for inducible nitric oxide synthase 
activity leading to the formation of large amounts of nitric oxide (NO), which could 
cause endothelial dysfunction and disruption followed by deposition of monocytes and 
platelets on the vessel wall, release of growth factors and migration of smooth muscle 
cells. Cytokines are potent inducers of a neutrophil free radical generation, which may 
facilitate oxidation of LDL-C, a key event in atherogenesis (Steinberg et al., 1989), and 
attract monocytes and other inflammatory cells to the area of endothelial injury. The 
dysfunctional endothelium permits monocyte deposition and infiltration of lipid-laden 
macrophages into the subendothelial layers. This is associated with a decrease in 
constitutive NO formation and activity. Nitric oxide may be rapidly broken down by 
release of large amounts of free radicals, resulting in focal vasospasm. Dyslipidemia, 
altered folate metabolism (and resultant increased homocysteine levels) and growth 
factor release cause smooth muscle cell (SMC) proliferation. Deposition and activation 
of inflammatory cells lead to release of procoagulant cytokines and thrombosis. 
Increased release of free radicals and a relative deficiency of endogenous antioxidant 
pool may oxidize lipids, inactivate NO and enhance thrombosis and prevent 
thrombolysis. Abnormalifies in lipid profiles, folate metabolism and other traditional risk 
factors (e.g., diabetes mellitus and hypertension) play a rather peripheral role and serve 
to amplify the atherosclerotic process initiated by persistence of infection and 
inflammation (Mehta et al, 1998) (Fig. 1.1). It is possible to develop a postulate wherein 
infection and inflammation play a very important role early in the initiation of 
endothelial injury and atherogenesis in some subjects. 
Since the discovery of tumor necrosis factor in 1985, rapid progress has been 
made in identifying mediators which are responsible for the development of local 
inflammation and the systemic inflammatory response syndrome (SIRS). Animal models 
of inflammation and SIRS offer a controlled and reproducible way to examine the role of 
inflammatory mediators and to test new therapies. Although the overproduction of 
inflammatory mediators is known to be detrimental in animal models of sepsis such as 
bacterial infection (i.e. cecal ligation and puncture) and the administration of endotoxin, 
it is now clear that the same mediators are involved in the pathogenesis of non-infectious 
(sterile) inflammatory models such as pancreatitis, ischemia reperfusion, subcutaneous 
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Fig. 1.1. Postulated steps in the pathogenesis of atherosclerosis. 
(Adapted from Mehta, J. L. 1998. Interactive role of infection, inflammation 
and traditional risk factors in atherosclerosis and coronary artery disease. J. Am. 
Coll. Cardiol. 31: 1217-25). 
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turpentine, and intraperitoneal zymosan (Denham and Norman, 1998). Endotoxin 
(lipopolysaccharide [LPS]), is a unique glycolipid that comprises most of the outer 
leaflet of the outer wall of Gram-negative bacteria (GNB). This complex molecule, found 
exclusively in GNB, consists of a highly variable carbohydrate portion and a unique lipid 
A region that is highly conserved across many GNB species. Gram-negative organisms 
colonize the human gastrointestinal, genitourinary, and respiratory tracts and generate 
endotoxin not only during overt infections but also in common subclinical or chronic 
conditions such as periodontitis, sinusitis, bronchitis, or diverticulitis (Stoll et al., 2004). 
Turpentine is a mixture of constituents. The type and amount of specific constituents is 
dependent on the type of pine tree, the geographical location of the trees, and the season 
of tree harvest. Turpentine produced in the United States is made up primarily of a-
pinene (75 to 85 %) with varying amounts of P-pinene (up to 3 %), camphene (4 to 15 
%), limonene (dipentene, 5 to 15 %), 3-carene, and terpinolene (percentages not 
provided). Occupational exposure to turpentine is expected to occur as a result of pulp 
and paper processes, turpentine production, the production of other chemicals from 
turpentine, use as a flavoring or fragrance agent, use in coatings, use as a metal cleaner, 
or as a solvent. The general public may be exposed to turpentine through foods, personal 
care products, household products, and external and internal medications (Haneke, 
2002). The injection of turpentine induces local tissue damage (sterile abscess) that is 
responsible for the development of a systemic acute phase response. Typically, steam-
distilled turpentine is injected subcutaneously or intramuscularly into the hind limb of 
rodents although other animals such as rabbits and chickens may be used. The resulting 
response is characterized by anorexia, weight loss, muscle proteolysis, hypoglycemia, 
fever, acute phase protein response, increased serum corticosterone, and 
hypermetabolism. Other changes that occurs after turpentine administration, includes 
elevated serum TG, TC, LDL-C, VLDL-C and decreased HDL-C levels in animals 
(Navarro et al., 2005), including increased serum and hepatic lipid peroxidation (Memon 
et al., 2000; Proulx and Du Souich, 1995). 
Zymosan is a substance derived from the cell wall of the yeast Saccharomyces 
cerevisiae. It is composed of polysaccharide chains of various molecular weights, 
containing approximately 73 % polysaccharides, 15 % proteins, and 7 % lipids and 
inorganic components. When injected into animals, it induces inflammation by inducing 
a wide range of inflammatory mediators (Volman et al., 2005). There is a triphasic 
response when zymosan is administered to rodents intraperitoneally in a dose of Img/g 
body weight. The first phase (days 0-2) demonstrates an acute reaction manifested by 
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fever, dyspnea, lethargy, tachycardia, and increased oxygen consumption with an 
associated 25-60% mortality. The second phase (days 3-7) is a period of improvement 
followed by the third phase (days 8-12) where the animals showed severe dyspnea, 
tachycardia, decreased oxygen consumption, lactic acidosis, leukocytosis, 
thrombocytosis, adult respiratory distress syndrome (ARDS)-like pulmonary changes 
with edema and microvascular changes in the lung, liver, and kidney. The role of 
inflammatory cytokines in this bacteria-independent model of multiple organ failure has 
been examined. The first phase of the response is associated with increased serum IL-1, 
TNF, and interleukin-6 levels. Serum IL-1 and TNF are also increased in the third phase 
of the response to zymosan injection. Zymosan administration to animals also resulted in 
increased serum and hepatic lipid peroxidation (Deitch et ai, 1992; Memon et al., 2000). 
The importance of these mediators in the progression of this multiple organ failure as 
well as the role of PAF in this experimental model have not been reported in the 
literature, but it is clear that the systemic cascade of events is mediated by non-
bacterial/lipopolysaccharide mediators (Volman et al, 2005; Denham and Norman, 
1998). 
1.1.1 Changes in lipid and lipoprotein metabolism during infection and 
inflammation 
Infection and inflammation induce the systemic host response known as acute 
phase response (APR), and produce many abnormalities that could increase the risk of 
developing atherosclerosis. In animal models. Infection and inflammation are produced 
by administration of LPS (acute systemic infection), zymosan (acute noninfectious 
systemic inflammation), and turpentine or croton oil (acute localized sterile 
inflammation). Each of these stimuli is a well-characterized inducer of APR. (Feingold et 
al., 1992a; Todd et al., 1990; Rao et al., 1994; Van lenten et al., 1995; Cabana et al., 
1989). The APR, an early, highly complex reaction of the host, is induced by injurious 
stimuli including infection and inflammation, trauma, bums, ischemic necrosis, and 
malignant growth (Gabay and Kushner, 1999). The APR is accompanied by specific 
changes in the concentration of plasma proteins. Proteins that increase by at least 25 % 
during the APR are positive acute-phase proteins [e.g., C-reactive protein (CRP), serum 
amyloid A (SAA), and fibrinogen], whereas proteins that decrease are negative acute-
phase proteins (e.g., albumin, transferrin, and a-fetoprotein). The APR induced during 
infection/inflammation protects the host from further injury. Changes in acute phase 
proteins neutralize invading microorganisms, minimize the extent of tissue damage, 
participate in the local immune response and tissue regeneration, and replenish proteins 
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used in the inflammatory process. These changes, if present for a prolonged period of 
time, can lead to detrimental consequences to the host, such as the development of 
systemic amyloidosis after chronic infection or inflammation (Khovidhunkit et ai, 
2004). Infection and inflammation are accompanied by cytokine-induced alterations in 
lipid and lipoprotein metabolism. Of note, inflammatory cytokines are increased and play 
a pathogenic role in a variety of very common disorders, such as diabetes, obesity, 
metabolic syndrome, hypertension, chronic heart failure, chronic renal failure, and 
atherosclerosis (Khovidhunkit, et al., 2004). Many of these disorders display 
abnormalities in lipid metabolism that are similar to those that occur during infection and 
inflammation. The characteristic disturbances of lipid metabolism found during APR are 
increased serum TG concentration and decreased HDL-cholesterol (HDL-C). During 
APR, changes in total cholesterol (TC) and LDL-cholesterol (LDL-C) may also occur. 
While in rodents and rabbits TC and LDL-C are raised during infection, in primates and 
humans the opposite is usually observed. This APR protects from tissue injury and 
facilitates the mechanisms of reparation. However, a wide range of disturbances in lipid 
metabolism occurs (Esteve et ai, 2005). These changes, which are mediated by 
cytokines, are aimed to decrease the toxicity of a variety of harmful biological and 
chemical agents and serve to redistribute nutrients to cells important in host defense 
(Khovidhunkit et al., 2000). Lipid disturbances linked to chronic inflammation will 
undoubtedly participate in the increased cardiovascular risk associated with 
hyperlipidemia. Lipid disturbances as hypercholesterolemia and low HDL-C levels are 
major cardiovascular risk factors. Lipid accumulation in macrophages results in the 
formation of lipid foam cells, which accumulate within the arterial wall to form fatty 
streaks, an early atherosclerotic lesion that ultimately evolves into advanced 
atherosclerotic plaques (Esteve et al., 2005). 
The most typical changes in lipoprotein metabolism during infection and 
inflammation are hypertriglyceridemia (Gallin et al., 1969). In subjects with frequent 
infections and/or chronic infection, hypertriglyceridemia is well described. It occurs in 
diseases such as AIDS, cystic fibrosis or systemic lupus erythematosus (SLE) 
(Fernandez-Real and Ricart, 2003; Svenungsson et al., 2003). In AIDS, plasma TG, 
VLDL-TG, VLDL-C and apoB correlate with IFN-a level (Fernandez-Miranda et al., 
1998; Christeff et al, 2002). Hypertriglyceridemia, due to an increase in VLDL, is 
commonly observed and is due to both enhanced hepatic production of VLDL and 
decreased triglyceride clearance (Khovidhunkit et ai, 2004). The stimulation of hepatic 
VLDL production is due to increased delivery of fatty acids to the liver from adipose 
tissue, increased hepatic de novo fatty acid synthesis, and decreased fatty acid oxidation 
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in the liver (Khovidhunkit et al., 2004). The delay in triglyceride clearance seen during 
infection and inflammation is due to decreased lipoprotein lipase activity and to less 
apolipoprotein E associated with VLDL (Feingold et al., 1994; Tripp et al., 1993). It 
could reflect a compensatory mechanism for the decrease in HDL-C and phospholipids 
levels (Esteve et al., 2005) (Fig. 1.2). The increase in hepatic TG-rich particles 
production is secondary to an increase in re-esterification of plasma fatty acid arising 
from both enhanced lipolysis and increased fatty acid synthesis in the liver (Hardardottir 
et al, 1994a; Feingold et al, 1989; Grunfeld et al, 1990; Hellerstein et al, 1993; Patton 
et al, 1986; Feingold et al, 1992a; Feingold et al, 1990). Increased lipolysis results in a 
greater free fatty acid flux to the liver, thereby promoting lipoprotein VLDL secretion 
(Liu et al, 1998). The increase in lipolysis which occurs in inflammation is mediated by 
both hormone and non-hormone-sensitive lipase (Okazaki et al, 2002). High doses of 
LPS can inhibit TO clearance by reducing lipoprotein lipase (LPL) activity (Gouni et al, 
1993; Bagby et al, 1987). The reduction observed in VLDL-associated apoE levels 
could be another mechanism through which TG clearance can be delayed (Lanza-Jacoby 
et al, 1998). Apolipoprotein E is essential for the cellular uptake of TG-rich particles. 
Tumor necrosis factor (TNF)-a and IL-1 leads to reduced hepatic and extra-hepatic apoE 
RNA messenger, decreasing apoE secretion in animals and cultured cells (Hardardottir et 
al, 1994b; Hardardottir et al, 1997). During inflammation, the lipid changes that are 
observed are not only quantitative but also qualitative, with changes in the composition 
of lipoproteins. Thus, the proportion of TGs, phospholipids and cholesterol is increased 
in VLDL, IDL and LDL lipoproteins while the proportion of cholesterol and TGs 
decrease in HDL particles (Cabana et al, 1989). 
Most of the LDL particles are derived from the intravascular catabolism of 
VLDL. Catabolism of LDL occurs in both peripheral cells and the liver and is facilitated 
by both LDL-receptor-(LDL-R-) mediated and non-receptor-mediated pathways. Clinical 
and epidemiological studies have shown LDL-C as one of the most important 
cardiovascular risk factors. The effect of cytokines on cholesterol metabolism is species 
specific, being different in primates and other species, including man. In rodents, LPS 
and cytokines lead to an increase in serum cholesterol (total and LDL-C) and to an 
increase in cholesterol synthesis whereas in primates these same factors lower 
cholesterol levels (Memon et al, 1993; Feingold et al, 1995; Feingold et al, 1993a; 
Ettinger et al, 1990; Kitagawa et al, 1992; De Vasconcelos et al, 1989; Liu et al, 
2004). The increase in cholesterol that occurs during APR may be the resuh of increased 
synthesis and/or decreased clearance by LDL-R. LPS, TNF-a and IL-1 administration in 
rodents produced an increase in hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 
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Fig. 1.2. Mechanisms of hypertriglyceridemia production associated to 
inflammation. 
(Adapted from Esteve, E. 2005. Dyslipidemia and inflammation: an 
evolutionary conserved mechanism. Clinical Nutrition. 24: 16-31). 
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reductase mRNA levels, the rate-limiting enzyme in hepatic cholesterol synthesis and 
secretion. In contrast, these agents caused minimal effects on hepatic LDL-R mRNA 
expression (Memon et al, 1993; Hardardottir et ai, 1994b; Feingold et al, 1995; 
Feingold et ah, 1993a). Plasma LDL-C levels decreases during sepsis in humans and this 
decrease is significantly associated with increased mortality rate (Fraunberger et al., 
1999; Gordon^/a/., 2001). 
LDL-receptor-(LDL-R-) activity is under tight metabolic control by intracellular 
cholesterol concentration through feedback system (Brown and Goldstein, 1986). 
Inflammation causes dysregulation of LDL-R expression, and TNF-a and IL-1 overrides 
the suppression of LDL-R induced by a high intracellular concentration of cholesterol 
(Ruan et al, 1998; Ruan et al, 2001). Chronic activation of the inflammatory cascade 
may activate pathways of cholesterol metabolism such as increased LDL-R expression 
leading to increased lipoprotein clearance, conversion of newly synthesized cholesterol 
into bile acids or enhanced esterification and storage of cholesterol (Lopes-Virella and 
Virella, 1996). In addition to the changes in LDL-C levels observed, a change in LDL 
size and increased susceptibility to the oxidation of these particles are also observed. 
TNF-a levels in humans correlate negatively with peak particle size (Skoog et al, 2002; 
Feingold et al, 1993b). Higher TNF-a level are associated with lower LDL size and LPS 
administration in primate's decrease LDL-C levels but increase the smaller and denser 
LDL. Smaller LDL particles show increased atherogenecity given their decreased 
affinity for LDL-Rs, higher capacity for oxidation and higher ability to cross over the 
intima artery wall and its increased uptake by foam cells (Skoglund-Andersson et al, 
1999; Gardner et al, 1996). Enhanced LDL oxidation has been documented during 
infection and inflammation (Memon et al, 2000). Oxidized LDL is more atherogenic, as 
they increase synthesis and secretion of adhesion molecules, enhance smooth muscle 
proliferation and increase cytotoxity to endothelial cells (Steinberg and Lewis, 1997). 
Oxidized LDL particles induce foam cell formation by increasing oxidized LDL affinity 
for the SR. Part of the increase in LDL oxidation is due to decreasing HDL protective 
action observed during the APR. The changes observed in HDL during inflammation, as 
the decrease of transfertin and PON activity and the increase in ceruloplasmin levels, can 
contribute to the increase in LDL susceptibility to oxidation (Feingold et al, 1998; Van 
lenten et al, 1995; Kunitake et al, 1992; Chisolm et al, 1999). 
It has been shown that the levels of several markers of lipid peroxidation, 
including conjugated diene, thiobarbituric acid reactive substances, lipid hydroperoxide, 
and lysophosphatidylcholine (LPC), are increased in serum and/or circulating LDL in 
11 
Introduction/Review of Literature 
animals treated with LPS (Memon et al, 2000). The protein and Hpid composition of 
LDL particles is altered during infection/inflammation. In humans, the majority of 
plasma platelet activating factor-acetyl hydrolase (PAF-AH) activity is associated with 
LDL, whereas in rodents, most plasma PAF-AH activity is found on HDL. However, 
PAF-AH also hydrolyzes lipoprotein-associated phosphatidylcholine, generating LPC, a 
molecule that exerts several proatherogenic effects (Steinbrecher el al., 1989; Quinn et 
al, 1988; Kugiyama et al, 1990). There is also a marked increase in the LPC content of 
circulating LDL in animal models of infection (Memon et al, 2000). Thus, increased 
plasma PAF-AH activity during the APR could have proatherogenic consequences. 
Circulating LDL is more enriched in several sphingolipids, including sphingomyelin, 
ceramide, and GlcCer, during infection/inflammation (Feingold et al, 1993b; Memon et 
al, 1998). 
Infection and inflammation are associated with a decrease in HDL cholesterol 
levels (Grunfeld et al, 1992; Feingold et al, 1993a; Cabana et al, 1989; Ly et al, 1995). 
The mechanism for the decrease in HDL cholesterol levels during infection and 
inflammation has not been firmly established. Nevertheless, a persistently low level of 
HDL-C in chronic infection and inflammation suggests that this change may be 
undesirable, since data from epidemiologic studies have shown a greater risk of CAD in 
subjects with low HDL cholesterol levels. The function of HDL is mediated through a 
variety of apolipoproteins associated with HDL particles. Moreover, HDL metabolism is 
regulated by several enzymes and transfer proteins that can affect various functions of 
HDL. During infection and inflammation, not only do HDL-C levels decrease, but there 
are also a wide range of changes in these apolipoproteins, enzymes, and transfer proteins. 
As a result, there are marked changes in lipid and protein composition of HDL, which 
can theoretically lead to alterations in function of HDL (Khovidhunkit et al, 2004). High 
density lipoprotein that circulates during infection and inflammation (also termed acute-
phase HDL) are depleted in cholesterol ester but enriched in free cholesterol, 
triglyceride, and sphingolipids (Memon et al, 1998; Feingold et al, 1993a; Ettinger et 
al, 1990). In addition, HDL-associated apoAI and paraoxonase (PON) levels decrease, 
but apoJ and serum amyloid A (SAA) levels increase (Feingold et al, 1998; Grunfeld et 
al, 1992; Hardardottir et al, 1994c). Moreover, there are reductions in other plasma 
proteins proposed to play a major role in HDL metabolism and reverse cholesterol 
transport (RCT), including lecithin:cholesterol acyltransferase (LCAT), cholesterol ester 
transfer protein (CETP), hepatic lipase (HL), and phospholipid transfer protein (PLTP) 
(Ly et al, 1995; Feingold et al, 1999; Jiang et al, 1995). Because of the above changes 
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in HDL metabolism, it is postulated that the main functions of HDL, namely its role in 
protecting LDL against oxidation and RCT, may be decreased during the APR. 
Reverse cholesterol transport (RCT) is a pathway by which cholesterol from 
peripheral cells is transported back to the liver for metabolism and/or excretion (Fielding 
and Fielding, 1995). This pathway is thought to play a key role in removing cholesterol 
from cells in atherosclerotic lesions, such as macrophage foam cells. The first step of 
RCT is cholesterol removal from cells, and two major mechanisms of cholesterol 
removal have been proposed: an apolipoprotein-mediated mechanism and a diffusion 
mechanism (Oram and Yokoyama, 1996). In the apolipoprotein-mediated mechanism, 
cholesterol is removed from plasma membrane of peripheral cells to small, lipid-poor 
prep HDL particles. Recent data suggest that this step requires apoAI on HDL and an 
ATP-binding cassette transporter 1 (ABCl) on the cell surface. Free cholesterol can also 
move from plasma membrane to HDL by the diffusion mechanism. Lecithin cholesterol 
acyltransferase (LCAT) plays a key role by converting free cholesterol in HDL into 
cholesterol ester, thus maintaining a free cholesterol gradient so that continuous diffusion 
of free cholesterol fi"om plasma membrane to HDL can occur. Cholesterol ester 
generated by LCAT then moves into the core of HDL particles, resulting in larger a-
HDL. After free cholesterol is esterified, cholesterol ester in HDL can be transported to 
the liver for elimination via several routes. In the presence of CETP, cholesterol ester 
from HDL is transferred to triglyceride-rich lipoproteins in exchange for triglyceride. 
HDL can also be directly endocytosed into liver parenchymal cells as intact particles. In 
addition, cholesterol ester in HDL can be exclusively taken up without proteins by a 
nonendocytotic process called selective uptake of cholesterol ester (Fig. 1.3). During 
infection and inflammation, there is a reduction in HDL cholesterol concentrations, 
apoAI levels, and plasma PLTP activity (Khovidhunkit et al, 2000). As HDL and apoAI 
are acceptors of cellular cholesterol, the decrease in HDL and apoAI levels could impair 
apolipoprotein-mediated cholesterol removal from cells. PLTP mediates a transfer of 
phospholipids and cholesterol between triglyceride-rich lipoproteins and HDL, and a 
reduction in PLTP activity results in lower HDL levels (Jiang et al, 1995). Therefore, a 
reduction in PLTP activity could presumably decrease cellular cholesterol removal as 
well. Plasma LCAT activity is reduced during infection and inflammation (Ly et al, 
1995). This reduction could potentially impair cholesterol removal, because free 
cholesterol gradient is not efficiently maintained for diffusion to occur. In addition, 
LCAT is required for the conversion of free cholesterol into cholesterol ester so that 
cholesterol ester can move into the core of HDL. Plasma activities of CETP and HL also 
decrease during infection (Feingold et al, 1999; Hardardottir et al, 1996). Both 
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Fig. 1.3. Reverse cholesterol transport process during infection and inflammation. 
(Adapted from Khovidhunkit, W. 2000. Infection and inflammation induced 
proatherogenic changes of lipoproteins. Journal of Infectious Diseases. 181(3): 
S462-72). 
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reductions in LCAT and CETP activities during infection and inflammation could retard 
the RCT pathway. After the exchange of HDL cholesterol ester for triglyceride, HL 
catabolizes triglyceride in HDL, leading to a decrease in HDL size and regeneration of 
preP HDL. A decrease in HL activity could potentially reduce the generation of preP 
HDL, which could in turn impair the transfer of cellular cholesterol to HDL. Plasma 
sPLA2, SAA and apoJ increases during infection (Pruzanski et al, 1993; Hardardottir et 
al., 1994c; Hoffman and Benditt, 1983). Therefore, during infection and inflammation, 
SAA-rich acute-phase HDL may be directed to macrophages instead of being taken up 
by hepatocytes. As a result, cholesterol in HDL may be less available to be metabolized 
or excreted into the bile. Moreover, more cholesterol directed to macrophages can result 
in foam cell formation in the arterial wall. 
ApolipoproteinAl is the principal structural apolipoprotein of HDL and RCT 
requires apoA-1 for cholesterol removal from cells (Oram and Yokoyama, 1996). In fact, 
HDL size is one of the major determinants of the rate of HDL catabolism (Rader and 
Lkewaki, 1996). Peripheral apolipoprotein J (apoJ) levels increase following endotoxin, 
TNF-a or IL-1 administration. Hepatic and extra-hepatic apoJ mRNA is also increased 
by endotoxin and cytokines (Hardardottir et al., 1997; Hardardottir et al, 1994c). 
Apolipoprotein J participates in mobilization, uptake and redistribution of lipids from 
damaged or lipid loaded cells and regulates vascular smooth muscle cell differentiation, 
an important component of atherosclerotic lesions (Esteve et al., 2005). Apolipoprotein 
M is another discovered apoprotein that is predominantly associated with HDL (Xu and 
Dahlback, 1999). Apolipoprotein M mRNA expression is greatest in the liver followed 
by the kidney with only low expression in other tissues. Moreover, apolipoprotein M 
deficient HDL was not as effective as normal HDL in facilitating the transport of 
cholesterol out of macrophages to HDL. These results suggest that apolipoprotein M 
regulates HDL function with increases in apolipoprotein M protecting from 
atherosclerotic lesions. Recently, Feingold et al. (2008) shows that, apolipoprotein M is a 
negative acute response protein that decreases during infection and inflammation. The 
decrease in hepatic apolipoprotein M expression is likely due to the decrease in HNF-1 
levels that occurs during infection and inflammation. 
Serum paraoxonase (PON) is a calcium-dependent esterase that is known to 
catalyze hydrolysis of organophosphates, and is widely distributed among tissues such as 
liver, kidney, intestine, and also serum, where it is associated with HDL (Mackness et 
al, 1996). Paraoxonase specificity towards endogenous serum and tissue substrates is 
not well characterized and therefore synthetic substrates, such as paraoxon and phenyl 
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acetate are used to monitor the enzyme's activity. Serum PON activity was shown to be 
reduced in patients after MI (Ayub et al, 1999), in patients with famihal 
hypercholesterolemia (Mackness et al, 1991), and in patients with diabetes mellitus 
(Mackness et al., 1991; Abbott et al., 1995), diseases that are associated with accelerated 
atherogenesis. One of the mechanisms by which HDL may be antiatherogenic is its 
ability to protect LDL against oxidation. Several HDL-associated proteins have these 
antioxidant effects, including PAF-AH, PON, ceruloplasmin and transferrin (Navab et 
al, 1998; Kunitake et al, 1992). Paraoxonase another HDL-associated protein protects 
LDL from oxidative stress. Paraoxonase, an enzyme initially known to hydrolyze 
organophosphate pesticides including paraoxon, was later recognized as being able to 
hydrolyze biologically active phospholipids in oxidized LDL. Therefore, it may have 
antiatherogenic functions. In contrast to PAF-AH, which is selective against 
phospholipids with short acyl chains, PON has a specific activity against oxidized 
phospholipids with longer acyl chains. Depletion of PON activity results in the loss of 
antioxidant function of HDL. Addition of PON to these HDL particles restores the 
protective function of HDL (Castellani et al., 1997). An increased susceptibility to 
atherosclerosis in PON-deficient mice further supports its important role in preventing 
lipoprotein oxidation and atherogenesis (Shih et al., 1998). During infection and 
inflammation, serum PON activity decreases in both humans and rodents (Feingold et 
al, 1998; Van Lenten et al, 1995). With a reduction in serum PON activity, acute-phase 
HDL may lose its ability to protect LDL against oxidation. One study has shown that 
acute-phase HDL with decreased PON activity is unable to protect against LDL 
oxidation (Van Lenten et al, 1995). Acute-phase HDL, on the contrary, becomes 
prooxidant, further promoting the oxidative process and the migration of monocytes into 
a smooth muscle endothelial coculture. Recently, Asian et al. (2008) showed that PONl 
and arylesterase activity as well as PON/LDL-C and arylesterase/LDL-C ratio were 
significantly decreased in H. pylori infected subjects. Boemi et al. (2001) have 
demonstrated that lower absolute PON concentrations and activities, higher LDL: PON 
concentration ratios and a lesser capacity to prevent LDL oxidation are consistent with 
the hypothesis that reduced serum PON in type 1 patients, similar to type 2 diabetics, 
could contribute to increased risk of vascular disease. Although PON can offer protection 
against the toxicity of some organophosphates, its physiological role is still not clear; 
however, evidence exists for a protective effect of PON against oxidative damage 
(Mackness et al, 1996). PON was suggested to contribute to the antioxidant protection 
conferred by HDL on LDL oxidation (Mackness et al, 1991; Navab et al, 1996; 
Kontush and Chapman, 2006). The effect of HDL-associated PON or of purified PON on 
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the LDL oxidation process, including its initiation (conjugated diene formation), 
propagation (peroxides formation), and decomposition (aldehydes formation) phases 
could be analyzed by using PON inhibitors. The inhibitory effect of HDL on LDL 
oxidation was suggested to be related to metal ion chelation, or to peroxidase, like 
activity. 
Diabetic mellitus confers an increased propensity to accelerated atherogenesis. 
Hyperglycemia is the most important factor in the onset and progress of diabetic 
complications mainly by producing oxidative stress (Giugliano et al., 1996). The 
Diabetes Control and Complications Trial (DCCT) and the UKPDS (U. K. Prospective 
Diabetes Study), established that hyperglycemia, is the initiating cause of the diabetic 
tissue damage that we see clinically (DCCTRG, 1993; UKPDS, 1998). Although this 
process is modified by both genetic determinants of individual susceptibility and by 
independent accelerating factors such as hypertension and hyperlipidemia. Although 
DCCT indicated that blood glucose is highly predictive of microvascular disease 
(DCCTRG, 1993), the contribution of all the commonly measured risk factors can 
explain no more than 25 % of the excess macrovascular CAD associated with diabetes 
(Pyorala et al, 1987). The dyslipidemic profile of diabetics includes increased levels of 
TG, TC, VLDL-C and LDL-C, increased small dense (sd-) LDL-C, glycation of LDL 
and decreased plasma HDL concentration (Grundy et al, 1999). Recent reviews indicate 
that altered plasma lipoprotein profile in the excess atherosclerosis associated with 
diabetes may be most critical, because at any TC level, diabetics have 3-to 5-fold higher 
CAD mortality rates than do nondiabetic subjects (Steiner, 1994). Consistent with these 
findings, in type 2 diabetics, the total plasma antioxidants capacity, susceptibility of LDL 
to oxidation and excretion of oxidized products of arachidonic acid are all increased in 
proportion to the severity of hyperglycemia (Grundy et al, 1999). The involvement of 
increased oxidative stress in diabetes is supported by several data such as increased 
concentrations of lipid peroxidation products (conjugated dienes, hydroperoxides and 
TBARS) and decreased levels of antioxidants in the plasma of patients (Karpen et al, 
1984; Wolf, 1987). In addition, an elevated glucose concentration in plasma could 
promote LDL oxidation by leading to glycated forms of the particle, which are more 
sensitive to transition metal-dependent autooxidation (Sakurai et al, 1991). High glucose 
concentrations have been reported to enhance in vitro LDL oxidative modification 
induced by copper ions (Hunt et al, 1994). A number of reports described shortened 
oxidative lag phase during copper-catalyzed oxidation of LDL and glycated LDL from 
diabetic patients. Increased TBARS were found in LDL and erythrocyte membranes of 
type 1 and type 2 diabetic patients after exposure to phenyihydrazine (Rabini et al. 
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1994). Vitamin E supplementation of glycated LDL during in vitro oxidation decreases 
it's susceptibility to oxidation (Li et al., 1996). Oxidative reactions also can contribute to 
enhanced glycation. However, a number of studies failed to show an effect of a-T on 
LDL glycation (Reaven, 1995; Li et al, 1996; Rabini et al, 1994). An elevated glucose 
concentration in the culture medium enhances superoxide production and the subsequent 
ability of endothelial and smooth muscle cells to oxidatively modify LDL (Maziere et 
al., 1995). Research has shown that human atherosclerotic plaques contain massive 
amounts of lipid peroxidation products, despite the presence of large quantities of a-
tocopherol and ascorbate (Suama et al., 1993). Thus, it is unclear whether oxidized 
lipoproteins originate in the arterial wall or are produced in the circulation and then enter 
the intimal space. Nevertheless, oxidative modification of LDL is one possible 
mechanism for an early development of atherosclerosis in diabetes. It is possible that 
increased atherogenecity of LDL during diabetes is associated with a preponderance of 
sd-LDL subpopulation, that is more prone to oxidative modification than large buoyant 
(lb-) LDL (Chancharme et al, 1999). Several studies have reported a 2- to 3-fold 
increase in CHD risk among patients with a predominance of sd-LDL particles (Austin et 
al, 1988; Austin et al, 1990; Austin et al, 1994). It has been shown that not only the 
prevalence of sd-LDL but also its concentration was substantially increased in type 2 
diabetic patients with and without CHD, as well as subjects with various types of 
hyperlipidemia (Hirano et al, 2004). Recently, Koba et al (2006) have reported that 
prognosis of CHD was closely linked not to the LDL particle size but to the 
concentration of sd-LDL. Therefore, sd-LDL has been highlighted as a new and useful 
marker for the risk of CHD or type 2 diabetes with and without CHD. In addition, 
because of greater preponderance of sd-LDL, a moderately high LDL-C (between 130 
and 160 mg/dl) in a type 2 diabetic patient is equivalent to a much higher LDL-C in 
terms of CHD risk for a nondiabetic subject (Grundy et al, 1999; Haffner et al, 1998; 
NCEP Expert Panel, 1993). Therefore, the primary target of therapy in type 2 diabetic 
patients is lowering of sd-LDL-C along with LDL-C. During long-term diabetes, oxidant 
stress may be increased owing to a higher production of ROS and/or deficiency in the 
antioxidant defense system (Baynes, 1991). Therefore, status of lipid and lipoprotein 
peroxidation and the status of plasma total antioxidants of diabetic subjects with 
hyperlipidemia are highly important. Furthermore, chronic diabetes may enhance 
oxidative stress not only through the increased production of ROS but also through 
weakening the antioxidant defense system. In this context, antioxidant role of serum 
HDL-complexed paraoxonase (PON)/arylesterase enzyme in the protection of LDL as 
well as HDL from oxidative modification is noteworthy. 
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1.2 Oxidants, Nonenzymatic and Enzymatic Antioxidants 
Oxidative stress has been implicated in various pathological conditions involving 
cardiovascular disease, cancer, neurological disorders, diabetes, ischemia/reperfusion, 
other diseases and ageing (Dalle-Donne et al, 2006; Dhalla et al, 2000; Jenner, 2003; 
Sayre et al., 2001). These diseases fall into two groups: (i) the first group involves 
diseases characterised by pro-oxidants shifting the thiol/disulphide redox state and 
impairing glucose tolerance-the so-called "mitochondrial oxidative stress" conditions 
(cancer and diabetes mellitus); (ii) the second group involves disease characterised by 
"inflammatory oxidative conditions" and enhanced activity of either NAD(P)H oxidase 
(leading to atherosclerosis and chronic inflammation) or xanthine oxidase-induced 
formation of ROS (implicated in ischemia and reperfiasion injury) (Valko et al., 2007). 
Oxygen free radicals or, more generally, reactive oxygen species (ROS), as well as 
reactive nitrogen species (RNS), are products of normal cellular metabolism. ROS and 
RNS are well recognized for playing a dual role as both deleterious and beneficial 
species, since they can be either harmful or beneficial to living systems (Valko et al., 
2006). 
Free radicals can be defined as molecules or molecular fragments containing one 
or more unpaired electrons in atomic or molecular orbitals (Halliwell & Gutteridge, 
1999). The addition of one electron to dioxygen forms the superoxide anion radical 
(02—) (Miller et al, 1990). Superoxide anion, arising either through metabolic 
processes or following oxygen "activation" by physical irradiation, is considered the 
"primary" ROS, and can further interact with other molecules to generate "secondary" 
ROS, either directly or prevalently through enzyme- or metal-catalyzed processes (Valko 
et al., 2005). Various pathways of ROS formation are outlined in Fig. 1.4. The 
production of superoxide occurs mostly within the mitochondria of a cell (Cadenas and 
Sies, 1998). The hydroxyl radical, 'OH, is the neutral form of the hydroxide ion. The 
hydroxy! radical has a high reactivity, making it a very dangerous radical with a very 
short in vivo half-life of approx. 10" s (Pastor et al, 2000). Thus when produced in vivo 
•OH reacts close to its site of formation. Additional reactive radicals derived from 
oxygen that can be formed in living systems are peroxyl radicals (R00»). The simplest 
peroxyl radical is HOO*, which is the protonated form (conjugate acid; pA'a~4.8) of 
superoxide (02«") and is usually termed either hydroperoxyl radical or perhydroxyl 
radical. It has been demonstrated that hydroperoxyl radical initiates fatty acid 
peroxidation by two parallel pathways: fatty acid hydroperoxide (LOOH)-independent 
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Fig. 1.4. Pathways of ROS formation, the lipid peroxidation process and the role of 
glutathione (GSH) and other antioxidants in the management of oxidative 
stress. 
(Adapted from Vaiko, M. 2007. Free radicals and aritioxidants in normal 
physiological functions and human disease. The international Journal of 
Biochemistry & Cell Biology. 39: 44-84). 
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peroxidation may be relevant to mechanisms of lipid peroxidation initiation in vivo 
(Valko et al, 2007). Peroxisomes are known to produce H2O2, but not 02*-, under 
physiologic conditions (Valko et al., 2004). Peroxisomes are major sites of oxygen 
consumption in the cell and participate in several metabolic functions that use oxygen. 
The organelle also contains catalase, which decomposes hydrogen peroxide and 
presumably prevents accumulation of this toxic compound. Thus, the peroxisome 
maintains a delicate balance with respect to the relative concentrations or activities of 
these enzymes to ensure no net production of ROS. How the organelle maintains this 
equilibrium is unclear. When peroxisomes are damaged and their H2O2 consuming 
enzymes down regulated, H2O2 releases into the cytosol which is significantly 
contributing to oxidative stress. 
Nitric oxide (N0») is a small molecule that contains one unpaired electron on the 
antibonding 27r*y orbital and is, therefore, a radical. Nitric oxide is generated in 
biological tissues by specific nitric oxide synthases (NOSs), which metabolise arginine 
to citrulline with the formation of NO* via a five electron oxidative reaction (Ghafourifar 
& Cadenas, 2005). Overproduction of RNS is called nitrosative stress (Valko et al., 
2007). This may occur when the generation of RNS in a system exceeds the system's 
ability to neutralize and eliminate them. Cells of the immune system produce both the 
superoxide anion and nitric oxide during the oxidative burst triggered during 
inflammatory processes. Under these conditions, nitric oxide and the superoxide anion 
may react together to produce significant amounts of a much more oxidatively acfive 
molecule, peroxynitrite anion (0N00~), which is a potent oxidizing agent that can cause 
DNA fragmentation and lipid oxidation (Carr et al, 2000). Thus, NO* toxicity is 
predominantly linked to its ability to combine with superoxide anions. 
At high concentrations, ROS can be important mediators of damage to cell 
structures, nucleic acids, lipids and proteins (Valko et al., 2007). It is known that metal-
induced generation of ROS results in an attack not only on DNA, but also on other 
cellular components involving polyunsaturated fatty acid (PUFA) residues of 
phospholipids, which are extremely sensitive to oxidafion (Siems et al, 1995). Once 
formed, peroxyl radicals (ROO*) can be rearranged via a cyclisation reaction to 
endoperoxides (precursors of malondialdehyde) with the final product of the 
peroxidation process being malondialdehyde (MDA) (Valko et al, 2007). Prooxidative 
enzymes, including NADPH-oxidase (Babior, 1999), NO-synthase (Stuehr et al, 1990) 
or the cytochrome P-450 chain (Stief, 2000), can generate ROS. Lipoxygenase generates 
free radicals. Lipoxygenase needs free PUFA, which are not present in healthy tissue. 
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Membrane-bound phospholipase produces PUFA and lysolecithins. Lysolecithins change 
the cell membrane structures, and free PUFA are oxidized to form lipid hydroperoxides. 
Lipoxygenase with Fe^^ is inactivated status. Once Fe^ "^  oxidized to Fe^ "^ , lipoxygenase 
can convert PUFA in to hydroperoxides (Spiteller, 2001). 
Xanthine oxidase (XO, EC 1.1.3.22) and xanthine dehydrogenase (XD, EC 
1.1.1.204) are interconvertible forms of the same enzyme, known as xanthine 
oxidoreductase (XOR) (Borges et ai, 2002). In purine catabolism, XOR catalyzes the 
oxidative hydroxylation of hypoxanthine to xanthine and subsequently of xanthine to 
uric acid. Uric acid acts as a potent antioxidant and free radical scavenger. Xanthine 
oxidoreductase has, therefore, important functions as a cellular defense enzyme against 
oxidative stress. With both XO and XD forms, but particularly with the XO form, 
numerous ROS and RNS are synthesized (Vorbach et ai, 2003). Thus, the synthesis of 
both an antioxidant (uric acid) and numerous free radicals (ROS and RNS) makes XOR 
an important protective regulator of the cellular redox potential. Xanthine oxidase 
generates Or' by catalyzing hypoxanthine and xanthine to uric acid. Under 
pathophysiologic conditions, this is another major source of vascular oxidative stress 
(Droge, 2002). Xanthine oxidase exists in plasma, liver, kidney and endothelial cells but 
not in smooth muscle cells (Harrison et al, 2003). There is overwhelming evidence that 
serum XO levels are significantly increased in various pathological states, like hepatitis, 
inflammation, hypercholesterolemia, atherosclerosis, ischemia-reperfusion, 
carcinogenesis and aging and that free radicals generated in the enzymatic process are 
involved in oxidative damage (Borges, et ah, 2002). Based on the above information, it 
may be possible that the inhibition of this enzymatic pathway by compounds that have 
both antiradical as well as XO inhibitory properties could provide additional therapeutic 
benefit. It has been reported that some flavonoids and structurally related antioxidants 
inhibit XO activity (Nagao et al, 1999; Khan and Sultana, 2004). 
The tripeptide y-glutamylcysteinylglycine or GSH is the major nonenzymatic 
regulator of intracellular redox homeostasis, ubiquitously present in all cell types at 
millimolar concentration (Meister, 1983). This cysteine-containing tripeptide exists 
either in reduced (GSH) or oxidized (GSSG) form, better referred to as glutathione 
disulfide, and participates in redox reactions by the reversible oxidation of its active thiol 
(Briviba et al, 1999). Under normal cellular redox conditions, the major portion of this 
regulator is in its reduced form and is distributed in nucleus, endoplasmic reticulum and 
mitochondria. In addition, GSH may be covalently bound to proteins through a process 
called glutathionylation and acts as a coenzyme of numerous enzymes involved in cell 
22 
Introduction/Review of Literature 
defense (Pompella et al., 2003). Glutathione can thus directly scavenge free radicals or 
act as a substrate for glutathione peroxidase (Gpx) and glutathione-S-transferases (GSTs) 
during the detoxification of hydrogen peroxide, lipid hydroperoxides and electrophilic 
compounds. Glutathione peroxidases constitute a family of enzymes, which are capable 
of reducing a variety of organic and inorganic hydroperoxides to the corresponding 
hydroxy compounds, utilizing GSH and/or other reducing equivalents. There are several 
tissue specific Gpx's that exhibit also tissue-specific functions. All of them are 
selenoproteins and their primary function is to counteract oxidative attack. During the 
catalytic cycle, selenium is oxidized by the hydroperoxide to a selenic acid derivative. 
This intermediate is subsequently reduced by the electron donor. When GSH is used, a 
seleno-disulfide is formed, which is cleaved by a second GSH molecule to yield the 
reduced Gpx. During catalysis, the oxidation state of the enzyme depends on the relative 
concentration of the reducing (GSH) and oxidized (hydroperoxides) substrates (Vari et 
al, 2005). Glutathione peroxidases are ubiquitously distributed. In the gastrointestinal 
tract the isoenzyme provides a barrier against hydroperoxides derived from the diet or 
from the metabolism of ingested xenobiotics. The phospholipid hydroperoxide Gpx-
discovered as a factor preventing lipid peroxidation is considered to be involved in the 
protection of biomembranes against oxidative stress. Glutathione-S-transferases (GSTS) 
are three enzymes families-cytosolic, mitochondrial and microsomal-that detoxify 
noxious electrophilic xenobiotics, such as chemical carcinogens, environmental 
pollutants and antitumor agents. Moreover, they protect against reactive compounds 
produced in vivo during oxidative stress by inactivating endogenous unsaturated 
aldehydes, quinones, epoxides and hydroperoxides, all of which are produced 
intracellularly after the exposure to pollutants, or consumption of overcooked or 
mycotoxin-contaminated food, or polluted water (Hayes et al, 2000). Glutathione-S-
transferases exert those protective effects because they are able to catalyze the 
conjugation of GSH with oxidation end products and represent a second line of defense 
against the highly toxic spectrum of substances produced by ROS-mediated reaction. 
Both Gpx and GSTS activities can eventually lower the level of total intracellular GSH. 
During the course of the reaction catalyzed by Gpx, the exaggerated production of GSSG 
can lead to the formation of mixed disulfides in cellular proteins, or to the release of 
GSSG excess by the cell, to maintain the intracellular GSH/GSSG ratio. Glutathione is 
synthesized in two sequential ATP-dependent reactions catalyzed by y-glutamylcysteine 
synthetase (y-GCS)-the rate-limiting enzyme-and glutathione synthetase. Other factors in 
the regulation of the de novo GSH synthesis are the availability of cysteine and the 
concentration of GSH itself that inhibits, by a feedback mechanism, y-GCS activity. In 
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the presence of oxidative stress, GSH concentration rapidly decreases while GSSG-
potentially highly cytotoxic-increases because of the reduction of peroxides or as a result 
of free radical scavenging. Glutathione disulfide can also be reduced back to GSH by the 
action of glutathione reductase (Gred) utilizing NADPH as a reductant (Vari et al., 
2005). Glutathione reductase is a flavoenzyme and is represented by a single-copy gene 
in humans. It has been observed that exposure to agents that lead to increased oxidative 
stress also leads to an increase in its mRNA content. Further experimental data have 
shown the importance of Gred activity in GSH metabolism, demonstrating that the 
enzymatic activity is regulated in response to stress, and that mutations affecting Gred 
activity would have deleterious consequences. The recycling pathway for GSH formation 
is thus fundamental in the metabolism of GSH dependent defense reactions. In 
conclusion, the presence of GSH is essential, but not in itself sufficient, to prevent the 
cytotoxicity of ROS, being of fundamental importance the functionality of the 
glutathione-dependent enzymes, which participate in the first and second lines of 
defense. Moreover, several experimental data indicate the tight interrelation between 
endogenous polyphenols, namely, GSH and its related enzymes, and dietary polyphenols 
(Vari et al., 2005). 
Superoxide dismutase (SOD) catalyzes the conversion of superoxide anion to 
hydrogen peroxide and oxygen. Superoxide dismutase activity was discovered by 
McCord and Fridovich in 1969; they later proved that the enzyme is required to sustain 
life in aerobic conditions (McCord et al., 1971). Several classes of the enzyme have 
since been specified, each containing a transition metal in its catalytic centre. In humans, 
mitochondrial MnSOD, and extra-and intracellular-CuZnSOD have been identified. 
Glutathione peroxidase is a selenium-dependent enzyme (selenoprotein). The substrate 
of the enzyme is reduced glutathione (GSH), and therefore it depends indirectly on the 
flavoprotein glutathione reductase (Gred) and cellular NADPH concentration. Catalase is 
a porphyrin containing enzyme of high molecular weight which destroys hydrogen 
peroxide in high concentration by catalyzing its two-electron dismutation into oxygen 
and water (Schonbaum and Chance, 1976). Alternatively, it can act as a peroxidase at 
low hydrogen peroxide concentration, using reducing co-substrates such as alcohols, 
including ascorbate and phenols. In mammalian cells, NADPH is bound to catalase and 
may protect the enzyme from inactivation by H2O2. In prokaryotes, the antioxidant 
function of catalase is well established. Unfortunately, in many animal cells, most of the 
enzyme is located in peroxisomes where the steady-state concentration of hydrogen 
peroxide is very high, that is, greater than 10"* M. Even in erythrocytes which have a 
high content of non-peroxisomal catalase, hydrogen peroxide is essentially degraded by 
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Gpx. Interestingly, catalase is also present in significant, albeit small amounts, in the 
mitochondrial matrix, where its function remains controversial. The increased sensitivity 
of transfected CAT-enriched cells to some drugs and oxidants is attributed to the 
property of CAT in cells to prevent the drug-induced consumption of O2 either for 
destroying H2O2 to oxygen or for direct interaction with the drug. As a rule, however, 
further investigations are required to assess the antioxidant function of catalase in vivo 
(Chaudiere and Ferrari-iliou, 1999). 
1.2.1 Enzymatic and nonenzymatic alterations during infection and inflammation 
The acute phase response (APR) represents the initial line of defense against 
injury as well as bacterial and parasitic infections. The APR has been shown to reduce 
the expression of certain conjugation enzymes as well as antioxidant enzymes. 
Cytokines, secreted from macrophages in response to infection and inflammation, have 
been implicated in the suppression of activity of these enzymes in addition to their role in 
oxidative stress. These enzymes are important in defending the body against free radicals 
as well as toxic substances by converting them to a form that can be readily excreted. 
Therefore, any changes in these enzymes could be potentially detrimental to the host by 
altering these defense mechanisms. Normal cellular metabolism involves the production 
of ROS (McCord, 1993), low levels of ROS are vital for proper cell functioning, while 
excessive in vivo generation of these products can adversely affect cell functioning 
(Gregorevic et al, 2001; Fattman et al., 2003). Considerable evidences implicate the role 
of oxygen free radicals in the pathogenesis of endotoxemia and sepsis leading to organ 
dysfunction (Bhattacharyya et al, 2004). One of the early events in the inflammatory 
cascades is an increased activation and migration of leukocytes into the area of 
inflammation. Leukocytes, especially neutrophils and macrophages, do posses the 
enzyme NADPH oxidase which catalyzes the one electron reduction of oxygen to 0 '2, 
which can further generate other oxygen free radicals through a series of reactions 
catalyzed by metal ions. However, in sepsis, an increased activation of neutrophils 
results in the generation of increased amounts of ROS leading to host tissue damage, 
which itself uncouples electron transport system and thus, generates even more ROS. 
Such ROS may directly injure cells, proximal to oxidant generating cells and may 
inactivate any proteolytic enzymes involved during inflammation, due to the production 
of LPS from Gram-negative bacteria. Using murine macrophages incubated with LPS, 
Jackson et al. (1989) recorded an electron spin resonance signal of oxygen-centered 
radicals, which disappeared after emission of SOD into the system. Galley et al. (1996) 
studied XO activity and the free radical generation in patients with sepsis syndrome and 
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found an increased enzyme activity in septic patients compared with non-septic patients. 
Further, the presence of XO might be interpreted as indicative of an enhanced superoxide 
production. Besides direct involvement of free radicals in sepsis, other indirect 
measurements have also been performed in animals and humans. Ortolani et al. (2000) 
have shown that the administration of high doses of n-acetylcysteine (NAC) in 
combination with GSH significantly decreased the peroxidative stress of patients with 
septic shock. Endotoxemia is known to decrease hepatic GSH levels and inhibit its 
synthesis and conjugation pathways as well as down-regulating the activity of Gpx, GST, 
SOD, and CAT, in rats, however, the underlying mechanism is unknown (Macdonald et 
al, 2003; Watson et al, 1999). Payabvash et al. (2006) described that liver and plasma 
GSH content, Gpx and GST activities were decreased after endotoxemia in rats. 
Following injection of LPS both hepatic GSH and GSH/GSSX ratios decreased very 
early after endotoxin exposure and reached their lowest concentration at 6 h after LPS 
injection and remained low for 48 h. Total SOD activity is the sum of manganese SOD, 
cupper/zinc SOD, and extracellular SOD activities. Each one of the aforementioned 
components may alter in different direction during endotoxemia. In rats, hepatic 
manganese SOD expression increases during endotoxemia, whereas, the levels of hepatic 
total and cupper/zinc SOD (Buetler, 1998; Watson et al, 1999) and renal extracellular 
SOD (Wang et al, 2003) decrease after endotoxin exposure. Celik et al. (2007) showed 
that the activities of antioxidant enzymes including SOD, CAT and Gpx were 
significantly increased in the kidneys of E. co//-induced pyelonephritis in rats when 
compared with control rats. They also showed an increase in XO activity when compared 
with the control group, and might indicate that superoxide radicals arise from the XO 
system, ft has been reported that endotoxin injection caused renal tissue damage and 
decreased the SOD, Gpx and CAT activities compared to control rats (Kanter et al., 
2005; Coskun et al., 2005). On the other hand, no significant difference was observed in 
XO, and SOD activities in gastric mucosa of Helicobacter pylori (HP) infected and non 
infected children (Akcam et al, 2006). Asian et al. (2008) observed that H. pylori 
positive subjects were under increased oxidative stress, as reflected by decreased SH 
levels. Lu et al. (2005) described that LPS-induced liver injury in rats resulted in an 
increased production of oxygen free radical, and activity of Cu/Zn-SOD and catalase 
were decreased dramatically, whereas, GSH levels was increased. Portoles et al. (1996) 
showed that inflammation with endotoxin causes decrease in liver GSH level and CAT 
activity of rats. Whereas, levels of GSH in spleens and kidneys of rats were not affected 
by the LPS injection or the diet (Paradkar et al, 2004). Dzakovic et al. (2004) showed 
that targeted trophic feeding of GSH amino acid precursors during parenteral nutrition 
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markedly increased hepatic GSH concentration. This was associated with decreased lipid 
peroxidation and enhanced hepatocellular protection after endotoxin challenge. A 
significant decrease in hepatic GSH as well as in enzymatic activities of SOD, CAT, Gpx 
and GST were observed in d-galactosamine/lipopolysaccharide-intoxicated rats as 
compared with the levels of normal control rats (Vimal and Devaki, 2004). In patients 
with fascioliasis, an increased serum lipid peroxidation and decreased erythrocytes SOD, 
Gpx and CAT activities were observed, indicating, an imbalance between ROS 
production and antioxidant host defenses in inflammatory fascioliasis disease (Kaya et 
al, 2007). Kaur et al. (2006) also observed that LPS challenge decreased the GSH and 
SOD activity in liver homogenate of rats. Increased XO activity in liver has been 
reported in mice during viral, bacterial and protozoal infection or with Ehrlich ascitic 
carcinoma (Tubaro et al., 1980). Increased expression of XDH/XO at both the activity 
and gene levels was observed in vitro after treatment with inflammatory cytokines 
(Pfeffer et al, 1994) and in vivo after LPS administration to mouse (Kurosaki et al., 
1995). Kahl and Elsasser (2004) observed that Hepatic XO activity was increased at 6 h 
after LPS challenge and remained elevated at the 24 h biopsy period in cattle (heifers). 
When zymosan was injected into animals, it induces inflammation by inducing a 
wide range of inflammatory mediators. These include activated components of the 
complement system, prostaglandins and leukotrienes, platelet aggregation factor, oxygen 
radicals, and lysosomal enzymes (Volman et al., 2005). Van Bebber et al. (1992) 
administered a combination of SOD and catalase to rats treated with zymosan and found 
that, although lipid peroxidation was significantly decreased, mortality and organ 
damage remained unchanged. Interestingly, Mn-containing SOD mimetics (e. g., Mn 
(Ill)ntetrakis (4-benzoid acid) and M40401) quench free radicals and protect rats against 
zymosan-induced lung injury (Cuzzocrea et al., 2004). Deitch et al. (1992) concluded 
that zymosan-induced intestinal mucosal injury and bacterial translocation do not require 
complement activation, or the release of macrophage or mast cell products and showed 
an increase in ileal and hepatic XO activity, while reduced CAT activity in mice. 
Yahyapour et al. (2001) showed that addition of GSH to the peritoneal dialysis fluid 
resulted in reduction of cytotoxical effects on the zymosan-induced and extracellular 
phorbol myristate acetate-induced respiratory burst. Masztalerz et al. (2006) measured 
superoxide anion production by neutrophils in whole blood before and after reperfusion 
(5 and 15 minutes) without and after stimulation with opsonized zymosan and found that 
superoxide anion production enhanced oxidative stress with a fall in antioxidant defense 
system activity during reperfusion. Demling et al. (1995) showed that after 24 h of 
zymosan administration in rats, lung catalase acivity was significantly decreased. It has 
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been observed that luminescence increased when hemocytes of the tick B. microplus 
were incubated with bacteria, zymosan, or phorbol 12-miristate 13-acetate (PMA). The 
luminescence was inhibited by SOD and catalase, which are antioxidant enzymes, 
remove superoxide and hydrogen peroxide, respectively (Pereira et al., 2001). 
Belmonte et al. (2007) showed that after 1 or 7 days of turpentine oil injection to 
rats, the GSH content in liver were significantly decreased in comparison to normal 
control rats. Proulx and Du Souich (1995) observed that turpentine-induced 
inflammatory reaction causes oxidative stress in the liver characterized by a decrease in 
activity of enzymatic scavengers i.e. CAT, Gpx, SOD and of reduced GSH, and an 
increase in hepatic XO activity. Proulx et al. (1995) have reported that subcutaneous 
administration of turpentine oil to rabbits induced oxidative stress, which reduced the 
hepatic activities of enzymatic scavengers of ROS. 
1.3 Cholesterol Dynamics 
Cholesterol is present in tissues and in plasma either as free cholesterol or as a 
storage form, combined with a long-chain fatty acid as cholesteryl ester. In plasma, both 
forms are transported in lipoproteins. Cholesterol is an amphipathic lipid and as such is 
an essential structural component of membranes and of the outer layer of plasma 
lipoproteins. It is synthesized in many tissues from acetyl-CoA and is the precursor of all 
other steroids in the body such as corticosteroids, sex hormones, bile acids, and vitamin 
D. Cholesterol has many biological functions. For instance, the concentration of 
cholesterol influences the fluidity of cell membranes and thereby biological activities of 
the cell. The total body cholesterol is derived from two sources: (i) dietary and (ii) de 
novo biosynthesis. Cholesterogenesis mostly occurs in the liver, which also regulates the 
level of circulating plasma cholesterol and serum lipoproteins. The biosynthesis of 
cholesterol also occurs in the other organs like the intestines, adrenal cortex, reproductive 
organs and skin. Although other cells and tissues do not synthesize cholesterol, they have 
the genomic information for its synthesis. Under normal circumstances, these cells and 
tissues take up cholesterol from serum lipoproteins. 
Starting from the 2-carbon unit acetyl-CoA, the biosynthesis of the cholesterol 
proceeds to several intermediates, including mevalonate and isopentenyl pyrophosphate 
(Fig. 1.5). Isopentenyl pyrophosphate is further processed in a series of steps to two 
branched pathways, one leading to isopentenyl tRNA and isopentenyl adenine, and the 
other to famesyl pyrophosphate. Famesyl pyrophosphate is in turn channeled to 
synthesis of cholesterol, ubiquinone or dolichols (Brown and Goldstein, 1983). Famesyl 
pyrophosphate was also converted to famesylated (Ras) proteins by famesyl-protein 
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Fig 1.5. The biosynthetic pathways of mevalonate, sterols and isoprenoid 
compounds. 
(Adapted from Maltese, W. 1990. Posttranslational modification of 
proteins by isoprenoids in mammalian cells. The FASEB J. 4: 3319-3328.) 
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transferase. Hepatic level of cholesterol are maintained by a precised balance between 
reactions catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA 
reductase, EC 1.1.1.34), cholesterol 7-a-hydroxylase, acyl CoA: cholesterol 
acyltransferase and cholesteryl ester hydrolase. The first two enzymes are the rate 
limiting enzymes for cholesterol and bile acid synthesis, respectively. Acyl CoA: 
cholesterol acyltransferase catalyzes esterification of free cholesterol, whereas 
cholesteryl ester hydrolase mediates release of free cholesterol from stored cholesteryl 
esters. The primary feedback loop for regulation of cholesterol synthesis appears to be at 
the site where HMG-CoA is converted to mevalonic acid by the rate-limiting enzyme 
HMG-CoA reductase, cholesterol and other oxysterols inhibit the activity of HMG-CoA 
reductase. Isolation, purification, and characterization of rat hepatic HMG-CoA 
reductase have been well documented (Srikantaiah et a!., 1977; Edwards et al, 1979). 
HMG-CoA reductase has also been studied in several other species including chicken 
liver (Beg et al., 1978; Beg et al., 1979), human liver (Beg et al., 1982; Beg et al., 
1984a) and human fibroblasts (Brown and Goldstein, 1983; Beg et al, 1987). Three 
basic control mechanisms for HMG-CoA reductase have been reported, (a) Long-term 
regulation, which involves the modulation of HMG-CoA reductase activity by changes 
in enzyme concentration through the regulation at transcriptional level and post-
transcriptional regulatory mechanisms such as mRNA and enzyme protein degradation 
(Edwards et al, 1983a; Edwards et al, 1983b; Liscum et al, 1983; Clarke et al., 1983; 
Clarke et al, 1984). For instance, the product feedback regulation by mavalonate (Kita et 
al, 1987; Brown and Goldstein, 1980), in vivo inhibition of HMG-CoA reductase by 
cholesterol feeding (Arebalo et al, 1981), cholesterylamine and mevinolin (Eisenberg 
and Levy, 1975), and mevalonolactone (Beg et al, 1984b) has been reported. 
Tocotrienols, a naturally occurring class of compounds of vitamin E family, have also 
been reported to regulate HMG-CoA reductase activity at the post-transcriptional level 
(Pearce et al, 1992; Parker et al, 1993). (b) Control of HMG-CoA reductase activity 
through changes in the membrane composition and membrane fluidity in the microsomal 
environment in the immediate vicinity of the enzyme (Siptal and Sabine, 1981; Richert et 
al, 1984). (c) Short-term regulation that involves reversible covalent modification 
(phosphorylation and dephosphorylation) of HMG-CoA reductase (Ingebritson and 
Gibson, 1980; Beg et al, 1981; Beg and Brewer, 1982). Three separate kinase systems 
for the regulation of HMG-CoA reductase involving short-term covalent modification 
have been demonstrated (Ingebritson and Gibson, 1980, Beg et al, 1987). Studies 
involving incubation of rat hepatocytes with insulin and glucagon or administration of 
glucagon to rats have been shown to modulate the bicyclic cascade system involving 
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phosphorylation of both HMG-CoA reductase and HMG-CoA reductase kinase 
(Ingebritson and Gibson, 1980; Gibson, 1985; Beg et al, 1987; Gibson and Parker, 
1987). 
Although cholesterol is essential to life, excess or deficit of free cholesterol is 
known to be harmful. Several factors are known which cause an overall increase in 
cholesterol concentration in the liver (i) uptake of lipoproteins by receptor mediated 
endocytosis, (ii) non-receptor mediated intake of lipoproteins, (iii) uptake of free 
cholesterol from the cholesterol rich lipoproteins by cell membranes, (iv) de novo 
synthesis of cholesterol, and (v) hydrolysis of cholesterol esters by cholesteryl ester 
hydrolase. Under above situations, not only increased cholesterol levels inhibits its own 
synthesis by inhibiting HMG-CoA reductase and suppressing low density lipoprotein 
(LDL) receptors (Russel et al, 1983), but also by activating cholesterol 7-a-hydroxylase 
and acyl CoA: cholesterol acyltransferase which utilize free cholesterol for bile acid 
synthesis and formation of cholesteryl esters, respectively. Conversely, some factors are 
involved in the decrease of hepatic cholesterol, they are (a) efflux of cholesterol from 
membrane to nascent high-density lipoproteins (HDL) and HDL3 which is catalyzed by 
lecithin: cholesterol acyltransferase, (b) esterification by acyl CoA: cholesterol 
acyltransferase and (c) utilization of cholesterol for synthesis of steroids and bile acids. 
Under these conditions, increase in cholesterol is achieved by activation of HMG-CoA 
reductase and cholesteryl ester hydrolase activities as well as induction in synthesis of 
LDL receptors in order to receive cholesterol from non-hepatic tissues by receptor 
mediated endocytosis. However, under normal conditions an intricate balance is 
maintained between the biosynthesis, utilization and transport of cholesterol, keeping its 
harmful effects to minimum. 
Lipids are transported through plasma compartment in lipoproteins, which are 
complex water soluble molecules consisting of a core of cholesteryl esters and TG 
covered by a surface monolayer of phospholipids, free cholesterol and apolipoproteins. 
In the last two decades, there have been major advances in our understanding of the role 
of plasma lipoproteins, apolipoproteins, lipolytic enzymes, and lipoprotein receptors in 
cholesterol and lipoprotein metabolism. This new information has provided major 
insights into the role of cholesterol and lipoproteins in the pathogenesis of premature 
atherosclerosis. There are six major classes of human plasma lipoproteins, these include 
chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoprotein 
(IDL), low density lipoprotein (LDL), high density lipoprotein (HDL) and lipoprotein (a) 
[Lp(a)] (Gofman et al, 1954; Berg et al, 1974). Nuclear magnetic resonance subdivides 
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the lipoproteins in plasma into the following subclasses: (1) for VLDL, \6-Wl with V6 
the largest and VI the smallest; (2) IDL; (3) for LDL, L3-L1 with LI being the smallest 
and denset (Kwiterovich, 2000). HDL can be further separated by hydrated density into 
HDL2a, HDL2b, HDL3a, HDL3b and HDL3c (Kontush et al, 2003). These lipoproteins 
are distinguished on the basis of their lipid content, ultracentrifugation size, 
electrophoretic mobility and surface proteins. Fifteen major human plasma 
apolipoproteins have been identified and their gene and protein structures determined 
(Brewer et al, 1988). The six most clinically relevant apolipoproteins are A-I, B-lOO, B-
48, C-II, E, J and M. The two major apolipoproteins on HDL are apoAI and apoAI 
(Suzuki et al, 1983). Apolipoprotein M is another apoprotein that is predominantly 
associated with HDL (Xu and Dahlback, 1999). In human plasma apoB exist as two 
isoproteins designated apoB-lOO and apoB-48, with molecular weights of 512 and 250 
kDa, respectively (Kane et al, 1980; Kane, 1983). Apolipoprotein B-48 and apoB-100 
are the principal structural apolipoproteins on chylomicrons, VLDL, IDL and LDL. 
ApoB-100 is virtually the only apolipoprotein on LDL. 
The metabolic relationship of the major classes of lipoproteins containing apoB-
48 and apoB-100 may be considered to consist of two major "apoB cascades". The first 
apoB cascade involves the stepwise delipidation of TG-rich chylomicrons secreted by the 
intestine. These lipoproteins transport dietary cholesterol and TG from the intestine to 
the liver and peripheral tissues. Shortly after secretion, chylomicrons acquire 
apolipoproteins C-II and E primarily from HDL. As already outlined, apoC-II activates 
lipoprotein lipase, which initiates TG hydrolysis and remodeling of the lipoprotein 
particles. With TG hydrolysis of the hydrated density the chylomicrons increases and 
chylomicron remnants are generated with a hydrated density of VLDL and then IDL. 
Chylomicron remnants are removed primarily by a hepatic remnant receptor. 
Apolipoprotein E has been proposed to interact and initiate the hepatic uptake of the 
chylomicron remnants (Hertz et al., 1988). The second apoB cascade is a parallel 
cascade involving TG rich VLDL containing apoB-100 secreted by the liver. 
Apolipoprotein C-II and apoE from HDL rapidly associate with the newly secreted 
hepatogenous VLDL. Apolipoprotein C-II activates lipoprotein lipase, which hydrolyzes 
VLDL triglycerides, and the VLDL is serially converted to smaller VLDL remnants, 
IDL, and finally LDL. During the conversion of VLDL to LDL approximately 50 per 
cent of VLDL remnants and IDL are removed directly from the plasma by interaction of 
apoE and apoB-100 with the remnant and LDL receptors. Another lipolytic enzyme, 
hepatic lipase and apoE have also been proposed to be necessary for the conversion of 
IDL to LDL. Hepatic lipase functions as both a triglyceryl hydrolase and phospholipase. 
32 
Introduction/Review of Literature 
LDL, the end product of the VLDL cascade, contains almost exclusively apoB-100 as its 
only protein constituent. ApolipoproteinB-100 on LDL interacts with LDL receptor on 
the plasma membrane of cells in the liver, adrenal and peripheral cells, including smooth 
muscle cells and fibroblasts (Brown and Goldstein, 1986), where it supplies cholesterol 
to the intracellular cholesterol pool. The work of Brown and Goldstein (1979 & 1983) on 
the cellular metabolism of LDL elucidated the LDL Pathway. The high affinity receptors 
bind LDL particles and extract them from the fluid that bathes the cell. LDL is 
transported to lysosomes where the protein is degraded and the cholesterol is transferred 
to the intracellular cholesterol pool (Brown and Goldstein, 1986). The receptor displayed 
on the surface of the cells varies with the cellular demand for cholesterol. When the need 
is low, the cells make fewer receptors and take up LDL at a reduced rate, this protects the 
cells excess cholesterol but at a higher price, the reduction in the number of receptors 
decreases the rate of removal of LDL from the circulation, blood level of LDL rises and 
atherogenesis is accelerated. LDL receptor plays an important role in the maintenance of 
plasma LDL-cholesterol levels. The serum concentration of LDL, therefore, depends on 
the rate that liver removes IDL from the circulation, which in turn, depends on the 
number of fimctioning LDL receptors on the liver cell surface. High blood cholesterol 
which results from the overproduction and/or underutilization of LDL is known to be 
caused by two metabolic irregularities: (i) the genetic disease familial 
hypercholesterolemia; (ii) the consumption of high cholesterol diet. 
The possible role of infection in atherosclerotic disease is attracting much 
attention. A possible relationship between infectious diseases and the genesis of 
atherosclerosis is intriguing, but as yet much remains hypothetical. It is important to 
distinguish between a potential role for infectious diseases in the genesis of 
atherosclerosis per se and the possibility that infection may enhance a smoldering 
inflammatory process in an atherosclerotic plaque already generated. Too often this 
distinction is not made, which confounds matters rather than illuminating them. The 
general consensus now is that at the onset of atherogenesis, endothelial cell dysftinction 
is a key factor, allowing an influx of lipids and attracting inflammatory cells. However, 
the mechanisms underlying these phenomena remain largely hypothetical. A variety of 
associated risk factors have been incriminated, such as smoking, hypercholesterolemia, 
hypertension, dyslipidimea and diabetes mellitus. More recently, additional factors have 
been identified, including homocysteinemia, raised plasma levels of lipoprotein (a), 
excessive iron load in the body, an imbalance between oxidant and antioxidant species, 
hypercoagulability, and genetic markers such as angiotensin-converting enzyme 
polymorphisms. At the same time, the concept of a primary (auto) immune disease 
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causing endothelial cell dysfunction has attracted interest, and in this context the option 
of a role for infectious diseases has been established. However, no convincing data yet 
support the latter hypothesis (Becker et al, 2001). Accumulating experimental and 
epidemiological evidence suggests that chronic inflammation associated with low-level 
endotoxemia, such as that resulting from chronic subclinical infections, may be an 
important risk factor for cardiovascular disease (Stoll et al, 2004). In animal studies, 
weekly injections of endotoxin accelerated the development of atherosclerotic lesions in 
rabbits on hypercholesterolemic diets (Lehr et al, 2001) and in apolipoprotein E-
deficient mice (Ostos et al, 2002). Engelmann et al. (2004) showed that low-dose 
bacterial LPS resulted in significant increase in lesion formation occurred after repeated 
LPS application in cholesterol-fed rabbits. In addition, turpentine injections in 
apolipoprotein E-deficient mice attenuated the size of atherosclerotic lesion (Tousa et al, 
2005). Since, it is well known, that infection and inflammation induce the systemic host 
response known as APR, and produce many abnormalities that could increase the risk of 
developing atherosclerosis, the APR might also promote the development of the 
atheromatous plaque. Macrophages within the vessel wall can ingest lipid, becoming 
foam cells; CRP might facilitate this process by opsonizing oxidized LDL, thus 
mediating macrophage uptake of LDL. Macrophages stimulated by APR effectors, as 
well as interferon-g and other cytokines, release growth factors that stimulate smooth 
muscle cell proliferation and migration. Smooth muscle cells then form a fibrous cap. 
Although smooth muscle cells and macrophages normally secrete extra-cellular matrix, 
APR activators and other cytokines can stimulate production of matrix 
metalloproteinases (MMPs), which degrade the extra-cellular matrix, weakening the 
structure of a fibrous plaque. Rupture of a vulnerable plaque can then lead to thrombosis. 
Thus APR activators and effectors can initiate and exacerbate atherogenesis (Lowenstein 
et al, 2004). 
1.4 Atherogenic Properties of Oxidized LDL and Small Dense LDL 
Oxidative modification of lipoproteins is believed to play a central role in the 
pathogenesis of atherosclerosis (Berliner and Heinecke, 1996; Steinberg, 1997). Because 
plasma contains several antioxidants (Frei, 1995) and lipoproteins with oxidative damage 
have been isolated from atherosclerotic lesions, (Berliner and Heinecke, 1996; Steinberg, 
1997) lipoprotein oxidation generally is considered to occur in the vessel wall. Although 
lipid oxidation in the vessel wall is thought to occur as a result of a local deficiency of 
endogenous antioxidants or an excess of free metal ions, only limited data support these 
hypotheses. Research has shown that human atherosclerotic plaques contain massive 
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amounts of lipid peroxidation products, despite the presence of large quantities of a-
tocopherol (vitamin E) and ascorbate (Suama, 1995). Therefore, it is unclear whether 
oxidized lipoproteins originate in the arterial wall or are produced in the circulation and 
then enter the intimal space. Although LDL is a major risk factor for CAD, experiments 
have shown that incubation of macrophages with native LDL does not result in foam cell 
formation, a characteristic feature of atheromatous lesions (Brown and Goldstein, 1983). 
However, after chemical modification of LDL, rapid uptake occurs, leading to 
cholesterol accumulation in the macrophage with subsequent foam cell formation, which 
suggests that LDL modification is a necessary step in atherogenesis. Oxidized LDL can 
induce foam cell formation, and oxidative modification of LDL is now recognized as an 
important process that occurs in vivo (Steinberg et al., 1989). Several lines of research 
support the occurrence of LDL oxidation in vivo (Steinberg and Lewis, 1997). Oxidized 
apo B-100 epitopes and increased levels of lipid peroxidation products can be detected in 
LDL extracted from both rabbit and human atherosclerotic lesions (Yla-Herttuala et al, 
1989). Immunohistochemical staining of atherosclerotic lesions with specific monoclonal 
antibodies has demonstrated the presence of Ox LDL (Palinski et al, 1989). 
Many cell types are capable of oxidizing LDL, including monocytes, 
macrophages, neutrophils, endothelial cells, smooth muscle cells and fibroblasts. 
However, cell types that are involved in the atherosclerotic lesion in which OX LDL is 
found, i.e. macrophages, endothelial cells and smooth muscle cells, would seem to be the 
most likely to contribute to LDL oxidation in vivo. Once initiated, oxidation of LDL is a 
free radical driven lipid peroxidation chain reaction. Lipid peroxidation is initiated by 
free radical attack on double bond associated with a polyunsaturated fatty acid (PUFA). 
This results in the removal of a hydrogen atom from a methylene (CH2) group, the rate of 
which determines the rate of initiation, a key step in lipid peroxidation. Molecular 
rearrangement of the resulting unstable carbon radical results in a more stable 
configuration, a conjugated diene. The conjugated diene reacts very quickly with 
molecular oxygen, and the peroxyl radical thus formed is a crucial intermediate (Abuja 
and Esterbauer, 1995) (Fig. 1.6). A PUFA peroxyl radical in LDL may abstract a 
hydrogen atom from an adjacent PUFA to form a hydroperoxide and another lipid 
radical, a reaction which results in chain propagation. Removal of hydrogen atoms by the 
peroxyl radical from other lipids, including cholesterol, eventually yields oxysterols. 
Lipid hydroperoxides fragment to shorter-chain aldehydes, including malondialdehyde 
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Fig. 1.6. Basic reaction sequence of lipid peroxidation. 
(Adapted from Young, I. S. and McEney, J. 2001. Lipoprotein oxidation and 
atherosclerosis. Niochemical Society Transactions. 29: 358-362). 
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apo B-lOO, giving the protein an increased net negative charge. The classical LDL 
receptor recognizes a specific domain of positive charges from lysine, arginine and 
histidine residues on apo B. Alteration of this domain results in failure of binding by the 
apo B/E receptor and an increase in negative surface charge on apo B-lOO results in 
increased recognition by the scavenger receptor. In vitro studies of LDL oxidation have 
verified the existence of "lag phase", during which significant oxidation of LDL can not 
be detected, prior to the onset of the "propagation phase", presumably after the 
endogenous antioxidants have been consumed. A steady increase in the detectable 
byproducts of oxidation continues, until the substrate, i.e. the PUFAs, has been depleted, 
and a plateau phase is reached. Assessment of resistance of LDL to oxidation has 
generally involved in measurement of the duration of the lag phase including other 
variables, such as the rate of propagation, are also noted. 
The increased atherogenecity of LDL is associated with a preponderance of small 
dense (sd-) LDL subpopulation that is more prone to oxidative modification than large 
buoyant (lb-) LDL (Chancharme et al., 1999). It has been shown that not only the 
prevalence of sd-LDL but its concentration was substantially increased in healthy 
subjects with various types of hyperlipidemia such as hyperLDLcholesterolemia, 
hypertriglyceridemia, combined hyperlipidemia and chylomicronemia, hyperlipidimea 
with CHD, type 2 diabetic patients with and without CHD (Hirano et al., 2004). 
Lipoprotein profiles that are relatively rich in sd-LDL particles are associated with up to 
a 3-fold greater risk of myocardial infarction than those mainly consist of Ib-LDL 
particles (Austin et al., 1988; Austin et a!., 1990; Stampfer et al., 1996). However, the 
mass of sd-LDL is independently associated with disease risk (Stampfer et al, 1996; 
Gardner et al, 1996; Lamarche et al, 1997; Austin et al, 1988), suggesting that these 
particles are more directly atherogenic than Ib-LDL. Similarly, Quebec cardiovascular 
study has confirmed that a predominance of sd-LDL is a strong and independent 
predictor of CHD in the first seven years of follow-up (St-Pierre et al., 2005). Recently, 
Koba et al. (2006) have reported that the progression of CHD was closely linked not to 
the LDL particle size, but to the concentration of sd-LDL. It has been suggested that in 
comparison to Ib-LDL, sd-LDL are highly atherogenic as a result of their enhanced 
susceptibility to oxidative modification, higher penetration in the arterial wall, their 
lower binding affinity for the LDL-receptor, and prolonged plasma half life (Chapman et 
al, 1998; Bjomheded et al, 1996). Differences in oxidative susceptibility between Ib-
LDL and sd-LDL have been attributed to differences in their physicochemical properties. 
Relative to Ib-LDL, sd-LDL have a reduced content of antioxidants (De Graaf et al, 
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1991; Tribble et al, 1994; Tribble et al, 1995) and free cholesterol (De Graaf et al, 
1991; Tribble et al, 1992; Tribble et al, 1994), and are enriched with polyunsaturated 
fatty acids (De Graaf e^  al, 1991) and, possibly, hydroperoxides (Sevanian et al, 1996). 
Antioxidant concentrations and free cholesterol content have been shown to predict 
differences in the oxidative susceptibility of LDL density subfraction (De Graaf et al., 
1991; Tribble et al, 1992; Tribble et al, 1994). Therefore, sd-LDL has been highlighted 
as a new powerful and useful marker for the risk of hyperlipidimea with and without 
CHD, type 2 diabetic patients with and without CHD (Austin et al, 1995; Hirano et al, 
2004; Koba et al, 2006). 
1.5 Management of Infection and Inflammation Induced Hyperlipidemia and 
Oxidative Stress 
Several line of research indicate that infection and inflammation induce the 
systemic host response known as APR, and produce many lipid abnormalities that could 
increase the risk of developing atherosclerosis. Lipid disturbances linked to chronic 
inflammation will undoubtedly participate in the increased cardiovascular risk associated 
with hyperlipidemia. A specialized feature of infection/inflammation is the activation of 
macrophages and neutrophils as target cells, which produce a plenty of the damaging 
oxygen free radicals in the system (Mehta et al, 1998; Bhattacharyya et al, 2004). In 
addition, the excessive production of ROS, associated with inflammation, leads to a 
condition of oxidative stress, which results an imbalance in antioxidant enzymes status, 
increase in PAF-AH and ceruloplasmin, and decrease in PON and transferrin, which can 
contribute to the increase in LDL susceptibility to oxidation (Feingold et al, 1998; Van 
lenten et al, 1995; Khovidhunkit et al, 2000). 
An encouraging development in the treatment and management of hyperlipidemia 
has been the introduction of a new class of fungal-derived compounds (statins) that are 
potent competitive inhibitors of HMG-CoA reductase, the rate controlling enzyme in the 
biosynthetic pathway for cholesterol. Statins have been widely used as the most potent 
class of drugs for the treatment of diabetes, CHD alone, diabetes with CHD, 
hypertriglyceridemia and combined hyperlipidemia (Maron et al, 2000; El-Swefy et al, 
2000). Currently, statins including atorvastatin calcium (Lipitor) are quite effective lipid-
lowering agents and universally marketed and used by diabetic and nondiabetic 
dyslipidemic patients with or without CHD. However, statins as well as fibrates and bile 
acid sequesterants have been reported to exert a host of side effects (Haffner et al, 1998; 
Assmann et al, 1998). In contrast, dietary tocotrienols have no toxicity and provide an 
effective lipid lowering property in addition to their potent antioxidant activity. Recently, 
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our lab has demonstrated a strong hypoglycemic, antidiabetic, hypolipidemic and 
antioxidant effect of dietary tocotrienols (Tocomin) and lovastatin after a 14-week 
treatment of STZ-induced diabetic rats (Ali, 2007). The tocotrienol isomers (a-, P-, y-
and 5-) are naturally occurring analogues of tocopherol isomers (Vitamin E) found 
mainly in cereal grains and palm oil. Tocotrienols differ from tocopherols by possessing 
three double bonds in the phytyl side chain. Unlike tocopherols, tocotrienols have been 
shown to have an intrinsic hypochlolesterolemic activity in animals and humans. The 
cholesterol lowering effect of tocotrienols was attributed mainly to their downregulation 
of HMG-CoA reductase-the rate-limiting enzyme of the cholesterol biosynthetic 
pathway. The tocopherol isomers, on the other hand, do not inhibit cholesterol synthesis 
and thus do not lower serum cholesterol (Minhajuddin et ai, 1999; Parker et ah, 1993). 
Previously published reports indicate a strong hypolipidemic and antioxidant effect of 
tocotrienol rich fraction (TRF) or purified tocotrienols (Tocomin) in normolipidemic and 
hyperlipidemic rats (Beg et ai, 1996; Minhajuddin et ai, 1999; Minhajuddin et al., 
2005; Sharma and Rukmini, 1986 and 1987; Seetharamaiah and Chandrasekhara, 1989; 
Watkins et al., 1993); normolipidemic and genetically hyperlipidemic swines and 
chickens (Qureshi et al., 1991c; Qureshi and Qureshi, 1993; Qureshi et al., 2000); 
hyperlipidemic rabbits (Teoh et al., 1994); cholesterol/oxidized cholesterol-induced 
hyperlipidemic/ atherosclerotic rabbits (Zainuddin, 2004; Zainuddin et ai, 2006); and 
hyperlipidemic hamsters (Raederstroff er al., 2002). It has been earlier demonstrated that 
tocotrienols or TRF exhibits a strong hypolipidemic activity in normolipidemic and 
hyperlipidemic humans (Beg et al., 1995; Beg et al., 1996, Beg et al., 1997; Minhajuddin 
et ai, 1999; Tan et al., 1991; Qureshi et al., 1991a, Qureshi et al., 1997; Qureshi et ai, 
2001b; Qureshi et al., 2002); and in a type II familial hypercholesterolemic patient with 
severe xanthomas (Beg et al., 1997). Our laboratory has demonstrated a strong 
hypolipidemic, antidiabetic and antioxidant impact of tocotrienols in type 2 diabetic 
patients with hyperlipidemia (Baliarsingh et al., 2005). Tomeo et al. (1995) also reported 
that T3 significantly decreased plasma lipid peroxidation in patients with hyperlipidemia 
and carotid stenosis with no change in their lipid and lipoprotein parameters. It has been 
established that LDL-C/HDL-C and HDL-C/TC ratios are good predictors for the 
presence and severity of CAD (Drexel et al., 1992). Experiments involving the effects of 
T3 on apoB (LDL) and apoA-1 (HDL) and apoB/apoA-1 ratio have been reported in 
chickens, swine and humans. The apoB/apoA-1 ratio, considered being a better indicator 
than LDL/HDL ratio, for assessment of CHD, was reduced in T3 treated subjects 
(Qureshi et al., 1991a). In addition, TRF treatment to hypercholesterolemic humans and 
type 2 diabetic patients significantly improved the HDL-C/LDL-C and HDL-C/TC ratios 
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(Qureshi et al., 2001a; Baliarsingh et ai, 2005). Desmethyl tocotrienol and didesmethyl 
tocotrienol also mediated a significant decrease in serum TG, TC, LDL-C, apoB, Lp(a), 
platelet factor 4 and thromboxane B2 levels of hypercholesterolemic humans after a 
double blind, 12-week study (Qureshi et ai, 1997). A dose-dependent effect of 
tocotrienol rich fraction containing mixture of the novel desmethyl- and didesmethyl 
tocotrienols (TRF25) has been investigated in hypercholesterolemic humans (Qureshi et 
al., 2002). The results showed that intake of a dose of 100 mg/day of TRF25 for 35 days 
caused maximum decrease in serum TC, LDL-C, apoB and TG levels when compared to 
baseline values (Qureshi et al, 2002). The synergistic effect of TRF25 has been reported 
in hypercholesterolemic humans. Administration of TRF in combination with lovastatin 
to hypercholesterolemic humans for 35 days exerted a synergistic lipid lowering effect, 
when compared to values obtained from subjects given TRF25 or lovastatin alone 
(Qureshi et ai, 2001b). In hyperlipidemic patients with type 2 diabetes, low doses of 
pitavastatin (1 mg) and fenofibrate (100 mg) were both effective in decreasing sd-LDL-C 
concentration but via a different mechanisms: the former decreases total LDL including 
sd-LDL, while the latter decreased sd-LDL specifically (Tokuno et al., 2007). Recently, 
May et al. (2008) demonstrates that, in diabetic patients with mixed dyslipidemia, 
combination therapy with simvastatin and fenofibrate had a greater positive effect on 
LDL cholesterol size profile, with a shift from more atherogenic sd-LDL-C to less 
atherogenic Ib-LDL-C, than either fenofibrate or simvastatin monotherapy. However, no 
one to date has reported the hypolipidemic coupled with antioxidant property of 
tocotrienols in the alleviation of hyperlipidemia/dyslipidemia and oxidative stress 
induced by infection and inflammation. 
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As discussed above, several epidemiological studies have documented an 
increased incidence of CAD in patients who have chronic infections and inflammatory 
disorders. Both infection and inflammation are accompanied by a systemic host response 
known as acute phase response (APR). Changes associated with APR could also be a 
mechanism for enhanced susceptibility to atherogenesis. In experimental animals, 
infection and inflammation are induced by administration of endotoxin, 
lipopolysaccharide (LPS, acute systemic infection), zymosan (acute noninfectious 
systemic inflammation), and turpentine or croton oil (acute localized sterile 
inflammation). Each of these stimuli is a well-characterized inducer of APR (Feingold et 
al., 1992a; Todd et al., 1990; Rao et ai, 1994). Acute phase response represents a 
complex reaction of the host that is accompanied by alterations in lipid and lipoprotein 
metabolism (Khovidhunkit et al, 2000). Among other changes that occur during APR 
include an increase in oxidative stress, with a consequent increase in lipid/lipoprotein 
peroxidation (Memon et al., 2000; Cordeiro et al, 2005), and a decreased in serum levels 
of cellular antioxidants such as a-tocopherol and ascorbic acid (Cordeiro et al., 2005; 
Coskun et al, 2005; Cadenas et al, 1998; Kanter et al, 2005). In rats, LPS treatment 
rapidly increases serum triglyceride levels by stimulating hepatic VLDL production and 
by decreasing triglyceride clearance (Feingold et al, 1992a). Administration of LPS to 
rodents was associated with increases in serum TC level by increasing LDL-C (Feingold 
et al, 1993a), whereas in primates, during infection LDL levels were decreased with an 
increase in more atherogenic sd-LDL subpopulation (Feingold et al, 1993b). The 
increase in serum and lipoprotein lipids in hamsters treated with LPS is apparently due to 
increase in hepatic HMG-CoA reductase activity (Feingold et al, 1993a). In both rodents 
and primates, LPS mediated a decrease in antiatherogenic HDL levels (Feingold et al, 
1992a; Feingold et al, 1993a; Feingold et al, 1993b). Enzymes and transfer proteins that 
are responsible for the remodeling of HDL, including LCAT, hepatic lipase, cholesterol 
ester transfer protein (CETP), and phospholipid transfer protein (PLTP), decrease while 
secretory phospholipase A2 (sPLA2) increases during inflammation (Khovidhunkit et 
al, 2004). In addition, during APR HDL-associated paraoxonase (PON)/arylesterase 
activity is also decreased (Khovidhunkit et al, 2004). Oxidative modification of 
lipoproteins plays a central role in the pathogenesis of atherosclerosis (Diaz et al, 1997). 
Although lipid oxidation in the vessel wall is thought to occur as result of local 
deficiency of endogenous antioxidants or an excess of free metal ions, only limited data 
support these hypotheses (Jialai and Devraj, 1996; Steinberg, 1997). Research has shown 
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that human atherosclerotic plaques contain massive amounts of lipid peroxidation 
products, despite the presence of large quantities of a-tocopherol and ascorbate (Suama 
et al., 1993). Thus, it is unclear whether oxidized lipoproteins originate in the arterial 
wall or are produced in the circulation and then enter the intimal space. In another study, 
vitamin E decreased LDL susceptibility to oxidation and reduced the plasma level of 
lipid peroxides with no change in plasma lipoprotein profiles in hyperlipidemic-diabetic 
hamsters. In addition, vitamin E, despite it's effect on reducing oxidative stress markers 
and lowering plasma TG levels, was not effective in inhibiting foam cell formation in the 
aortic arch of hyperlipidemic-diabetic hamster model (El-Swefy et al., 2000). 
Furthermore, circulating LDL is protected from oxidative stress by HDL-associated 
enzymes, particularly PON, which destroys biologically active phospholipids (Mackness 
et al, 1996). The serum PON activity is decreased in rabbits after administration of 
croton oil and PON depleted HDL is unable to protect LDL from oxidation in vitro. 
Recently, Asian et al. (2008) have reported a significant decrease in PON and 
arylesterase activities in H. pylori infected subjects, which seems to be related to 
decrease in HDL-C, and in part, to increased oxidative stress and inflammatory condition 
induced by H. pylori infection. 
Memon and coworkers (2000) have demonstrated that the host response to 
infection and inflammation can lead to LDL oxidation in vivo, which was measured in 
three distinct models of infection and inflammation in hamsters. Lipopolysaccharide, 
zymosan and turpentine were used to mimic acute systemic infection, acute 
noninfectious systemic inflammation and acute localized sterile inflammation, 
respectively. Their results demonstrate a significant increase in ex vivo levels of serum 
and LDL conjugated diene and TEARS. Lipopolysaccharide also produce a 17-fold 
increase in LDL content of lysophosphatidylcholine (LPC), formed during the in vivo 
LDL oxidation. Finally, LDL from LPS treated hamsters was more susceptible to in vitro 
Cu"^-catalyzed oxidation, resulting in a 3-fold decrease in lag phase (Memon et al, 
2000). It is possible that increased atherogenecity of LDL during infection and 
inflammation is associated with a preponderance of sd-LDL subpopulation, that is highly 
susceptible to oxidative modification than Ib-LDL (Tribble et al, 1992; Tribble et al, 
1994). Several studies have reported a 2- to 3-fold increase in CHD risk among patients 
with a predominance of sd-LDL particles (Austin et al, 1990; Austin et al, 1994). 
Similarly, Quebec cardiovascular study has confirmed that a predominance of sd-LDL is 
a strong and independent predictor of CHD in the first seven years of follow-up (St-
Pierre et al, 2005). Recently, Koba et al (2006) have reported that the progression of 
CHD was closely linked not to the LDL particle size, but to the concentration of sd-LDL. 
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Therefore, sd-LDL has been highUghted as a new strong and useful marker for the risk of 
CHD. However, considering the enhanced oxidizability and greater atherogenecity of sd-
LDL subpopulation than Ib-LDL or LDL, its role in oxidative stress mediated 
dyslipidemia during infection and inflammation has not yet been reported. 
Several lines of research have established that during acute infection and 
inflammation in rodents, oxidant stress may be increased owing to a higher production of 
ROS, which are controlled by antioxidant enzymes, SOD, catalase, Gpx, Gred and 
nonenzymatic scavenger, GSH (Bhattacharyya et al, 2004; Mehta et al., 1998). An 
impaired radical scavenger function has been linked to decreased activity of enzymatic 
and nonenzymatic scavengers of free radicals (Payabvash et ah, 2006; Vimal and 
Devaki, 2004; Deitch et al, 1992; Proulx and Du Souich, 1995). Therefore, status of 
lipid and lipoprotein peroxidation and the status of oxidants, enzymatic and 
nonenzymatic antioxidants in plasma, erythrocytes and other tissues such as liver and 
kidney of LPS, turpentine and zymosan stressed hamsters with dyslipidemia were highly 
important. In addition, acute infection and inflammation may enhance oxidative stress 
not only through the increased production of ROS but also through weakening the 
antioxidant defense system. In this context, antioxidant role of serum HDL-complexed 
PON/arylesterase enzyme in the protection of LDL as well as HDL from oxidative 
modification is noteworthy. In contrast to PON, xanthine oxidase is known to be an 
important biological source of free radicals. Xanthine oxidase activity in plasma, liver 
and kidney has been reported to be increased during acute infection and inflammation 
stressed rodents with dyslipidemia and that free radicals generated in the enzymatic 
processes are involved in oxidative damage (Deitch et al, 1992; Proulx and Du Souich, 
1995; Kurosaki et al, 1995; Celik et al, 2007; Kaur et al, 2006; Coskun et al, 2005). 
Therefore, the antioxidants that have both antiradical and xanthine oxidase inhibitory 
properties may have additional therapeutic benefit in the treatment of dyslipidemia and 
CHD in patients with chronic infections and inflammatory disorders. Finally, risk of 
complications including chronic infections and inflammatory disorders would be further 
exacerbated by an inadequate dietary intake of antioxidants such as a-tocopherol 
(vitamin E). Moreover, few scattered reports demonstrated that vitamin E or C treatment 
decreases lipid peroxidation, increases antioxidant enzyme activity and also prevents 
renal tissue damage in experimentally induced endotoxaemic rats. Histopathological 
changes also revealed a healing process (Coskun et al, 2005; Cadenas et al, 1998). 
Demling et al (1995) observed that 24 h after zymosan was administered in rats, the 
vitamin E levels in plasma and tissue, and CAT activity were significantly decreased, a-
Tocopherol treatment increased the postzymosan plasma vitamin E levels and maintain 
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tissue CAT activity, however, the degree of lung injury and lipid peroxidation was 
significantly attenuated. 
Based on the above information, therapeutic intervention involving a 
hypolipidemic drug coupled with antioxidant property has not been used to alleviate the 
complications associated with oxidative stress and dyslipidemia during acute infection 
and inflammatory disorders. Furthermore, all the published reports related to acute 
infection and inflammation indicate that no coordinated and detailed investigation on 
cholesterol dynamics, overall oxidative status including the indices of free radical-
mediated lipid/lipoprotein peroxidation and status of enzymatic and nonenzymatic 
antioxidant defense system in plasma, erythrocytes and tissues, particularly, ex vivo and 
in vitro oxidizability of more atherogenic sd-LDL, Ib-LDL, including LDL, and plasma 
PON/arylesterase activity has been reported. In the present study, we used hamsters 
because of its similarities to humans with regards to: (1) cholesterol and bile acid 
metabolism (Andersen et al, 1986); (2) lipoprotein metabolism closely resembles that in 
humans (Spady et al., 1988); (3) exclusive hepatic production of apolipoprotein (apo) B-
100 (Arbeeny et al, 1992); and (4) development of atherosclerotic lesions similar to 
those found in early stages of human disease (Nistor et al., 1987). Infection and 
inflammation are produced in hamsters by the administration of LPS (acute systemic 
infection), zymosan (acute noninfectious systemic inflammation), and turpentine (acute 
localized sterile inflammation). We have thus investigated the hypolipidemic and 
antioxidant impacts of dietary tocotrienols (Tocomin) in the above three distinct models 
of infection and inflammation in hamsters and compared them with respective controls. 
Tocomin were fed to hamsters for 10 days before and 12 h after LPS or 24 h after 
turpentine or zymosan injection, respectively. In one group, 12 h prior to killing, LPS 
and 5 mg Tocomin was administered simultaneously to hamsters (L-T2). The protective 
efficacy of feeding 10 mg Tocomin on plasma TL, TG, TC, VLDL-C, LDL-C, sd-LDL-
C, Ib-LDL-C and HDL-C including non-HDL-C was investigated. In addition, 
quantification of cholesterol and apoB content in LDL and its subpopulation, sd-LDL 
and Ib-LDL, of stressed hamsters pretreated with and without Tocomin have been done. 
In order to understand the mechanism(s) of lipid lowering action of Tocomin, we have 
measured the enzymatic activity of hepatic HMG-CoA reductase. The acute effect of 
infection and inflammation, induced by LPS, turpentine and zymosan, on plasma total 
antioxidants, arylesterase activity, plasma, liver and kidney xanthine oxidase activity; 
plasma, erythrocytes, liver and kidney lipid peroxidation products, that is, conjugated 
diene, lipid hydroperoxide and MDA as well as MDA release in intact erythrocytes was 
determined. In addition, ameliorating effect of Tocomin on the above parameters was 
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investigated. Moreover, antioxidant impacts of Tocomin on base line levels of ex vivo 
diene conjugation and lag phase time of in vitro Cu'^ '^ -induced oxidation of more 
atherogenic sd-LDL, Ib-LDL, including LDL, was undertaken. In addition, the 
antioxidant impact of Tocomin on LPC content of LDL, which is known to exert several 
proatherogenic effects and is a marker for oxidative modification of LDL, was also 
determined. Furthermore, the role of dietary tocotrienols in the protection and restoration 
of the altered enzymatic and nonenzymatic antioxidant defense system in erythrocytes, 
liver and kidney of LPS, turpentine and zymosan stressed hamsters has also been 
investigated. 
Several studies have established that in both men and women diabetes mellitus 
(DM) is a major independent risk factor for cardiovascular disease (CVD) (Grundy et al, 
1999; Assmann et al, 1998; Haffner et al., 1998). Hyperglycemia is the most important 
factor in the onset and progress of diabetic complications mainly by producing oxidative 
stress (Giugliano et al., 1996). Altered cellular metabolism caused by hyperglycemia 
play an important role in increasing the risk of cardiovascular, renal, ophthalmic and 
neurological complications of DM (Nathan, 1993). Although blood glucose is known to 
be highly predictive of microvascular disease, the contribution of all the measured risk 
factors can explain no more than 25 % of the excess macrovascular CHD associated with 
diabetes (Pyorala et al, 1987). The excessive non-enzymatic glycosylation of proteins 
associated with markedly increased free radical production, stimulate formation of 
glycosylated hemoglobin and advanced glycosylation end products, which cause 
extensive cellular and tissue damage, including vascular injury (Lyons, 1991). The 
dyslipidemic profile of diabetics includes increased levels of plasma TG, TC, VLDL-C, 
LDL-C and sd-LDL-C, increased glycation of LDL and decreased plasma 
antiatherogenic HDL concentration (Grundy et al., 1999). Previous reports indicate that 
altered plasma lipoprotein profile in the excess atherosclerosis associated with DM may 
be most critical, because at any TC level, in comparison to non diabetic subjects, diabetic 
patients have 3- to 5-fold higher CHD mortality rates (Stamler, 1987). In addition, 80 % 
of all type 2 diabetics will die of an atherosclerofic event (Garber, 1995). It is possible 
that increased atherogenecity of LDL during DM is associated with a preponderance of 
sd-LDL subpopulation, that is more prone to oxidative modification than Ib-LDL 
(Hirano et al, 2004; Tribble et al, 1992; Tribble et al, 1994; Tribble et al, 2001). 
Several studies have reported a 2- to 3-fold increase in CHD risk among patients with a 
predominance of sd-LDL particles, which have lower resistance to oxidative stress than 
Ib-LDL (Austin et al, 1990; Austin et al, 1994). It is interesting to mention that sd-LDL 
is known to be generated from large triglyceride-rich VLDL particle, production of 
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which is enhanced by insulin resistance during diabetes, thus resulting in an increased 
prevalence of sd-LDL (Bemeis and Krauss, 2002; Tribble et ai, 2001). Therefore, the 
greater atherogenic potential of sd-LDL, in comparison to Ib-LDL, may explain the 
higher incidence of CHD in diabetic patients than in isolated hypercholesterolemia 
(Hirano et al., 2004; Koba et al., 2006). In addition, because of greater preponderance of 
sd-LDL, a moderately high LDL-C (between 130 and 160 mg/dl) in a type 2 diabetic 
patient is equivalent to a much higher LDL-C in terms of CHD risk for a non diabetic 
subjects (Haffner et al., 1998; Grundy et al., 1999). It is well known that diabetes is 
associated with increased oxidative stress which is not only due to the increased 
production of ROS but also through weakening the antioxidant defense system. 
Therefore, protection of LDL from oxidative modification by HDL associated 
arylesterase/PON enzyme is important. In diabetics, a lower arylesterase activity and 
concentration, higher LDL-C: PON concentration ratio and a reduced capacity to prevent 
LDL oxidation have been reported (Boemi et al., 2001; Patel et a!., 1990). In addition, 
antioxidant supplementation may be expected to influence PON/arylesterase activity by 
altering oxidative stress (Aviram et al., 1999). The involvement of increased oxidative 
stress in diabetes is supported by several data such as increased concentration of plasma 
lipid peroxidation products, namely, conjugated diene, lipid hydroperoxide and TBARS 
and decreased levels of antioxidants (Nazaimoon et al., 1996; El-Swefy et al., 2000). 
Increased rates of lipid peroxidation in type 2 diabetics may be related in part to 
increased amounts of sd-LDL in their plasma (Selby et al., 1993). However, sd-LDL has 
been highlighted as a useful and potent new marker for the risk of type 2 diabetes, 
diabetes linked hyperlipidemia with CHD and CHD alone. However, a detailed 
investigation pertaining to distribution of cholesterol and apoB contents between sd-LDL 
and Ib-LDL and their percent share of LDL including the in vivo and in vitro Cu^-
catalyzed differential oxidizability of more atherogenic sd-LDL, less atherogenic Ib-
LDL, as well as LDL in type 2 diabetics with varying degree of hypercholesterolemia 
has been lacking. 
Therefore, in the second part of the investigation, we have utilized serum samples 
of 58 type 2 diabetic subjects, previously treated with atorvastatin plus fenofibrate for 
different duration [4-126 weeks] and exhibited different degree of hypercholesterolemia. 
Based on their individual TC, LDL-C and sd-LDL-C levels, they were categorized into 
five groups and their pooled serum samples were quantified for TG, TC, VLDL-C, LDL-
C, sd-LDL-C, Ib-LDL-C, HDL-C and non-HDL-C. In order to understand the clinical 
significance of more atherogenic sd-LDL, distribution pattern of cholesterol and apoB 
concentrations of sd-LDL and Ib-LDL and there percent share of LDL-C and LDL-apoB 
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were determined and correlated with varying degree of hypercholesterolemia in five 
groups of type 2 diabetics. We have also examined the in vivo and in vitro Cvt*-
catalyzed differential oxidizability of sd-LDL and Ib-LDL as well as LDL from 
normolipidemic and five groups of diabetic-hypercholesterolemic subjects. Relative to 
Ib-LDL, sd-LDL susceptibility to in vivo oxidation, measured as ex vivo base line diene 
conjugation (BDC), lipid hydroperoxide and MDA was measured. Whereas, Cu"^ "^ -
induced oxidizability of sd-LDL and Ib-LDL was compared by measuring lag phase, 
lipid hydroperoxide and MDA. In order to correlate the different degree of in vivo and in 
vitro oxidizability of sd-LDL and Ib-LDL including LDL with their relative 
electrophoretic mobility, unoxidized and maximally oxidized samples of sd-LDL, Ib-
LDL and LDL from normolipidemic and five groups of diabetics were analyzed by 
agarose gel electrophoresis. In addition, the above parameters including oxidative indices 
were correlated with total antioxidants as well as arylesterase activity present in serum 






The chemicals and reagents were obtained from various sources listed below. 
Chemical Source 
1 -Chloro 2, 4-Dinitrobenzene 
1, 1,3, 3-Tetra Methoxy Propane 
2, 2-Diphenyl-l-Picryl Hydrazyl 
2, 4, 6-Tripyridyl-s-Triazine 
Bovine Serum Albumin 
Butylated Hydroxyl Toluene 
Cholesterol (Extra pure) 
Coommassie Brilliant Blue G 250 
Dextran Sulfate 
Digitonin 
5, 5'-Dithiobis (2-Nitrobenzoic Acid) 
Glutathione Oxidized 
Glutathione Reduced 
Hemoglobin Assay Kit 
Hydroxylamine Hydrochloride 










Sodium Dodecyl Sulfate 
Thiobarbituric Acid 
Triphenyl Phosphine 
Triglyceride Assay Kit 
Turpentine Oil 
Central drug house, Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Miles Ltd. Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Sisco Research Laboratories Pvt. Ltd., India 
Ploysciences Inc., USA 
Sigma-Aldrich Inc., USA 
Central drug house, Pvt. Ltd., India 
Sisco Research Laboratories Pvt. Ltd., India 
Sisco Research Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Ranbaxy Diagnostics, India 
HiMedia Laboratories Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Loba Chemie, India 
Ashirwad Industries, Chandigarh, India 
Bio-Rad Laboratories, USA 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Recombigen Laboratories, India 
Vasco drug Laboratories, India 
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Xanthine HiMedia Laboratories Pvt. Ltd., India 
Xylene] Orange HiMedia Laboratories Pvt. Ltd., India 
Zymosan A from Saccharomyces cerevisiae Sigma-Aldrich Inc., USA 
Twenty five percent palmvitae oil suspension of tocotrienols containing d-a-
tocopherol and purified individual d-a-tocotrienol (80 %), d-y-tocotrienol (90 %), d-5-
tocotrienol (60 %) and d-a-tocopherol {60 %) as well as RBD palm olein were supplied 
as a gift from CAROTECH BHD, Chemor, Malaysia. Tocomin*^ suspension (250 mg/g) 
contained 6.4 % d-a-tocotrienol, 1 % d-P-tocotrienol, 10.2 % d-y-tocotrienol, 3.2 % d-5-
tocotrienol and 5.7 % d-a-tocopherol. 
All other chemicals and reagents used in this study were of analytical grade. 
2.1.2 Animals 
Male golden hamsters, weighing about 175-200 g were purchased from Central 
Drug Research Institute, Lucknow, India, were acclimatized to animal house environment 
prior to the experiment. 
2.1.3 Diet/Injection 
The hamsters were given pelleted rodent chow and water ad libitum. For the 
induction of acute systemic infection, acute localized sterile inflammation or acute 
noninfectious systemic inflammation, hamsters were injected with endotoxin 
(lipopolysaccharide, LPS), turpentine oil or zymosan, respectively. Lipopolysaccharide, 
200 jig in 0.5 ml saline and zymosan, 20 mg in 0.5 ml warm {SQpC) PBS, pH 7.0, were 
injected intraperitoneally, whereas, turpentine oil, 0.5 ml, was injected subcutaneously. 
Hamsters in control group were injected intraperitoneally with 0.5 ml saline only. 
Subsequently, food was withdrawn from both control and treated hamsters (Memon et 
al, 2000). Tocomin (1 g) was solublized in 5 ml ethanol and diluted to 100 ml in 
palmvitae oil. Tocomin suspension was administrated through gastric intubation in two 




2.2.1 Experimental Design 
2.2.1.1 Studies in hamsters 
For investigating the hypolipidemic and overall antioxidative impacts of 
Tocomin, hamsters were divided in the following groups as described below: 
• Normal Control (N-C) 
Five hamsters were given 1.0 ml palmvitae oil/hamster/day, through gastric intubation, 
10 days before and 24 h after saline injection. 
• Normal Tocomin Control (N-T) 
Five hamsters were given 10 mg Tocomin/hamster/day, through gastric intubation, 10 
days before and 24 h after saline injection. 
• LPS Stressed Control (L-C) 
Five hamsters were given 1.0 ml palmvitae oil/hamster/day, through gastric intubation, 
10 days before and 12 h after LPS injection. 
• LPS Tocomin Treated-1 (L-Ti) 
Five hamsters were given 10 mg Tocomin/hamster/day, through gastric intubation, 10 
days before and 12 h after LPS injection. 
• LPS Tocomin Treated-2 (L-T2) 
Three hamsters were administered LPS and 5 mg Tocomin/hamster simultaneously, 12 h 
prior to killing. 
• Turpentine Stressed Control (T-C) 
Five hamsters in this group were fed 1.0 ml palmvitae oil/hamster/day, through gastric 
intubation, 10 days before and 24 h after turpentine injection. 
• Turpentine Tocomin Treated (T-T) 
Five hamsters in this group were fed 10 mg Tocomin/hamster/day, through gastric 
intubation, 10 days before and 24 h after turpentine injection. 
• Zymosan Stressed Control (Z-C) 
Five hamsters in this group were fed 1.0 ml palmvitae oil/hamster/day, through gastric 
intubation, 10 days before and 24 h after zymosan injection. 
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• Zymosan Tocomin Treated (Z-T) 
Five hamsters in this group were fed 10 mg Tocomin/hamster/day, through gastric 
intubation, 10 days before and 24 h after zymosan injection. 
2.2.1.2 Studies in human subjects 
Fasting serum samples of 58 type 2 diabetic-hypercholesterolemic subjects were 
provided from Endocrine clinic of the Department of Medicine, J. N. Medical College 
and Hospital, A. M. University, Aligarh, India. These subjects were under treatment with 
hypoglycemic, hypotensive and hypolipidemic drugs for different duration. Based on 
their duration of treatment with atorvastatin plus fenofibrate, and individual serum Total 
cholesterol (TC), low density lipoprotein (LDL)-C and small dense (sd-) LDL-C values, 
58 type 2 diabetic-hypercholesterolemic subjects were assigned into five groups (A-E) 
(Table 22 and 23), as given below: 
Group A, Seventeen subjects were previously treated with metamerfin (500 mg), 
glimeperide (2 mg), ramipril (2.5 mg) and atorvastatin (20 mg) plus fenofibrate (160 mg) 
drugs, for 98 weeks [70 (min) - 126 (max) weeks]. Their average TC, LDL-C and sd-
LDL-C values of pooled serum samples in this group were 92.42±9.30, 66.54±6.78 and 
18.68±2.20 mg/dl, respectively. 
Group B, Ten subjects were previously treated with metamerfin (500 mg), glimeperide 
(1 or 2 mg), ramipril (2.5 or 5.0 mg) and atorvastatin (20 mg) plus fenofibrate (160 mg) 
drugs, for 47.5 weeks [43 (min) - 52 (max) weeks]. Their average TC, LDL-C and sd-
LDL-C values of pooled serum samples in this group were 140.98±13.85, 99.96±9.33 
and 34.4416.57 mg/dl, respectively. 
Group C, Fourteen subjects were previously treated with metamerfin (500 mg), 
glimeperide (1 or 2 mg), ramipril (2.5 or 5.0 mg) and atorvastatin (20 mg) plus 
fenofibrate (160 mg) drugs, for 39.5 weeks [34 (min) - 45 (max) weeks]. Their average 
TC, LDL-C and sd-LDL-C values of pooled serum samples in this group were 
184.96117.59, 127.17+12.58 and 51.06l8.62 mg/dl, respectively. 
Group D, Ten subjects were previously treated with metamerfin (500 mg), glimeperide 
(1 or 2 mg), ramipril (2.5 or 5.0 mg) and atorvastatin (20 mg) plus fenofibrate (160 mg) 
drugs, for 15 weeks [10 (min) - 20 (max) weeks]. Their average TC, LDL-C and sd-LDL-
C values of pooled serum samples in this group were 255.62117.89, 179.96112.32 and 
104.1819.54 mg/dl, respectively. 
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Group E, Seven subjects were previously treated with metamerfin (500 mg), glimeperide 
(1 or 2 mg), ramipril (2.5 or 5.0 mg) and atorvastatin (20 mg) plus fenofibrate (160 mg) 
drugs, for 5.5 weeks [4 (min) - 7 (max) weeks]. Their average TC, LDL-C and sd-LDL-C 
values of pooled serum samples in this group were 342.47±57.17, 242.68±40.05 and 
162.06±32.72 mg/dl, respectively. 
Fasting serum samples of 4 normolipidemic subjects were also taken, pooled and their 
average TC, LDL-C and sd-LDL-C values were 140.71±0.098, 85.50±0.173, 
24.87±0.135 mg/dl, respectively. 
2.2.2 Analytical Procedures 
2.2.2.1 Collection of blood and packed erythrocytes 
At indicated times after LPS, turpentine or zymosan injection, hamsters in each 
group were anaesthetized and blood drawn from cardiac puncture. The blood from each 
hamster in a given group was collected in heparinized tubes, for 2-3 h, mixed gently by 
inversion 2-3 times and incubated at 4°C. Plasma was separated from blood by 
centrifligation at 2,500 rpm for 30 min, aliquoted and either stored at 4*^ C or frozen at -
20°C for use in other experiments. 
Packed erythrocytes hemolysate was prepared as described by Lakshmi and 
Rajagopal (1998). After the separation of plasma and buffy coat, the packed erythrocytes 
obtained were washed thrice with physiological saline and a portion of washed 
erythrocytes was lysed in hypotonic (lOmM) sodium phosphate buffer, pH 7.4. A portion 
of the washed packed erythrocytes was stored at 4°C for future use. 
2.2.2.2 Preparation of liver, kidney homogenate and post-mitochondrial supernatant 
At the end of the experiment, liver and kidney from each hamster were promptly 
excised and chilled in ice-cold saline. After washing with saline, liver and kidney were 
blotted and weighed. Each liver and kidney were cut into pieces, mixed and 10 g of wet 
tissue was homogenized with 90 ml of chilled 0.1 M sodium phosphate buffer, pH 7.4, 
containing 1.17 % KCL in a waring blender. The volume of each homogenate was 
recorded and centrifuged at 1,000 rpm for 10 min at 4'^ C. After centrifugation, a portion 
of each homogenate from liver and kidney thus obtained was aliquoted and stored at -
20 C. The remaining portions of the liver and kidney homogenates were centrifuged at 
12,000 rpm for 20 min at 4 C. The post-mitochondrial supernatant thus obtained was 
aliquoted and stored at -20 C for future use. 
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2.2.2.3 Determination of free radical scavenging activity (antioxidant capacity) of 
Tocomin, a-tocotrienol, y-tocotrienol, 8-tocotrieno] and a-tocopherol 
The procedure of Mellors and Tappel (1966) as modified by Khanduja and 
Bhardwaj (2003) was used for determining the free radical scavenging activity of 
Tocomin, a-Ts, y- T3, 5- T3, and a- T. The assay was carried out in a medium containing 
40 mM tris buffer, pH 7.4 and 125 i^M ethanolic solution of 2, 2-diphenyl-l-picryl 
hydrazyl (DPPH). The reaction was started by the addition of ethanolic solution of 
Tocomin, a-Ts, y- T3, 6- T3, and a- T (25-200 (iM) in a total volume of 2 ml. The samples 
were mixed thoroughly and the absorbance was recorded in dark at 517 nm (27 ± 2°C) at 
1 min time interval up to 10 min against absolute ethanol. A control blank containing all 
the above ingredients except the test compounds was used in order to monitor the 
absorption of DPPH. The percent inhibition of the DPPH by the above antioxidants was 
calculated according to the formula reported by Yen and Duh (1994). 
2.2.2.4 Determination of plasma triglyceride 
Triglyceride was determined by using enzymatic kit. The method uses a modified 
Trinder color reaction to produce a fast, linear, end point reaction (Trinder, 1969). The 
intensity of the color produced after incubation is directly proportional to the 
concentration of the triglyceride in the plasma samples when measured at 500 nm in a 
Beckman DU 640 spectrophotometer. Triglyceride in plasma samples were calculated by 
using a triolein standard. 
Plasma very low density lipoprotein-cholesterol (VLDL-C) was calculated by 
dividing plasma triglyceride values (mg/dl) by a factor of 5 as described by Friedewald et 
al (1972). 
2.2.2.5 Determination of plasma free fatty acid 
Free fatty acid in plasma was estimated as described by Duncombe (1963). The 
procedure of Folch et al. (1957) was used for extracting free fatty acid from plasma 
lipids. Fifty microliter of plasma was mixed with 2.5 ml of chloroform:methanol (2:1), 
followed by centrifligation at 1,000 rpm for 5 min to separate the phases, most of the 
upper layer was removed and 1.5 ml of the lower chloroform layer was recovered. 
Chloroform layer was placed in a test tube and incubated at 45°C till dryness. Lipid 
residues were dissolved in 500 \i\ of chloroform and to this 2.5 ml of copper reagent, 
prepared by mixing 9 vol of aqueous 1 M triethanol amine, I vol of 1 N acetic acid and 
10 vol of 0.269 M copper nitrate, was added. The tubes were vortexed for at least 2 min 
and centrifuged at 3,000 rpm for 5 min to separate the phases clearly. The supernatant 
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aqueous phase was removed and 0.1 ml of chloroform layer was taken in triphcate into 
clean dry tubes. Then, 1.0 ml of (0.05 % w/v) sodium diethyl dithiocarbonate, prepared in 
butanol and used within 7 days, was added to the chloroform solution and mixed. The 
absorbance was recorded at 440 run against a reagent blank in Beckman DU 640 
spectrophotometer. The free fatty acid content was calculated by using palmitic acid as a 
standard, after subjecting it to the same procedure. 
2.2.2.6 Determination of plasma, LDL phospholipids and LDL-
lysophosphatidylcholine (LPC) content 
Lipid contents from plasma and LDL were extracted according to the method of 
Folch et al. (1957). One volume of plasma or LDL was mixed with 5.0 volume of 
chloroform: methanol (2:1), followed by centrifugation at 1,000 rpm for 5 min to separate 
the phases. Most of the upper layer was removed and 3.0 ml of the lower chloroform 
layer was recovered. The chloroform layer was placed in a test tube and incubated at 
45°C till dryness. The dried residues extracted from plasma or LDL was used for the 
estimation of phospholipids by employing the procedure as described by Bartlett (1959), 
with a minor modification. To dried lipid residues of plasma or LDL, 0.5 mi of 10 N 
H2SO4 was added and the samples were placed in an oven at 140°C-160*^0 for at least 3 h. 
Two drops of fuming HNO3 was added and the solution was returned to the oven for at 
least 2 h to complete the combustion. Tubes were removed, cooled at room temperature 
and volume was adjusted to 4 ml with distilled water. The reagent blank consists of 4 ml 
distilled water. Now, 4 ml of color reagent, freshly prepared by mixing 1 vol of 6 N 
H2SO4, 2 vol of distilled water, 1 vol of 2.5 % ammonium molybdate and 1 vol of 10 % 
ascorbic acid, was added and mixed. All the tubes were incubated at 37°C for 2 h. After 
cooling the tubes at room temperature, the absorbance of each sample was read against 
the blank at 820 nm in Beckman DU 640 spectrophotometer. Monopotassium phosphate 
was used as a standard. The values were expressed as phospholipids multiplying by a 
factor of 25. 
In order to determine the LPC content in LDL, dried lipid residues were dissolved 
in chloroform and quantification of LPC was done according to method of Quinn et al. 
(1988). Lipids were fractionated on 20x20 cm silica gel G plates that had been activated 
at 110°C for I h. Lipids (20 \i\) extract in chloroform and reference standard (LPC 
dissolved in chloroform) was applied to the plate. Plates were developed in 
chloroform/methanol/acetic acid/water, 70;30:2:4 (v/v). After development, the plates 
were air dried and lipids band were detected by lightly staining with I2 vapor. The 
location of LPC band was identified by comigration with standard, which were scraped 
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off and eluted two times with chloroform/methanol (1:1). The chloro|emi\fiVer''W2is4akeh-
and dried at 45°C. The lipid phosphorous content in these fraction^ and stand^rd^as ,, 
determined as described above. '' 
2.2.2.7 Fractionation of plasma lipoproteins 
The precipitation method described by Wieland and Seidel (1989).,was.-iisfj 
the isolation of plasma low density lipoprotein (LDL). The precipitation buffer consisted 
of 64 mM trisodium citrate adjusted to pH 5.05 with 5 N HCL, containing 50,000 lU/L 
heparin. Before precipitation of LDL, plasma samples and precipitation reagent were 
allowed to equilibrate to room temperature. One ml of plasma sample was added to 7.0 
ml of heparin-citrate buffer. After mixing with a vortex mixer, the suspension was 
allowed to stand for 10 min at 22 C. The insoluble LDLs were then sedimented by 
centrifugation at 1,500 rpm for 10 min at 22°C. The pellet was resuspended in 1.0 ml of 
0.1 M sodium phosphate buffer, pH 7.4, containing 0.9 % NaCl. 
The method for the isolation of small dense (sd)-LDL and large buoyant (Ib)-LDL 
from isolated LDL is based on the two-step procedure of Hirano et al. (2004), which 
employs quantification of sd-LDL from serum by heparin-Mg"^ "*" precipitation. In our 
modified method of sd-LDL and Ib-LDL isolation, 0.1 ml of precipitation reagent 
containing 15 lU of heparin and 90 mM MgCb was added to 0.1 ml of isolated LDL 
sample as described above. After mixing, the sample was incubated at 37°C for 10 min. 
Then each sample was incubated in an ice-bath for 15 min and centriftiged at 10,000 rpm 
for 15 min at 4''C. The supernatant containing sd-LDL was careftilly removed and saved. 
The pellet containing Ib-LDL was dissolved in 0.1 M sodium phosphate buffer, pH 7.4, 
containing 0.9 % NaCl. Appropriate aliquots of LDL, sd-LDL and Ib-LDL fractions were 
used for the analysis of their cholesterol and apoB content. 
The method of Patsch et al. (1989) was used for the isolation of high density 
lipoprotein (HDL). According to this method 100 ^1 of reagent containing 1.0 g of 
dextran sulfate dissolved in 100 ml of 0.5 mM MgCl2 solution was added to 1.0 ml of 
plasma, and vortexed-mixed for 3 sec. After an incubation period of 10 min at 22^C, the 
mixture was centrifuged at 1,500 rpm for 15 min at 22°C and the supernatant containing 
HDL was removed. The clear supernatant was used for the analysis of HDL-C. 
2.2.2.8 Determination of cholesterol and plasma lecithin cholesterol acyltransferase 
(LCAT) activity 
Total cholesterol in plasma, LDL, sd-LDL, Ib-LDL, and HDL was determined as 
described by Annino and Giese (1976), with a minor modification. For the determination 
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of cholesterol in plasma and lipoproteins, 0.1 volume of plasma was mixed with 1 
volume of isopropanol, allowed to stand for 5 min and centrifuged at 3,000 rpm for 10 
min. A suitable aliquot of isopropanol extract was used for cholesterol determination in a 
total volume of 0.75 ml. To each tube 0.25 ml of 7.02 mM ferric chloride dissolved in 
glacial acetic acid, was added, mixed instantly, followed by the addition of 0.8 ml of 
sulphuric acid with thorough mixing. After 5 min, the absorbance was read at 550 nm in a 
Beckman DU 640 spectrophotometer. The cholesterol content in the samples was 
determined by using a cholesterol standard. 
For the determination of free and esterified cholesterol, a suitable aliquot of the 
isopropanol extract of each plasma sample was treated with 2.0 ml of the ice-cold acetone 
and 1.0 ml of digitonin solution (8.13 mM of digitonin dissolved in 60 ml of absolute 
ethanol, diluted to 100 ml with distilled water and mixed well). The tubes were allowed 
to stand in an ice bath for 30 min and then centrifuged for 10 min at 4,000 rpm. The 
supernatant was decanted completely. The precipitate was again washed with 3.0 ml of 
ice-cold acetone and dissolved in isopropanol. A suitable aliquot of isopropanol extract 
was used for cholesterol estimation as described above. Plasma esterified cholesterol 
levels were calculated by deducting the free cholesterol values (mg/dl) from total 
cholesterol values (mg/dl). Plasma LCAT activity was determined as described by Ly et 
al, (1995). The extent of decrease in the free cholesterol/esterified cholesterol ratio was 
taken as a measure of LCAT activity in plasma. 
2.2.2.9 Measurement of ex vivo and in vitro Cu^^-mediated susceptibility of LDL, 
sd-LDL and Ib-LDL to oxidation 
The ex vivo and in vitro Cu'^ '^ -mediated susceptibility of isolated LDL, sd-LDL 
and Ib-LDL to oxidation was assessed by determining the lag phase of conjugated diene 
formation using the method of Esterbauer et al. (1989; 1992). Prior to oxidation studies 
LDL, sd-LDL and Ib-LDL samples were dialyzed against 5 mM phosphate buffer saline 
(PBS), pH 7.4, for 12 h. The incubation mixture contained 50 j^ g of LDL, sd-LDL or Ib-
LDL in 1.0 ml of 10 mM PBS, pH 7.0. At time zero, before the initiation of Cu""""-
mediated oxidation, 1,0 ml aliquot of each sample was added to a tube containing 0.5 )iM 
EDTA, pH 7.4, for the assessment of ex vivo levels of conjugated diene. At zero time, 
another 600 |il (30 i^g) aliquot was added to a tube containing 0.6 \xM BHT and stored at 
A^C, which were used for the determination of ex vivo level of lipid hydroperoxide. Then, 
lipoprotein samples were mixed with CUSO4 to a final concentration of 2.5 |aM and 
incubated at 37°C. In one series, at different time intervals of oxidation, 1.0 ml aliquots 
from LDL, sd-LDL and Ib-LDL incubation mixture were taken out, mixed with 0.5 mM 
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EDTA, pH 7.4, stored at 4°C and used for the assessment of conjugated diene. In another 
series, for the analysis of lipid hydroperoxide formation, 600 ^1 aliquots were added to 
tubes containing 0.6 jiM BHT, mixed and stored at 4^C. The oxidation for LDL and Ib-
LDL was carried out for 12 h, whereas for sd-LDL it was 30 min. The formation of 
conjugated diene in each aliquot was measured by monitoring absorbance at 234 nm in a 
Beckman DU 640 spectrophotometer. Conjugated diene was calculated by using an 
extinction coefficient of 2.52 x 10"* M"' cm"' and expressed as nmole malondialdehyde 
(MDA) equivalent per mg LDL, sd-LDL or Ib-LDL protein. 
For the measurement of basal and Cu"^-induced generation of lipid 
hydroperoxide, 5 volume of chloroform: methanol (2:1) was added to the samples, 
vortexed and centrifiiged at 3,000 rpm for 10 min. Chloroform layer of each sample was 
taken out in a tube containing 0.6 jj,M BHT, dried at 45°C and residues were dissolved in 
methanol. The assay was done according to the method of Nourooz-Zadeh et al. (1996) 
with minor modification. Ninety microliter of these samples in triplicate were transferred 
to microcentrifiige tubes, pre incubated for 5 min at 30''C, followed by the addition of 
900 \i\ of a reagent containing 250 JLIM ammonium sulphate, 100 (iM xylenol orange, 25 
mM sulphuric acid and 4 mM BHT in 90 % methanol. The samples were incubated either 
for 60 min at SO^ 'C or, for 60 min at 4°C (used as control) and the absorbance was read at 
560 nm in Beckman DU 640 spectrophotometer. The levels of lipid hydroperoxide in 
lipoprotein samples were determined using the difference between mean absorbance of 
samples and control values. Hydroperoxide contents were determined using a molar 
absorption coefficient of 4.3 x 10'' M"' cm"'. The MDA content in LDL, sd-LDL and Ib-
LDL were assayed by the method of Niehaus and Samuelsson (1968). Briefly, 0.3 ml of 
LDL, sd-LDL and Ib-LDL mixture in triplicate was thoroughly mixed with 2 ml of 
trichloroacetic acid (TCA)-thiobarbituric acid (TBA)-hydrochloric acid (HCL) reagent 
containing 15 % TCA, 0.375 % TBA and 0.25 N HCL. The solution was heated for 15 
min in a boiling water bath. After cooling, the flocculent precipitate was removed by 
centrifugation at 1000 rpm for 10 min. The absorbance of the samples was determined at 
535 nm against a blank that contained all the reagents except the LDL, sd-LDL or Ib-
LDL. The MDA concentration of the samples was calculated by using an extinction 
coefficient (1.56 x 10^  M"'cm"'). 
In another experiment, susceptibility of Cu'""'-mediated oxidation of LDL, sd-LDL 
and Ib-LDL, isolated from pooled serum of normolipidemic and type 2 diabetic-
hypercholesterolemic subjects were investigated. Prior to oxidation studies LDL, sd-LDL 
and Ib-LDL samples were dialyzed against 5 mM PBS, pH 7.4, for 12 h. The incubation 
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mixture contained 22-110 fjg of LDL, sd-LDL and Ib-LDL in 180-400 ^l of 10 mM PBS, 
pH 7.0. At time zero, before the initiation of Cu"^ "^ -mediated oxidation, appropriate aliquot 
of each lipoprotein sample was taken out into a tube containing 1 mM BHT and used for 
the assessment of ex vivo levels of conjugated diene, lipid hydroperoxide, MDA and 
electrophoretic mobility. Then, lipoprotein samples were mixed with CUSO4 to a final 
concentration of 5 (JM and incubated at 37 C. At the indicated times, aliquots were taken 
out and oxidation of LDL, sd-LDL and Ib-LDL was terminated by addition of 1 mM 
BHT. Lipid content in each sample was extracted according to the method of Folch et al. 
(1957). One volume of sample was mixed with 5.0 volume chloroform: methanol (2:1), 
vortexed and centrifuged at 3,000 rpm for 10 min. Chloroform layer of each sample was 
transferred in a tube containing 1 mM BHT, dried at 45*^ 0 and methanol was added to 
dissolve the residues. For the determination of conjugated diene, samples in methanol 
were dried at 45''C and dissolved in 1.5 ml of cyclohexane. The absorbance was recorded 
at 234 rmi against a cyclohexane blank in a Beckman DU 640 spectrophotometer. The 
formation of conjugated diene was calculated by using an extinction coefficient of 2.52 x 
10^M"^cm"'. 
Lipid hydroperoxide formation in these samples was estimated by the method of 
Nourooz-Zadeh et al. (1996) as described above. The method of Niehaus and Samuelsson 
(1968) was employed for the quantificafion of MDA in these samples. The agarose gel 
electrophoresis of the above LDL, sd-LDL and Ib-LDL samples were done according to 
the method of Noble (1968), with minor modification. Lipoprotein samples were 
prestained for lipids with sudan black using a method of Blom et al. (2003). One volume 
of lipoprotein samples (5 |ig) was incubated with 0.5 volume of lipid stain (1 % w/v 
Sudan black in ethylene glycol) for an hour at 4°C and centrifuged for 20 min at \Q,QOO 
rpm. Supernatant (20-30 |il) was directly applied to wells. Electrophoresis was carried 
out in 0.5 % agarose gel in 0.05 M barbital buffer, pH 8.6 at a constant voltage of 100 V 
(2-3 h). Electrophoretic mobility was expressed as a distance of lipid band migration 
from origin of the gel. 
2.2.2.10 Measurement of plasma "total antioxidant power" (FRAP) 
The method of Benzie and Strain (1996) was used for measuring the ferric 
reducing ability of plasma, the FRAP assay, which estimate the "total antioxidant 
power", with minor modification. Ferric to ferrous ion reduction at low pH results in the 
formation of a colored ferrous-tripyridyl triazine complex. The assay was carried out in a 
total volume of 1.0 ml containing a suitable aliquot of plasma in 0.1 ml and 900 \x\ of 
freshly prepared FRAP reagent, prepared by mixing 10.0 ml of 22.78 mM sodium acetate 
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buffer, pH 3.6, 1.0 ml of 20 mM ferric chloride and 1.0 ml of 10 mM 2, 4, 6-tripyridyl-s-
triazine solution prepared in 40 mM HCl. Before starting the reaction, both FRAP reagent 
and plasma samples were preincubated for 5 min at 30^C. Incubation was done for 5 min 
at BO^ C and absorbance was recorded at 593 nm against a reagent blank in a Beckman 
DU 640 spectrophotometer. Ferrous sulphate was used as a standard for calculating the 
"total antioxidant power". 
2.2.2.11 Assay of arylesterase activity in plasma and HDL 
Plasma and HDL arylesterase activity was determined by the method of Ayub et 
al. (1999) by using phenyl acetate as the substrate. The reaction mixture included 100 
mM tris buffer, pH 8.0, 1 mM CaCb, suitable aliquots of plasma and 1 mM phenyl 
acetate. After 5 min preincubation at 25°C, the reaction was started by the addition of 
phenyl acetate and the samples were incubated for different time intervals at 25°C. The 
initial rates of hydrolysis (within linear range) were determined spectrophotometrically at 
270 nm against a reagent blank. Nonenzymatic hydrolysis of phenyl acetate was 
substracted from the total rate of hydrolysis. Arylesterase activity in the above samples 
was calculated by using the molar extinction coefficient of 1.31 x 10^  M"' cm'' (La Du 
andEckerson, 1984). 
2.2.2.12 Assay of xanthine oxidase activity 
Xanthine oxidase activity in plasma, liver and kidney homogenate was assayed by 
the method described by Noro et al. (1983) with suitable modification. The reaction 
mixture consisted of 70 mM sodium phosphate buffer, pH 7.4, 10 |al of plasma or 100 |al 
of 10 % liver or kidney homogenate and 8 mM xanthine. After a 5 min preincubation, the 
reaction was started by the addition of xanthine and incubation was carried out for 15 min 
at 37°C. The reaction was terminated by the addition of 0.5 ml ice-cold 10 % perchloric 
acid, followed by incubation for 10 min at room temperature. Samples were then 
centriftiged at 4,000 rpm for 10 min. The absorbance of the supernatant was recorded at 
290 nm against a reagent blank in a Beckman DU 640 spectrophotometer. Xanthine 
oxidase activity was calculated by using a standard uric acid. 
2.2.2.13 Measurement of malondialdehyde release from intact erythrocytes 
The procedure of Cynamon et al. (1985) was employed for the determination of 
MDA release from erythrocytes. Two aliquots of 0.22 ml of washed packed erythrocytes 
in duplicate were taken in two separate tubes. One series of aliquots were suspended in 
4.18 ml of phosphate buffered saline, pH 7.4, and the second series of aliquots of 
erythrocytes were suspended in 4.18 ml of phosphate buffered saline, pH 7.4, containing 
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4 mM sodium azide. Both the suspensions were vortexed for 15 seconds. One ml of 
erythrocytes suspension of series one was taken in triplicate and mixed with 1.0 ml of 
freshly prepared 3 % hydrogen peroxide, whereas, 1.0 ml of 0.75 % hydrogen peroxide 
was added to the second series of erythrocytes suspension. The samples were mixed for 
10 seconds and incubated for 1 h at 37'^ C. At the end of incubation, 1.0 ml of 28 % TCA 
containing 100 mM sodium arsenite was added to each tube and centrifuged at 3,000 rpm 
for 10 min. Two ml of the supernatant from each tube was taken in triplicate and mixed 
with 0.5 ml of 1 % thiobarbituric acid prepared in 50 mM NaOH. The samples were then 
boiled for 15 min at 95 C, cooled to room temperature and the absorbance was recorded 
at 535 nm against a reagent blank in a Beckman DU 640 spectrophotometer. The 
concentration of MDA was calculated by using a standard malondialdehyde (Liu et al, 
1982). 
2.2.2.14 Determination of malondialdehyde in erythrocytes 
The determination of MDA in erythrocytes was carried out according to the 
method of Stocks and Dormandy (1971). Briefly, 0.3 ml of packed erythrocytes in 
triplicate was made up to 1.0 ml in phosphate buffered saline, pH 7.4. To each tube, BHT 
in ethanol (0.75 mM) was added, followed by the addition of 0.5 ml of 30 % TCA. Tubes 
were vortexed and allowed to stand in ice-bath for 2 h. Tubes were then centrifuged at 
2,000 rpm for 15 min and 1.0 ml of the supernatant of each tube was transferred to 
another tube. To each tube, 75 \x\. of 100 mM EDTA and 250 |al of 1 % thiobarbituric acid 
in 50 mM NaOH was added, mixed and kept in a boiling water bath for 15 min. After 
cooling the tubes to room temperature the absorbance of each sample was read against a 
reagent blank at 532 nm in a Beckman DU 640 spectrophotometer. Malondialdehyde was 
used as a standard for the calculation of MDA concentration (Liu et al, 1982J. 
2.2.2.15 Determination of triglyceride, free fatty acid and total cholesterol in liver 
and kidney homogenates 
The method of Folch et al. (1957) was employed for the extraction of Lipid 
contents from liver and kidney homogenates. One ml of liver and kidney homogenate 
was mixed with 5.0 ml of chloroform: methanol (2:1), followed by centrifligation at 
1,000 rpm for 5 min to separate the phases. Most of the upper layer was removed and 3.0 
ml of the lower chloroform layer was recovered. The chloroform layer was placed in a 
test tube and incubated at 45°C till dryness. The lipid residues were dissolved in 1.0 ml of 
chloroform. One hundred microliter of samples (in triplicate) was taken for the 
determination of triglyceride in liver and kidney, by using enzymatic kit. The method 
uses a modified Trinder color reaction to produce a fast, linear, end point reaction 
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(Trinder, 1969). The intensity of the color produced after incubation is directly 
proportional to the concentration of the triglyceride in the samples when measured at 500 
nm in a Beckman DU 640 spectrophotometer. Triglyceride was calculated by using a 
triolein standard. 
Free fatty acid in liver and kidney were estimated as described by Buncombe 
(1963). The above dissolved lipid residues (500 ^1) in chloroform was taken and free 
fatty acid was determined as described for plasma (page no. 53). 
For the determination of total cholesterol in liver and kidney homogenates the 
method of Annino and Giese (1976) was used, with a minor modification. Fifty microliter 
of lipid residues in chloroform was mixed with 500 \x\ of isopropanol, allowed to stand 
for 5 min and centrifuged at 3,000 rpm for 10 min. A suitable aliquot of isopropanol 
extract was used and cholesterol was estimated as described earlier (page no. 56). 
2.2.2.16 Estimation of lipid peroxides in plasma, liver and kidney homogenates 
For the extraction of Lipid contents from plasma and tissues, the method of Folch 
et al. (1957) was employed. One volume of plasma or tissue homogenate was mixed with 
5.0 volume of chloroform: methanol (2:1), followed by centriftigation at 1,000 rpm for 5 
min to separate the phases. Most of the upper layer was removed; and 3.0 ml of the lower 
chloroform layer was recovered. The chloroform layer was placed in a test tube and 
incubated at 45°C till dryness. For the determination of conjugated diene in plasma, liver 
and kidney, corresponding lipid residues were dissolved in 1.5 ml of cyclohexane and the 
absorbance was recorded at 234 nm against a cyclohexane blank in a Beckman DU 640 
spectrophotometer. The concentration of conjugated diene formation was calculated by 
using a molar extinction coefficient of 2.52 x 1 O^'M" cm'". 
In another experiment, quantification of lipid hydroperoxide was done according 
to the method Nourooz-Zadeh e/ al. (1996). The dried residues extracted from liver and 
kidney homogenates were dissolved in methanol and 90 \x\ of the samples or plasma were 
transferred into 1.5 ml microcentriftige tubes together with 10 \x\ of methanol (in 
triplicate) or 10 )al of 10 mM triphenyl phosphine (TPP) in methanol (in triplicate). The 
samples were then vortexed and incubated for 30 min at 25°C, followed by the addition 
of 900 \x\ of a reagent containing 250 mM ammonium sulphate, 100 mM xylenol orange, 
25 mM sulphuric acid and 4 mM BHT in 90 % methanol. The samples were incubated 
for additional 30 min at 25°C, and centrifuged at 12,000 rpm for 10 min prior to the 
determination of the absorbance of the supematants at 560 nm in a Beckman DU 640 
spectrophotometer. The levels of lipid hydroperoxide in tissue homogenates and plasma 
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samples was then determined using tlie difference between the mean absorbance of 
samples with and without TPP pretreatment. Hydroperoxide contents were determined 
using a molar absorption coefficient of 4.3 x lO"* M"' cm' . 
Lipid peroxide contents in plasma were assayed by the method of Yagi (1987). 
Plasma (25 ^1) was mixed with 4.0 ml of 0.083 N H2SO4 followed by the addition of 0.5 
ml of 10 % phosphotungstic acid. The samples were mixed and incubated for 5 min at 
room temperature and then centrifuged at 3,000 rpm for 10 min. The supernatant was 
discarded and the sediment was mixed with 2.0 ml of 0.083 N H2SO4 and 0.3 ml of 10 % 
phosphotungstic acid. The mixture was centrifuged at 3,000 rpm for 10 min, the sediment 
was suspended in 4.0 ml of water and 1.0 ml of TBA reagent (a mixture containing equal 
volumes of 0.67 % aqueous TBA solution and glacial acetic acid) was added. The 
reaction mixture was heated for 60 min at 95°C, cooled and the tubes were centrifiiged at 
3,000 rpm for 10 min. The absorbance of the supernatant was determined at 532 nm 
against a reagent blank in a Beckman DU 640 spectrophotometer. The concentration of 
MDA was calculated by using a standard malondialdehyde (Liu et al, 1982). 
The method of Ohkawa et al. (1979) was used for the determination of Lipid 
peroxides in liver and kidney homogenates. To 100 \i\ of 10 % liver or kidney 
homogenate samples, 200 \i\ of 8.1 % SDS, 1.5 ml of 20 % acetic acid (pH 3.5) and 1.5 
ml of 0.8 % aqueous solution of TBA were added and mixed. The mixture was made up 
to 4.0 ml with water and heated in a water bath for 60 min at 95°C. After cooling, the 
samples were centrifuged at 3,000 rpm for 5 min and the supernatant of each sample was 
read at 532 nm against a reagent blank in a Beckman DU 640 spectrophotometer. 
Malondialdehyde was used as a standard for the calculation of MDA concentration (Liu 
etal, 1982;. 
2.2.2.17 Assay of HMG-CoA reductase activity in liver homogenate 
HMG-CoA reductase enzyme activity in liver homogenate was estimated 
indirectly as described by Rao and Ramakrishnan (1975). Fresh 10 % tissue homogenate 
(1 g) were mixed with 9 ml of saline arsenate (0.1 % sodium arsenate in physiological 
saline) and 10 ml of 5 % perchloric acid was added, kept for 5 min at room temperature 
and centrifuged at 2,000 rpm for 10 min. One ml of the supernatant from each tube was 
taken out and mixed with 0.5 ml of freshly prepared 1 M aqueous hydroxylamine 
hydrochloride, whereas for the assay of HMG-CoA, 0.5 ml of alkaline hydroxylamine 
hydrochloride were added and mixed. After an incubation of 5 min at room temperature, 
1.5 ml of a 0.616 M ferric chloride reagent containing 5.2 % TCA, prepared in 0.65 N 
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HCI was added, mixed and absorbance was read at 540 nm against a reagent blank in a 
Beckman DU 640 spectrophotometer after 10 min of incubation at room temperature. 
2.2.2.18 Activities of antioxidant enzymes 
2.2.2.18.1 Determination ofcatalase activity in erythrocytes, liver and kidney 
The enzymatic activity of catalase in erythrocytes hemolysate and post-
mitochondrial supernatant (PMS) of Hver and kidney was measured by the procedure 
described by Sinha (1972). The reaction was carried out in a total volume of 1.0 ml 
containing 10 mM phosphate buffer, pH 7.0 and erythrocytes hemolysate equivalent to 
22-33 |ig hemoglobin, 1053-1144 ^g liver or 698-781 \i% kidney PMS protein. After a 
preincubation of 10 min at 30 C, the reaction was started by the addition of hydrogen 
peroxide resulting in a final concentration of 100 mM and the tubes were incubated for 5 
or 10 min at 30''C. At the end of incubation, the reaction was terminated by the addition 
of 1.0 ml of potassium dichromate-acetic acid reagent, prepared by mixing 1 volume of 5 
% aqueous solution of potassium dichromate with 3 volumes of glacial acetic acid. For 
zero time control, hydrogen peroxide was added after stopping the reaction. The tubes 
were heated in a boiling water bath for 15 min, cooled and the optical density was 
measured at 590 imi against a reagent blank in a Beckman DU 640 spectrophotometer. 
Liver, kidney and erythrocytes catalase activity was calculated by using a standard 
hydrogen peroxide calibration curve. 
2.2.2.18.2 Determination of superoxide dismutase activity in erythrocytes, liver and 
kidney 
Enzymatic activity of superoxide dismutase (SOD) in erythrocytes hemolysate 
and PMS fraction of liver and kidney was determined by the method as described by 
Kakkar et al. (1984). The assay mixture containing 52 mM sodium pyrophosphate buffer, 
pH 8.3, 300 ^M nitroblue tetrazolium, 186 )LIM phenazine methosulphate and 
erythrocytes hemolysate equivalent to 44-66 |ig hemoglobin, 1053-1144 |j,g liver or 698-
781 |ag kidney PMS protein was preincubated for 5 min at 30°C and the reaction was 
initiated by the addition of NADH (780 ^M), by incubating the samples for different time 
intervals at 30°C. The reaction was stopped by the addition of 0.5 ml of glacial acetic acid 
at 1 min time interval up to 4 min. For zero time control, to the above incubation mixture, 
0.5 ml of glacial acetic acid was added prior to the addition of NADH. To each tube 
including reagent blank 2.0 ml of n-butanol was added, rigorously extracted and 
centrifuged at 3,000 rpm for 5 min, color intensity of the chromogen in the butanol 
extract was measured at 560 nm against a reagent blank in a Beckman DU 640 
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spectrophotometer. Superoxide dismutase activity was calculated in terms of an arbitrary 
unit, which is defined as the enzyme concentration required to inhibit the chromogen 
formation by 50 % in one min under the above assay conditions. 
2.2.2.18.3 Determination of glutathione peroxidase activity in erythrocytes, liver and 
kidney 
Glutathione peroxidase (Gpx) activity in erythrocytes hemolysate and liver and 
kidney homogenate was assayed by a modification of Mill's procedure 2 (1959) as 
reported by Hafeman et al. (1974). The reaction mixture contained 80 mM sodium 
phosphate buffer, 80 i^ M EDTA, pH 7.0, 1 mM sodium azide, 400 \xM GSH and 
erythrocytes hemolysate equivalent to 22-33 ^g hemoglobin, 698-725 )ug liver or 398-
440 pg kidney homogenate protein in a total volume of 0.5 ml reaction mixture. After a 5 
min preincubation at 37 C, the reaction was started by the addifion of hydrogen peroxide 
(250 pM) and the tubes were incubated for 2, 4, 6 and 8 mins at ?>1^C. At the indicated 
time intervals, the reaction was terminated by the addition of 0.5 ml 10 % TCA. The 
tubes were centrifuged at 3,000 rpm for 10 min and 0.5 ml supernatant from each tube 
was added to tubes containing 2.0 ml of 0.4 M sodium phosphate buffer, 0.4 mM EDTA, 
pH 7.0 and 0.5 ml of 1 mM 5, 5'-dithiobis (2-nitrobezoic acid, DTNB). The samples were 
mixed and optical density was recorded at 412 nm against a reagent blank within 2 min of 
DTNB addition in a Beckman DU 640 spectrophotometer. The erythrocytes, liver and 
kidney glutathione peroxidase activity was calculated after deducting the OD value of 
samples from the zero time control values by utilizing a standard glutathione. 
2.2.2.18.4 Assay of glutathione reductase activity in erythrocytes, liver and kidney 
The method of Carlberg and Mannervik (1975) was employed for the 
determination of Glutathione reductase (Gred) activity. The incubation mixture consisted 
of 82.5 mM sodium phosphate buffer containing 25 pM EDTA, pH 7.6, 25 pM oxidized 
glutathione and erythrocytes hemolysate equivalent to 22-33 pg hemoglobin, 526-572 pg 
liver or 349-391 pg kidney PMS protein. After a 5 min preincubation at 25°C, the 
reaction was started by the addition of NADPH (5 pM) and the tubes were incubated for 
1-4 min at 25°C. The reaction was terminated at 1 min time interval by incubating the 
samples in an ice-bath. Zero time control tubes were prepared as above except 5 pM 
NADPH was added after stopping the reaction. The absorbance of each sample was 
recorded at 340 am against a reagent blank in a Beckman DU 640 spectrophotometer. By 
using the zero time control value the enzyme activity was calculated on the basis of a 
molar extinction coefficient of NADPH (6.22x10^M"'cm"'). 
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2.2.2.18.5 Determination of glutathione-S-transferase activity in liver and kidney 
Glutathione-S-transferase (GST) activity was measured in PMS fraction of liver 
and kidney by the method of Habig et al. (1974). The assay was carried out in a total 
volume of 1.0 ml containing 100 mM potassium phosphate buffer, pH 6.5, 1 mM GSH 
and 263-286 ^g liver or 174-196 jig kidney PMS protein. The samples were preincubated 
for 10 min at 30°C, the reaction was started by the addition of 1-chloro 2, 4-
dinitrobenzene (CDNB) prepared in absolute ethanol (1 mM) followed by an incubation 
for 2 and 4 min at 30°C. At the end of incubation the tubes were placed in an ice-bath for 
15 min, after which the optical density was recorded at 340 nm against a reagent blank in 
a Beckman DU 640 spectrophotometer. The GST activity was calculated on the basis of 
molar extinction coefficient of CDNB (9.6 x 10^  M"'cm"') after an appropriate deduction 
of zero time control values. 
2.2.2.19 Determination of total, free and protein-bound-sulfhydryl content of 
glutathione in liver and kidney 
The total sulfhydryl content of glutathione in liver and kidney homogenate was 
determined by the method of Ellman (1959) as modified by Sedlack and Lindsay (1968). 
The incubation mixture contained 60 mM tris buffer and 6 mM EDT A, pH 8.2, 1.4-1.48 
mg liver or 0.797-0.897 mg kidney protein and 0.2 mM DTNB. The reaction mixture was 
mixed and made up to 5.0 ml by the addition of 3.2 ml absolute methanol. The tubes were 
centrifiiged at 6,000 rpm for 5 min at 4°C and the absorbance of the clear supematants 
were read at 412 nm against a reagent blank in a Beckman DU 640 spectrophotometer. 
The total glutathione content was calculated by using a standard curve of reduced 
glutathione. 
For the determination of free sulfhydryl group of glutathione content in liver and 
kidney homogenate, the method of Ellman (1959) as modified by Sedlack and Lindsay 
(1968) was employed. In order to assay free sulfhydryl content of glutathione, 0.5 ml of 
10 % homogenate was precipitated by the addition of 0.5 ml of 4 % sulphosalicylic acid 
(Jollow et al, 1974). The samples were incubated for 1 h at 4°C, centrifuged at 6,000 
rpm for 5 min and 0.5 ml aliquots of the supernatant were used for the assay of free 
sulfhydryl group. The reaction mixture contained 267 mM tris buffer, 13 mM EDTA, pH 
8.9 and 0.33 mM DTNB (prepared in absolute methanol). The absorbance of the sample 
was read against a reagent blank at 412 nm within 2 minutes of DTNB addition. Free 
sulfhydryl content in the samples were calculated using a standard calibration curve of 
reduced glutathione. The protein bound sulfhydryl content of glutathione was calculated 
as the difference between total and free sulfhydryl content of glutathione. 
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Free sulfhydryl group of glutathione content in packed erythrocytes was 
determined essentially by the method of Ellman (1959) as modified by Sedlack and 
Lindsay (1968). Briefly, to 100 and 200 fal of washed packed erythrocytes, 1.0 ml of 10% 
TCA was added, mixed and incubated for 1 h at 4°C. At the end of incubation, the tubes 
were centrifuged at 1,200 rpm for 20 min at 4°C and 0.5 ml of the supernatant was used 
for the quantification of free sulfhydryl group. The free sulfhydryl group of erythrocytes 
was determined according to the procedures described above for liver and kidney 
homogenate, except 1.7 mM DTNB was used. 
2.2.2.20 Protein estimation 
The protein was determined by the method of Bradford (1976), using bovine 
serum albumin as standard. Aliquots of liver and kidney homogenates, PMS, LDL, sd-
LDL, Ib-LDL and HDL were first precipitated with 10 % TCA. The protein pellets were 
dissolved in 0.5 N NaOH and suitable aliquots were used for protein determination. 
2.2.2.21 Statistical evaluation 
Statistical analysis of data was done by employing two-tailed Student t- test as 




3.1 Antioxidative Activities of Tocomin, a-Tocotrienol, y-Tocotrienol, 5-TocotrienoI 
and a-Tocopherol 
Antiradical activity or liydrogen donating ability of Tocomin, a-tocotrienol, 
y- tocotrienol, 5-tocotrienol and a-tocopherol was measured by using 2, 2-diphenyl, 
1-picrylhydrazyl (DPPH), which reflects the antioxidative properties of these 
compounds. As shown in Fig. 3.1, the half quenching concentrations (IC50) were as 
follows: Tocomin, 50.27 |iM; a-tocotrienol, 46.94 \iM; y-tocotrienol, 44.56 |iM; 
6-tocotrienol, 38.13 |aM; and a-tocopherol, 70.68 ^M. These findings indicate that as 
compared to a-tocopherol, y-, a-and 5-tocotrienols were more efficient scavengers of 
peroxyl radicals by 37 %, 34 % and 46 %, respectively. Since Tocomin is a mixture of 
a-tocotrienol (25.6 %), y-tocotrienol (40.8 %), 5-tocotrienol (12.8 %) and a-tocopherol 
(22.8 %), its efficiency as a scavenger of peroxyl radical was higher by 29 %, in 
comparison to a-tocopherol. The reduction in the quenching efficiency of Tocomin in 
comparison to a-, y- and 5-tocotrienols is apparently due to the presence of 23 % 
a-tocopherol, which has a lowest peroxyl radical scavenging efficiency of 70.75 pM. 
3.2 Impact of Tocomin pretreatment on Plasma Lipids, Plasma Lipoprotein Lipids, 
Hepatic HMG-CoA Reductase Activity, and Lipid Peroxidation Status in 
Plasma, Liver, Kidney and Erythrocytes in LPS, Turpentine or Zymosan 
Stressed Hamsters 
3.2.1 Effect on plasma lipids 
Experimentally induced infection and inflammation in hamsters by LPS (acute 
systemic infection), turpentine (acute localized sterile inflammation) or zymosan (acute 
noninfectious systemic inflammation) had a profound impact on lipid parameters when 
compared to normal hamsters. As shown in Table 1, plasma total lipid (TL), triglyceride 
(TG), and free fatty acid (FFA) significantly increased from 427, 186, and 109 mg/dl in 
N-C to 663, 311, and 180 mg/dl, respectively, in LPS control group (L-C), after 12 h of 
LPS administration. Treatment of LPS stressed hamsters with Tocomin (L-Ti) for 10 
days before and 12 h after LPS injection, resulted in a significant decline in TL, TG, 
and FFA levels by 21 %, 19 %, and 16 %, respectively, when compared to 
corresponding L-C values. Whereas, feeding of Tocomin to hamsters (L-T2) along with 
LPS injection, 12 h prior to killing, failed to affect the above lipid parameters, when 
compared to corresponding values in L-C group. After 24 h of turpentine injection to 
hamsters in T-C group, TL, TG, and FFA levels were significantly increased by 25 %, 
37 %, and 29 %, respectively, in comparison to corresponding values in N-C group. 
Administration of Tocomin to turpentine stressed hamsters (T-T) for 10 days before and 
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Fig. 3.1. Free radical scavenging activities of Tocomin, a-tocotrienol, y-tocotrienol, 
6-tocotrienol and a-tocopherol. The antioxidant activities of the above compounds at 
the indicated concentrations were carried out as described in methods. The assay is 
based on the reduction of 2,2-diphenyl, l-picrylhydrazyl (DPPH), which gives strong 
absorption maxima at 517nm. Values represent the mean of triplicate determinations. 
The average error in the data points in these assay were mean ± less than 3 %. The 
average absolute absorbance value of 100 % DPPH was 0.00784 ± 0.00026. 
TABLE 1 
EFFECT OF TOCOMIN PRETREATMENT ON PLASMA TOTAL LIPID, 
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Values are mean (mg/dl) 1 SD from pooled plasma of 5 hamsters in each group 
except L-T2 (n=3). 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; N-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
saline injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, 
fed 10 mg Tocomin/hamster/day, 10 days before and 12 h after LPS injection; L-T2, 
administered LPS and 5 mg Tocomin/hamsters simultaneously, 12 h prior to 
killing; T-T, Z-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
turpentine or zymosan injection. 
Significantly different from N-C at ''p<0.001. 
Significantly different from L-C at ''p<0.001. 
Significantly different from T-C at ''p<0.001. kjbi»^**'^  
Significantly different from Z-C at ''p<0.001. v i^^ 
Results 
24 h after turpentine injection, resulted in a significant decline in TL, TG, and FFA 
levels by 8 %, 19 %, and 14 %, respectively, when compared to corresponding T-C 
values. Similarly, after 24 h of zymosan injection (Z-C), TL, TG, and FFA levels were 
significantly increased by 38 %, 48 %, and 48 %, respectively, in comparison to 
corresponding values in N-C group. Feeding of Tocomin to zymosan stressed hamsters 
(Z-T) for 10 days before and 24 h after zymosan injection, resulted in a significant 
decrease in TL, TG, and FFA levels by 21 %, 16 %, and 13 %, respectively, when 
compared to corresponding values in Z-C group. These results demonstrate that TL, 
TG, and FFA levels were significantly increased in LPS, turpentine or zymosan stressed 
hamsters. Treatment with Tocomin significantly blocked the increase in above lipid 
parameters. 
As depicted in Table 2, after 12 h of LPS administration to hamsters, total 
cholesterol, free cholesterol and esterified cholesterol significantly increased from 158, 
40 and 118 mg/dl, respectively, in N-C to 243, 100 and 144 mg/dl in L-C group. 
Whereas, LCAT activity in L-C was significantly reduced by 107 %, in comparison to 
N-C value. Tocomin pretreatment to LPS stressed hamsters (L-Ti) blocked the increase 
in total cholesterol, free cholesterol and esterified cholesterol and restored their levels to 
86 %, 60 and 99 %, respectively, of corresponding N-C values. On the other hand, 
LCAT activity in L-Ti was significantly decreased by 66 % in comparison to N-C 
value. However, the above parameters were not significantly affected when LPS and 
Tocomin were administered simultaneously to hamsters, 12 h prior to killing. In 
turpentine stressed hamsters (T-C), total cholesterol, free cholesterol and esterified 
cholesterol were significantly increased by 29 %, 53 % and 22 %, respectively, in 
comparison to corresponding values in N-C. Whereas, the plasma LCAT activity was 
significantly reduced by 26 %, when compared to N-C value. Feeding of Tocomin to 
turpentine stressed hamsters (T-T) for 10 days before and 24 h after turpentine injection, 
significantly prevented the increase in total cholesterol, free cholesterol and esterified 
cholesterol levels and restored them to 90 %, 81 % and 93 %, respectively, whereas a 
decrease of only 15 % in LCAT was seen, when compared to corresponding values in 
N-C. Similarly, after 24 h of zymosan injection (Z-C), total cholesterol, free cholesterol 
and esterified cholesterol were significantly increased by 33 %, 94 % and 13 %, 
respectively, when compared to corresponding values in N-C group. In contrast, when 
compared to N-C value, LCAT activity was significantly reduced by 72 %. Tocomin 
pretreatment to zymosan stressed hamsters (Z-T) restored the total cholesterol, 
free cholesterol and esterified cholesterol levels by 81 %, 73 % and 96 %, respectively, 
of corresponding N-C values. As expected, in comparison to N-C value, a significant 
70 
TABLE 2 
IMPACT OF TOCOMIN PRETREATMENT ON PLASMA TOTAL 
CHOLESTEROL, FREE CHOLESTEROL, ESTERIFIED CHOLESTEROL AND 
LECITHIN CHOLESTEROL ACYLTRANSFERASE ACTIVITY IN THREE 






















































































^Expressed as ratio of free cholesterol to esterified cholesterol; higher the ratio 
lower the enzyme activity. 
Values are mean 1SD from pooled plasma of 5 hamsters in each group except L-T2 
(n=3). 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; N-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
saline injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, 
fed 10 mg Tocomin/hamster/day, 10 days before and 12 h after LPS injection; L-T2, 
administered LPS and 5 mg Tocomin/hamsters simultaneously, 12 h prior to 
killing; T-T, Z-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
turpentine or zymosan injection. 
Significantly different from N-C at ''p< 0.001. 
Results 
decline of only 33 % in LCAT activity was observed in Z-T hamsters. The results 
indicate that total cholesterol in LPS, turpentine or zymosan stressed hamsters were 
significantly increased. This increase in plasma cholesterol level is accounted for by an 
increase in the percentage of free cholesterol from 25 % in N-C to 30 % to 41 % in 
stressed hamsters. The disproportionate increase in plasma free cholesterol versus 
esterified cholesterol in stressed hamsters resulted in a decreased plasma LCAT activity. 
Tocomin pretreatment to these hamsters significantly prevented the increase in TC, 
including free and esterified cholesterol and restored these levels close to N-C value. 
Similarly, consistent with free and esterified cholesterol values, plasma LCAT activity 
in Tocomin pretreated groups was also increased. 
3.2.2 Effect on plasma lipoprotein lipids 
As shown in Table 3, plasma VLDL-C, LDL-C and non-HDL-C levels were 
significantly increased from 37, 87 and 123 mg/dl in N-C to 62, 149 and 210 mg/dl, 
respectively, in LPS stressed (L-C) group, after 12 h of LPS injection. On the other 
hand, in L-C, there was a little (6 %) but significant decrease in HDL-C level. 
Pretreatment of Tocomin to LPS stressed hamsters (L-Ti), significantly decreased the 
VLDL-C, LDL-C and non-HDL-C levels by 19 %, 32 %, and 28 %, respectively, when 
compared to corresponding L-C values. In contrast, an increase of only 3 % in HDL-C 
was seen after Tocomin pretreatment. A significant increase of 37 %, 39 % and 39 % 
was observed in VLDL-C, LDL-C and non-HDL-C levels, respecfively, after turpentine 
injection (T-C). Whereas, HDL-C level was decreased by 3 %, when compared to N-C 
value. Tocomin pretreatment to turpentine stressed hamsters (T-T), resulted in a 
significant decline in VLDL-C, LDL-C and non-HDL-C levels by 19 %, 20 % and 19 
%, respectively, whereas, HDL-C level was increased by 12 %, when compared to 
corresponding T-C values. Similarly, after 24 h of zymosan injection (Z-C), VLDL-C, 
LDL-C and non-HDL-C levels were significantly increased by 48 %, 45 % and 47 %, 
respectively, when compared to corresponding N-C values. In contrast, HDL-C level 
was significantly decreased by 17 %, when compared to value in N-C group. 
Pretreatment of these hamsters with Tocomin (Z-T), resulted in a significant reduction 
in VLDL-C, LDL-C and non-HDL-C levels by 16 %, 21 % and 20 %, respectively. In 
Z-T, HDL-C was significantiy increased by 10 %, when compared to Z-C value. These 
results demonstrate that pretreatment of Tocomin significantly prevented the increase in 
VLDL-C, LDL-C and non-HDL-C levels showing its lipid lowering properties in LPS, 
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Results 
3.2.3 Effect on plasma LDL, small dense LDL and large buoyant LDL subfractions 
Table 4 shows plasma LDL-C, LDL-apoB, small dense (sd-) LDL-C, 
sd-LDL-apoB, large buoyant (lb-) LDL-C and Ib-LDL-apoB concentrations. In normal 
hamsters, LDL-C and its apoB content were 87 and 120 mg/dl, respectively. The 
cholesterol and apoB content of sd-LDL, isolated from LDL particle, were 26 and 32 
mg/dl, respectively, whereas, cholesterol and apoB concentrations associated with Ib-
LDL were 61 and 88 mg/dl. In comparison to values in N-C, LPS stressed hamsters 
(L-C) showed a significant increase in plasma LDL-C from 87 to 149 mg/dl (70 %) and 
LDL-apoB content from 120 to 135 mg/dl (13 %). In contrast, sd-LDL-C level was 
substantially and significantly increased from 26 mg/dl in N-C to 89 mg/dl (238 %) in 
L-C hamsters, whereas, its apoB content was significantly increased by 153 %, when 
compared to corresponding values in N-C. On the other hand, in L-C hamsters, 
Ib-LDL-C and Ib-LDL-apoB levels were decreased only by 9 % and 38 %, respectively, 
in comparison to corresponding N-C values. Treatment of LPS stressed hamsters (L-Ti) 
with Tocomin for 10 days before and 12 h after LPS injection significantly reduced the 
LDL-C level by 32 % and its apoB content was decreased by 4 % only. Similarly, a 
significant decrease in cholesterol (55 %) and apoB (36 %) contents of sd-LDL was 
seen, when compared to corresponding L-C values. In comparison to values in L-C, 
cholesterol and apoB levels of Ib-LDL in L-Ti were increased by 9 % and 44 %, 
respectively. 
In normolipidemic hamsters, the percent wise distribution of cholesterol and 
apoB from LDL particle to sd-LDL and Ib-LDL fractions were 30 %, 27 %, 69 % and 73 
%, respectively. In L-C group, the percent sd-LDL-C and sd-LDL-apoB were 
significantly increased by 99 % and 125 %, when compared to the corresponding percent 
values in N-C. Whereas, the percent Ib-LDL-C and Ib-LDL-apoB in L-C hamsters were 
significantly decreased by 46 % and 45 %, in comparison to corresponding percent 
values of N-C hamsters. In Tocomin pretreated group (L-Ti), percent sd-LDL-C and 
sd-LDL-apoB levels were significantly reduced by 34 % and 33 %, respectively. In 
contrast, percent Ib-LDL-C and Ib-LDL-apoB in L-Ti hamsters were significantly 
increased by 61 % and 50 %, respectively, when compared to corresponding values in L-
C group. After 24 h of turpentine injection (T-C), plasma LDL-C and LDL-apoB levels 
were increased by 39 % and 4 %, respectively, when compared to corresponding N-C 
values. Whereas, in T-C, both sd-LDL-C and sd-LDL-apoB contents were significantly 
increased by 84 % and 44 %, respectively. In contrast, Ib-LDL-C was significantly 
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Results 
corresponding values in N-C. Similar to L-T|_ feeding of Tocomin to turpentine stressed 
hamsters (T-T) for 10 days before and 24 h after turpentine injection, resulted in a 
significant decline of 20 % in LDL-C level, whereas no decrease in LDL-apoB content 
was observed. In T-T hamsters, cholesterol and apoB concentrations associated with sd-
LDL were significantly decreased by 32 % and 16 % respectively, when compared to 
corresponding values in T-C group. On the other hand, in T-T hamsters, Ib-LDL-C were 
moderately decreased by 13 %, whereas, its apoB content was minimally increased by 
5 %, when compared to corresponding values in T-C group. In T-C group, the percent 
wise distribution of cholesterol and apoB from LDL to sd-LDL fraction was 
significantly increased by 33 % and 38 %, respectively. Whereas, both the percent 
Ib-LDL-C and its apoB in T-C hamsters were decreased by 14 %, when compared to 
corresponding N-C values. Pretreatment of these hamsters with Tocomin (T-T) 
significantly reduced the percent increase in sd-LDL-C and sd-LDL-apoB by 15 % and 
14 %, respectively. In contrast, percent Ib-LDL-C and Ib-LDL-apoB in T-T group were 
increased by 9 % and 8 %, respectively, when compared to corresponding percent values 
in T-C group. 
After 24 h of zymosan injection (Z-C), a significant increase in plasma LDL-C 
(45 %) level was seen, whereas its apoB content was increased only by 8 %, when 
compared to corresponding N-C values. Sd-LDL-C and sd-LDL-apoB content were 
substantially and significantly increased by 140 % and 95 %, respectively. In Z-C 
hamsters, an increase of only 4 % in Ib-LDL-C level was seen, whereas, Ib-LDL-apoB 
shows a significant decline of 23 %, when compared to corresponding values in N-C. 
Administration of Tocomin to zymosan stressed hamsters (Z-T) for 10 days before and 
24 h after zymosan injection, resulted in a significant decline of 21 % in LDL-C level, 
whereas, no significant decrease in LDL-apoB content was observed. The cholesterol 
and apoB content associated with sd-LDL significantly decreased by 45 % and 30 % 
respectively, when compared to corresponding values in Z-C group. On the other hand, 
in Z-T, level of Ib-LDL-C was not affected, whereas, its apoB content was significantly 
increased by 20 %, when compared to corresponding values in Z-C group. In Z-C 
hamsters, the percent wise distribution of cholesterol and apoB from LDL to sd-LDL 
fraction were significantly increased by 66 % and 81 %, respectively, when compared to 
corresponding values in N-C group. On the other hand, the percent Ib-LDL-C (28 %) 
and its apoB (29 %) in Z-C hamsters were significantly decreased. Pretreatment of 
zymosan stressed hamsters with Tocomin (Z-T) significantly reduced the percent 
increase in sd-LDL-C and sd-LDL-apoB by 31 % and 28 %, respectively. In contrast, 
percent Ib-LDL-C and Ib-LDL-apoB in Z-T hamsters were significantly increased by 31 
76 
..^•' ':%^'f::^ 
% and 24 %, respectively, when compared to corresponding percent values^ in/Z-C 
group. These results demonstrate that the prevalence and concentration of sd-LDL, 
which is considered more atherogenic than LDL, was substantially increased in LPS, 
turpentine or zymosan stressed hamsters. Pretreatment of Tocomin to stressed hamsters 
significantly reduced the sd-LDL concentrations to a level close to control value (N-C). 
3.2.4 Impact on the ratios ofLDL-C/HDL-C, HDL-C/TC and sd-LDL-C/HDL-C 
Data presented in Table 5 depicts LDL-C/HDL-C, HDL-C/TC and sd-LDL-
C/HDL-C ratios, calculated from the results presented in Table 2, 3 and 4. In L-C, T-C 
and Z-C hamsters, LDL-C/HDL-C ratios were substantially increased by 82 %, 43 % and 
74 %, respectively, when compared to value in N-C. Tocomin pretreatment to stressed 
hamsters significantly reduced these increases in LDL-C/HDL-C ratios and restored 
close to ratio value in N-C. On the other hand, the ratios of HDL-C/TC in L-C, T-C and 
Z-C hamsters were significantly decreased by 39 %, 25 % and 37 %, respectively, in 
comparison to N-C value. After Tocomin pretreatment, HDL-C/TC ratios in L-Ti, T-T 
and Z-T were significantly increased and restored by 84 %, 98 % and 82 % of control 
value. 
In N-C, when sd-LDL-C values were divided by HDL-C, a ratio of 0.751 was 
obtained, which is substantially lower than LDL-C/HDL-C ratio of 2.49. In LPS stressed 
hamsters (L-C), sd-LDL-C/HDL-C ratio was substantially increased to a ratio value of 
2.691 (258 %), when compared to N-C value. As expected, sd-LDL-C/HDL-C ratio in 
Tocomin pretreated hamsters (L-Ti) was significantly reduced to a value of 1.166 (55 
%). Similarly, sd-LDL-C/HDL-C ratio was significantly increased by 90 % (1.430) in 
turpentine stressed hamsters, when compared to an N-C value of 0.751. Tocomin 
pretreatment to these hamsters (T-T) significantly prevented the increase in sd-LDL-
C/HDL-C ratio and fully restored to a ratio value similar to N-C. In Zymosan stressed 
hamsters (Z-C), sd-LDL-C/HDL-C ratio was markedly increased to 2.16 (188 %), in 
comparison to N-C value. Pretreatment of zymosan stressed hamsters with Tocomin 
(Z-T) significantly blocked the increase in sd-LDL-C/HDL-C ratio (36 %) and restored 
by 73 % of N-C value. These results indicate that sd-LDL-C/HDL-C ratio may be 
considered as a better and novel predictor for CAD risks than LDL-C/HDL-C ratio. The 
ratio related to sd-LDL-C and HDL-C in Tocomin pretreated hamsters were positively 
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Results 
3.2.5 Hypolipidemic impact on liver and kidney triglyceride, total cholesterol and free 
fatty acid 
As evident from the data in Table 6, in comparison to corresponding values in 
N-C group, hepatic TG, TC and FFA levels in L-C group were significantly increased 
by 71 %, 32 % and 28 %, respectively. Similarly, kidney TG, TC and FFA levels were 
also increased by 62 %, 74 % and 30 %, respectively, when compared to corresponding 
N-C values. Pretreatment of LPS stressed hamsters with Tocomin (L-Ti) mediated a 
decline in liver TG, TC and FFA levels by 25 %, 12 % and 6 %, respectively, whereas, 
TG, TC and FFA levels in kidney were significantly decreased by 23 %, 25 % and 
15 %, respectively, when compared to corresponding L-C values. After 24 h of 
turpentine injection, a significant increase in hepatic TG (28 %), TC (16 %) and FFA 
(12 %) levels were observed in T-C group. Triglyceride, TC and FFA levels in kidney 
were significantly increased by 39 %, 46 % and 20 % respectively, when compared to 
corresponding values in N-C group. Tocomin pretreatment to turpentine stressed 
hamsters (T-T), caused a decrease in hepatic TG, TC and FFA levels by 11 %, 5 % and 
7 %, respectively, whereas, a reduction of 19 %, 16 % and 8 % in kidney TG, TC and 
FFA were observed in T-T group, when compared to corresponding values in T-C. 
Hepatic TG, TC and FFA levels in zymosan stressed hamsters (Z-C) were significantly 
increased by 28 %, 16 % and 12 %, respectively, whereas, a significant increase of 38 
%, 46 % and 21 % in kidney TG, TC and FFA levels was observed in Z-C. Tocomin 
pretreatment (Z-T) prevented the increase in hepatic TG, TC and FFA levels and 
decreased them by 11 %, 6 % and 7 %, respectively. Kidney TG, TC and FFA levels 
were decreased by 19 %, 15 % and 9 %, respectively, in Z-T, when compared to 
corresponding values in Z-C. The combined results demonstrate that hamsters 
administered with the above three infection and inflammatory agents, which are well 
characterized inducers of acute phase response, have mediated a significant increase in 
plasma, liver and kidney lipids, as well as, plasma lipoprotein lipids. Pretreatment of 
these stressed hamsters with Tocomin (10 mg/day/hamster) for 10 days before and 12 h 
after LPS or 24 h after turpentine or zymosan injection significantly blocked the 
increase in the above lipid parameters. 
3.2.6 Regulation of enzymatic activity of hepatic HMG-CoA reductase 
As shown in Table 7, hepatic HMG-CoA reductase activity in LPS stressed 
hamsters (L-C) was significantly increased by 55 %, when compared to N-C value. 
Feeding of Tocomin for 10 days before and 12 h after LPS injection (L-Ti) significantly 
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TABLE 7 
IN VIVO MODULATION OF HEPATIC HMG-CoA REDUCTASE ACTIVITY IN 
THREE GROUPS OF STRESSED HAMSTERS PRETREATED WITH TOCOMIN 









(-15.10 % f 
T-C 2.00910.019* 
(+40.70 % ) ' 
T-T 2.44610.020* 
(-21.75 % ) ' 
Z-C 1.80910.024* 
(+46.60 % ) ' 
Z-T 2.37610.077* 
(-31.34 Vof 
^Expressed as ratio of HMG-CoA to Mevelonate; lower the ratio higher the enzyme 
activity. 
Values are mean 1 SD from homogenate of pooled liver of 5 hamsters in each 
group except L-T2 (n=3). 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; N-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
saline injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Tj, 
fed 10 mg Tocomin/hamster /day, 10 days before and 12 h after LPS injection; L-T2, 
administered LPS and 5 mg Tocomin/hamsters simultaneously, 12 h prior to 
killing; T-T, Z-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
turpentine or zymosan injection. 
Significantly different from N-C at ''p< 0.001. 
Significantly different from L-C at ''p< 0.001. 
Significantly different from T-C at '•p< 0.001. 
Significantly different from Z-C at 'p< 0.001. 
Results 
49 %. However, the decline in HMG-CoA reductase activity of L-C hamsters 
simuhaneously treated with 5 mg Tocomin and LPS for only 12 h (L-Ti) was 
considerably less (15 %) than L-Ti group. In turpentine stressed hamsters, HMG-CoA 
reductase activity was significantly increased by 41 %, which was significantly 
decreased by 22 %, in Tocomin pretreated group (T-T). Similarly, in Z-C, a significant 
increase of 47 % was observed. Pretreatment with Tocomin (Z-T) caused a significant 
reduction of 31 % in HMG-CoA reductase activity, when compared to value in Z-C. 
These results demonstrate that Tocomin mediated decrease in elevated lipid parameters 
of LPS, turpentine or zymosan stressed hamsters, is due to decrease in the enzymatic 
activity of hepatic HMG-CoA reductase, the rate limiting enzyme in the biosynthetic 
pathway of cholesterol. 
3.2.7 Impact on plasma total antioxidants and lipid peroxidation products 
As seen in Table 8, feeding of tocotrienols (Tocomin) to normal hamsters for 10 
days (N-T) was associated with a significant increase of 13 % in plasma total 
antioxidants level, whereas, no significant effect of Tocomin was seen on plasma 
concentrations of conjugated diene, lipid hydroperoxide and malondialdehyde (MDA), 
when compared to corresponding N-C values. After 12 h of LPS injection (L-C), 
plasma total antioxidants was significantly reduced from a control value of 75 to 30 (61 
%) ^mole/dl, which was significantly increased to 61 (106 %) i^mole/dl in Tocomin 
pretreated hamsters (L-Ti). However, as expected, simultaneous administration of LPS 
and Tocomin to hamsters (L-T2), 12 h prior to killing, caused a significantly lower 
increase (19 %) in plasma total antioxidants than seen in L-Ti hamsters. Plasma 
conjugated diene, lipid hydroperoxide and MDA were significantly increased by 109 
%, 145 %, and 172 %, respectively, in L-C, which were significantly reduced by 29 %, 
35 % and 46 %, respectively after Tocomin pretreatment (L-Ti). In contrast, feeding of 
Tocomin along with LPS injection for only 12 h (L-T2) failed to influence plasma 
conjugated diene, lipid hydroperoxide and MDA. Similar to results in L-C, turpentine 
stressed hamsters (T-C) also showed a significant decline of 33 % in plasma total 
antioxidants, whereas, due to increase in oxidative stress, formation of conjugated 
diene, lipid hydroperoxide and MDA in plasma were significantly increased by 70 %, 
77 % and 79 %, respectively, in comparison to corresponding values in N-C. Tocomin 
pretreatment to turpentine stressed hamsters, significantly increased the plasma total 
antioxidants level by 40 %. Conjugated diene and lipid hydroperoxide were 
significantly decreased by 19 % and 29 %, respectively, whereas, a 21 % decrease in 
MDA was not significant, when compared to corresponding values in T-C. Similarly, 
82 
TABLE 8 
ANTIOXIDANT IMPACT OF TOCOMIN PRETREATMENT ON PLASMA TOTAL 
ANTIOXIDANTS, CONJUGATED DIENE, LIPID HYDROPEROXIDE AND MDA IN 
THREE GROUPS OF STRESSED HAMSTERS 
Group Total antioxidants Conjugated diene Lipid hydroperoxide MDA 

































































Values are mean (^mole/dl) 1SD from pooled plasma of 5 hamsters in each group except 
L-T2(n=3). 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline injection; N-
T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after saline injection; L-C, T-C, 
Z-C, LPS, turpentine or zymosan stressed control; L-Ti, fed 10 mg Tocomin/hamster /day, 
10 days before and 12 h after LPS injection; L-T2, administered LPS and 5 mg 
Tocomin/hamsters simultaneously, 12 h prior to killing; T-T, Z-T, fed 10 mg 
Tocomin/hamster/day, 10 days before and 24 h after turpentine or zymosan injection. 
Significantly different from N-C at ''p< 0.001. 
Significantly different from L-C at ''p< 0.001 and *not significant. 
Significantly different from T-C at "p< 0.001 and *not significant. 
Significantly different from Z-C at ^p< 0.001 and *not significant. 
Results 
in Z-C, plasma total antioxidants level was significantly decreased by 40 %, whereas, 
plasma conjugated diene, lipid hydroperoxide and MDA were significantly increased 
by 75 %, 99 % and 89 %, respectively, when compared to corresponding N-C values. 
Pretreatment of zymosan stressed hamsters with Tocomin (Z-T) significantly increased 
the plasma total antioxidants level by 44 %. On the other hand, conjugated diene, lipid 
hydroperoxide and MDA were decreased by 13 %, 36 % and 27 %, respectively; 
however, the decrease in MDA was insignificant, when compared to corresponding 
values in Z-C. These results demonstrate that in stressed hamsters, due to increase in 
oxidative stress, plasma total antioxidants level was decreased, whereas, plasma 
conjugated diene, lipid hydroperoxide and MDA were significantly increased. Tocomin 
(tocotrienols) pretreatment significantly restored the plasma total antioxidants level and 
blocked the increase in plasma conjugated diene, lipid hydroperoxide and MDA to a 
level close to normal value. 
3.2.8 Effect on membrane lipid peroxidation in erythrocytes 
Since, infection and inflammatory diseases are characterized by excess 
generation of oxygen free radicals, which exhibit erythrocytes membrane lipid 
peroxidative damage in vivo, we have examined the cause of this membrane damage by 
quantifying an end product of fatty acid peroxidation, namely, malondialdehyde 
(MDA). As shown in Table 9, MDA content of erythrocytes hemolysate was increased 
from 9.2 in N-C tol4.0 nmole/g Hb in L-C. In comparison to MDA value in L-C, 
MDA content in L-T] was significantly decreased by 14 %. In T-C, erythrocytes MDA 
content was significantly increased by 26 %, in comparison to value in N-C, which was 
reduced by 10 %, after Tocomin pretreatment (T-T). In zymosan stressed hamsters, a 
significant increase of 30 % in MDA content was seen, when compared to N-C value. 
Pretreatment of zymosan stressed hamsters with Tocomin significantly prevents the 
increase in MDA content and decreased it by 13 %, in comparison Z-C value. 
Furthermore, erythrocytes from LPS stressed group showed a greater susceptibility to 
hydrogen peroxide-induced lipid peroxidation than those fi-om N-C group. A significant 
increase of 109 % in the release of MDA in L-C was observed, when compared to N-C 
value. Formation of MDA was markedly decreased by 31 % in Tocomin pretreated 
hamsters (L-Ti). The release of MDA was significantly increased by 54 % in turpentine 
stressed hamsters (T-C), in comparison to N-C value. Pretreatment of turpentine 
stressed hamsters with Tocomin significantly prevented the increase in MDA release 
and reduced it by 20 %. Similarly, percent MDA release was increased from 29 in N-C 
to 50 in zymosan stressed group (Z-C). Tocomin pretreatment to zymosan stressed 
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TABLE 9 
IMPACT OF TOCOMIN PRETREATMENT ON ERYTHROCYTES MDA AND 
IN VITRO MDA RELEASE IN THREE GROUPS OF STRESSED HAMSTERS 
MDA Erythrocytes MDA release 
^"«"P (nmole/gHb) (percent) 
N-C 9.20±0.082 28.67±0.867 
L-C 14.01±0.167 60.04+0.55* 
(+52.28 %)" (+109.41 %)" 
L-Ti 12.03+0.138 41.48+1.03* 
(-14.13 %)" (-30.91 %)" 
T-C 11.59+0.128 44.12+0.819* 
(+25.97%)" (+53.88%)" 
T-T 10.43±0.127 35.37±0.731* 
(-10.008 %)" (-19.83 %))" 
Z-C 11.98±0.135 49.61±0.957* 
(+30.21 %)" (+73.03 %)" 
Z-T 10.46±0.124 39.7011.55* 
(-12.68 %)" (-19.97 %)" 
Values are mean ± SD from pooled packed erythrocytes of 5 hamsters in each group. 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline injection; N-
T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after saline injection; L-C, T-C, 
Z-C, LPS, turpentine or zymosan stressed control; L-Ti, fed 10 mg Tocomin/hamster /day, 
10 days before and 12 h after LPS injection; T-T, Z-T, fed 10 mg Tocomin/hamster/day, 10 
days before and 24 h after turpentine or zymosan injection. 
Significantly different from N-C at "p< 0.001. 
Significantly different from L-C at "p< 0.001. 
Significantly different from T-C at ''p< 0.001. 
Significantly different from Z-C at ''p< 0.001. 
Results 
hamsters significantly blocked the increase in MDA release and decreased it by 20 %, 
when compared to Z-C value. These results demonstrate that the induction of infection 
and inflammation in hamsters is associated with a significant increase in erythrocytes 
membrane lipid peroxidation, which is significantly prevented by the administration of 
Tocomin. 
3.2.9 Impact on liver and kidney lipid peroxidation products 
As depicted in Table 10, conjugated diene, lipid hydroperoxide and MDA in 
liver were increased from 5.99, 1.53 and 3.51 in N-C to 7.51 (25 %), 2.40 (57 %) and 
4.78 (36 %) nmole/mg protein, respectively, in LPS stressed hamsters (L-C). Similarly, 
in L-C, kidney conjugated diene, lipid hydroperoxide and MDA were significantly 
increased by 31 %, 48 % and 25 %, respectively, in comparison to corresponding 
values in N-C. After Tocomin pretreatment (L-T|), the increase in hepatic conjugated 
diene, lipid hydroperoxide and MDA were significantly prevented and reduced by 7 %, 
25 % and 21 %, respectively. Formations of conjugated diene, lipid hydroperoxide and 
MDA in kidney were also reduced by 7 %, 10 % and 15 %, respectively, in Tocomin 
pretreated hamsters (L-Ti). A significant increase of 17 %, 37 % and 18 % in the 
formation of liver conjugated diene, lipid hydroperoxide and MDA were observed in 
turpentine stressed hamsters (T-C), whereas, in kidney, conjugated diene, lipid 
hydroperoxide and MDA were significantly increased by 21 %, 32 % and 19 %, 
respectively, when compared to corresponding values in N-C. In Tocomin pretreated 
hamsters (T-T), increase in conjugated diene, lipid hydroperoxide and MDA in liver 
and kidney were blocked and decreased by 7 %, 15 %, 8 % and 5 %, 16 % and 12 %, 
respectively. Similarly, in zymosan stressed hamsters (Z-C), a significant increase in 
hepatic conjugated diene (17 %), lipid hydroperoxide (37 %) and MDA (18 %) were 
seen, when compared to corresponding N-C values. Similar to liver, kidney conjugated 
diene, lipid hydroperoxide and MDA were also significantly increased by 21 %, 31 % 
and 18 %, respectively. Pretreatment of zymosan stressed hamsters with Tocomin 
(Z-T) mediated a decrease in liver and kidney conjugated diene, lipid hydroperoxide 
and MDA and restored these values close to corresponding normal values (N-C) in 
each tissue. These results demonstrate that increased formation of conjugated diene, 
lipid hydroperoxide and MDA in liver and kidney of the above stressed hamsters were 
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Results 
3.3 Ex Vivo and Cu^^-Mediated In Vitro Oxidation of LDL, Sd-LDL and Lb-LDL 
in LPS, Turpentine or Zymosan Stressed Hamsters Pretreated with Tocomin 
3.3.1 Antioxidant effect on basal and maximal levels of conjugated diene formation 
and lag phase in LDL, sd-LDL and Ib-LDL 
As seen in Table 11, the ex vivo base line diene conjugation (BDC) levels of 
LDL, sd-LDL and Ib-LDL of LPS stressed hamsters (L-C) were increased by 82 %, 119 
% and 38 %, respectively, in comparison to the corresponding N-C values. Pretreatment 
of these stressed hamsters with Tocomin (L-Ti) partially blocked the in vivo oxidation of 
LDL, sd-LDL and Ib-LDL and reduced their BDC levels by 19 %, 11 % and 14 %, 
respectively. Maximal in vitro Cu"^-mediated oxidation of LDL and Ib-LDL was 
achieved after 12 h of incubation, whereas, for sd-LDL, maximal value was obtained 
after 30 min. The maximal conjugated diene values of LDL, sd-LDL and Ib-LDL in N-C 
group were substantially increased by 309 %, 314 % and 306 %, respectively, when 
compared to corresponding basal values in N-C. Compared to corresponding maximal 
values in N-C, LDL, sd-LDL and Ib-LDL associated maximal conjugated diene 
formation of L-C hamsters were increased by 100 %, 135 % and 46 %, respectively. In 
L-Ti, due to Tocomin pretreatment, the decrease in maximal conjugated diene values of 
LDL, sd-LDL and Ib-LDL were 33 %, 20 % and 11 %, respectively, in comparison to 
corresponding values in L-C. As expected, the lag phase time of LDL and Ib-LDL 
oxidation was reduced from 90 min and 60 min in N-C to 30 min and 30 min in L-C, 
respectively. In contrast, sd-LDL oxidation resulted in a strikingly lower lag phase time 
of 18 min in N-C, which was reduced to only 8 min in L-C. Pretreatment with Tocomin 
restored the lag phase time of LDL and Ib-LDL oxidation and increased them to 60 min 
and 40 min, respectively, whereas, the lag phase time of sd-LDL oxidation was 
increased from 8 min in L-C to 12 min in L-Ti. In Turpentine stressed hamsters (T-C), a 
significant increase of 36 %, 56 % and 13 % in ex vivo BDC values were observed in 
LDL, sd-LDL and Ib-LDL, respectively, when compared to corresponding values in N-
C. Tocomin pretreatment to turpentine stressed hamsters (T-T) partially blocked the 
increase and reduced the BDC level of LDL, sd-LDL and Ib-LDL by 13 %, 13 % and 6 
%, respectively, in comparison to corresponding basal values of T-C. In T-C, maximal 
conjugated diene values of LDL, sd-LDL and Ib-LDL were increased by 44 %, 47 % 
and 21 %, respectively, when compared to corresponding maximal N-C values. After 
Tocomin pretreatment (T-T), a decline of 30 %, 25 % and 3 % was observed in maximal 
conjugated diene formation of LDL, sd-LDL and Ib-LDL, respectively, in comparison to 
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Results 
oxidation was reduced from a value of 90 min, 18 min and 60 min in N-C to 60 min, 14 
min and 40 min, respectively, in T-C hamsters. As expected, pretreatment with 
Tocomin inhibited the conjugated diene formation and increased the lag phase time of 
LDL, sd-LDL and Ib-LDL from 60 min, 14 min and 40 min in T-C to 72 min, 16 min 
and 42 min, respectively, in T-T. 
In zymosan stressed hamsters (Z-C), an increase of 59 %, 80 % and 25 % in 
ex vivo BDC level of LDL, sd-LDL and Ib-LDL, respectively, were observed, when 
compared to corresponding values in N-C. Pretreatment of zymosan stressed hamsters 
with Tocomin (Z-T) decreased the BDC levels of LDL, sd-LDL and Ib-LDL by 20 %, 5 
% and 10 %, respectively, in comparison to corresponding basal values of Z-C. In Z-C, 
after complete Cu"*'"*"-induced oxidation of LDL, sd-LDL and Ib-LDL, maximal 
conjugated diene levels were significantly increased by 75 %, 82 % and 39 %, 
respectively, when compared to corresponding maximal values in N-C. In Tocomin 
pretreated group (Z-T), a decrease of 37 %, 14 % and 11 % in maximal conjugated diene 
formation of LDL, sd-LDL and Ib-LDL were observed, in comparison to corresponding 
Z-C values. As expected, lag phase time of LDL, sd-LDL and Ib-LDL oxidation were 
reduced from a value of 90 min, 18 min and 60 min in N-C to 50 min, 12 min and 40 
min, respectively, in Z-C. Pretreatment with Tocomin increases the lag phase time of 
LDL, sd-LDL and Ib-LDL from 50 min, 12 min and 40 min in Z-C to 70 min, 14 min 
and 44 min, respectively, in Z-T. The above results demonstrate a markedly enhanced ex 
vivo (3.1- to 4.3-fold) and Cu"^ "^ -induced in vitro (2.1- to 3.6-fold) susceptibility of 
sd-LDL to oxidative modification than Ib-LDL, which may contribute to the increased 
risk associated with atherogenesis. In addition, Tocomin pretreatment to stressed 
hamsters, exhibited a potent antioxidant effect by preferentially blocking the ex vivo and 
in vitro formation of conjugated diene and increased the lag phase time of more 
atherogenic sd-LDL, relative to Ib-LDL. 
3.3.2 Antioxidant impact on basal and maximal levels of Lipid hydroperoxide and 
MDA in LDL, sd-LDL and Ib-LDL 
As seen in Table 12, the ex vivo basal level of lipid hydroperoxide in LDL, 
sd-LDL and Ib-LDL were increased from 4.18, 2.01 and 2.78 nmole/mg protein in N-C 
to 12.24 (2.93-fold), 8.06 (4.0-fold) and 7.13 (2.5-fold) nmole/mg protein, respectively, 
in LPS stressed hamsters (L-C). Pretreatment of LPS stressed hamsters with Tocomin 
(L-Ti) significantly prevented the increase in basal lipid hydroperoxide levels of LDL, 
sd-LDL and Ib-LDL and decreased their levels by 1.58-, 1.4- and 1.48-fold, 
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Results 
conjugated diene formation, maximal in vitro Cu'^ '^ -mediated oxidation of LDL and 
Ib-LDL was achieved after 12 h of incubation, whereas, for sd-LDL, maximal value was 
obtained after 30 min. Compared to corresponding basal lipid hydroperoxide values in 
N-C, the maximal lipid hydroperoxide content of LDL, sd-LDL and Ib-LDL in N-C 
were increased by 118-, 224- and 104-fold, respectively. In L-C, a 2.84-, 1.95- and 2.24-
fold increase in maximal lipid hydroperoxide were observed in LDL, sd-LDL and Ib-
LDL, respectively, when compared to corresponding maximal values in N-C. In 
Tocomin pretreated hamsters (L-Ti), maximal lipid hydroperoxide levels in LDL, 
sd-LDL and Ib-LDL were significantly decreased by 1.86-, 1.33- and 1.44-fold, 
respectively, in comparison to corresponding maximal values in L-C. In turpentine 
stressed hamsters (T-C), an increase of 2.18-, 2.16- and 1.45-fold in basal lipid 
hydroperoxide of LDL, sd-LDL and Ib-LDL were observed. Pretreatment with Tocomin 
(T-T) significantly blocked the in vivo oxidation of LDL, sd-LDL and Ib-LDL, thus 
decreased the formation of basal lipid hydroperoxide of LDL, sd-LDL and Ib-LDL by 
1.68-, 1.40- and 1.18-fold, respectively, when compared to corresponding basal T-C 
values. In T-C, the maximal formation of lipid hydroperoxide content in LDL, sd-LDL 
and Ib-LDL were significantly increased by 1.66-, 1.22- and 1.45-fold, respectively, 
when compared to corresponding maximal values in N-C. Pretreatment of Tocomin 
prevented this increase in maximal lipid hydroperoxide of LDL, sd-LDL and Ib-LDL 
and decreased it by 1.49-, 1.09- and 1.39-fold, respectively, in comparison to 
corresponding maximal values in T-C. Similarly, compared to basal lipid hydroperoxide 
values in N-C, a significant increase in the level of basal lipid hydroperoxide in LDL 
(2.63-fold), sd-LDL (2.85-fold) and Ib-LDL (1.89-fold) was observed in zymosan 
stressed hamsters (Z-C). In hamster pretreated with Tocomin (Z-T), a substantial decline 
in basal lipid hydroperoxide of LDL, sd-LDL and Ib-LDL from 2.63-, 2.85- and 1.89-
fold in Z-C to 1.65-, 1.15- and 1.21-fold in Z-T was seen. In Z-C hamsters, the maximal 
lipid hydroperoxide content of LDL, sd-LDL and Ib-LDL were increased by 2.33-, 1.55-
and 1.79-fold, respectively, which were significantly reduced by 1.918-, 1.207- and 
1.48-fold, respectively, in Z-T. 
As evident from the data in Table 13, the ex vivo base line levels of MDA in 
LDL, sd-LDL and Ib-LDL were significantly increased by 169 %, 83 % and 71 %, 
respectively, in L-C hamsters than N-C group. Pretreatment with Tocomin blocked the 
in vivo increase in MDA of LDL, sd-LDL and Ib-LDL in L-Ti hamsters and reduced 
their levels by 42 %, 27 % and 22 %, respectively, when compared to corresponding 
basal values in L-C. The maximal MDA content of LDL, sd-LDL and Ib-LDL in N-C 
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Results 
compared to corresponding base line values of N-C. In comparison to corresponding 
maximal values in N-C, the maximal MDA of LDL, sd-LDL and Ib-LDL in L-C 
hamsters were increased by 127 %, 77 % and 63 %, respectively. In L-Ti, the formation 
of maximal MDA in LDL, sd-LDL and Ib-LDL were significantly decreased by 39 %, 
29 % and 21 %, respectively. Furthermore, in turpentine stressed hamsters (T-C), base 
line levels of MDA in LDL, sd-LDL and Ib-LDL were significantly increased by 75 %, 
51 % and 42 %, respectively, in comparison to corresponding basal values in N-C. 
Pretreatment of turpentine stressed hamsters with Tocomin (T-T) prevented the increase 
in basal MDA content of LDL, sd-LDL and Ib-LDL and reduced their levels by 33 %, 
12 % and 10 %, respectively. The maximal MDA in LDL, sd-LDL and Ib-LDL of T-C 
hamsters were significantly increased by 42 %, 17 % and 9 %, respectively, when 
compared to corresponding N-C values. Supplementation of Tocomin (T-T) blocked the 
increase in the formation of maximal MDA content of LDL, sd-LDL and Ib-LDL and 
substantially restored their values close to N-C values. 
Similarly, in Z-C, base line levels of MDA in LDL, sd-LDL and Ib-LDL were 
significantly increased by 125 %, 75 % and 49 %, respectively, when compared to 
corresponding basal values in N-C. Tocomin pretreatment to zymosan stressed hamsters 
(Z-T) decreased the basal MDA content of LDL, sd-LDL and Ib-LDL by 41 %, 30 % 
and 15 %, respectively, in comparison to corresponding basal values in Z-C. Compared 
to maximal MDA in N-C, the LDL, sd-LDL and Ib-LDL associated MDA in Z-C 
hamsters were increased by 104 %, 46 % and 19 %, respectively. Pretreatment with 
Tocomin significantly blocked the increase in maximal MDA content of LDL, sd-LDL 
and Ib-LDL and decreased their levels by 45 %, 28 % and 11 %, respectively, in 
comparison to maximal MDA values in Z-C. These combined results indicated that 
similar to ex vivo and in vitro conjugated diene formation in LDL, sd-LDL and Ib-LDL, 
the ex vivo and in vitro formation of lipid hydroperoxide and MDA are also increased in 
stressed hamsters, which were significantly blocked following pretreatment with 
Tocomin. 
3.3.3 Impact on Plasma, LDL Phospholipids and LDL-Lysophosphatidylcholine 
Content 
Lysophosphatidylcholine (LPC) is known to exert several proatherogenic effects 
and is a marker for oxidative modification of LDL. Lysophosphatidylcholine is 
produced by hydrolysis of phosphatidylcholine, a reaction primarily mediated by 
plasma-activating factor-acetylhydrolase (PAF-AH), an enzyme associated with 
lipoproteins. The increase in plasma, LDL phospholipids and LDL-LPC content during 
94 
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infection and inflammation is well known. Therefore, we have investigated the possible 
inhibitory effect of Tocomin on plasma, LDL phospholipids and LDL-LPC content in 
LPS, turpentine or zymosan stressed hamsters. As shown in Table 14, phospholipids 
levels in plasma and LDL was significantly increased by 52 % and 66 %, respectively, 
in L-C, when compared to corresponding values in N-C. Lysophosphatidylcholine 
content in LDL was substantially increased from 5.04 in N-C to 40.93 (712 %) mg/dl in 
L-C, when compared to N-C value. Significantly decreased concentration of plasma (20 
%) and LDL (20 %) phospholipids were observed in Tocomin pretreated hamsters 
(L-Ti), when compared to corresponding L-C values. Furthermore, a 38 % reduction in 
LDL-LPC value was seen after Tocomin pretreatment. Simultaneous administration of 
Tocomin and LPS to hamsters, 12 h prior to killing, caused a significant decline in 
plasma (10 %) and LDL (7 %) phospholipids, whereas, LDL-LPC content was 
decreased by 13 %, when compared to corresponding values in L-C. In comparison to 
N-C values, hamsters in turpentine stressed group (T-C) showed an increase in plasma 
(6 %) and LDL (6 %) phospholipids, whereas, LDL-LPC content was markedly 
increased by 295 %. Pretreatment of turpentine stressed hamsters with Tocomin (T-T) 
decreased the plasma phospholipids, LDL phospholipids and LDL-LPC content by 6 %, 
6 % and 24 %, respectively, when compared to corresponding values in T-C. Similarly, 
a 17 % increase in both, plasma and LDL phospholipids was seen in zymosan stressed 
hamsters (Z-C), when compared to corresponding values in N-C, whereas, a substantial 
and significant increase of 510 % in LDL-LPC content was observed in Z-C. 
Pretreatment of hamsters with Tocomin for 10 days before and 24 h after zymosan 
injection (Z-T), mediated a significant reduction in plasma phospholipids, LDL 
phospholipids and LDL-LPC levels by 12 %, 12 % and 34 %, respectively, in 
comparison to corresponding Z-C values. These results indicate that induction of 
infection and inflammation in hamsters was associated with a moderate increase in 
plasma total phospholipids and circulating LDL phospholipids. However, LDL-LPC 
content was markedly increased, which may be due to increase in plasma PAF-AH 
activity. These levels were significantly prevented by the administration of Tocomin. 
3.4 Regulatory Effect of Tocomin Pretreatment on Plasma, HDL Arylesterase 
Activity and LDL-C: Plasma Arylesterase Activity Ratio in LPS, Turpentine or 
Zymosan Stressed Hamsters 
It is well known that enzyme arylesterase, also known as paraoxonase, is 
associated with plasma HDL. The antioxidant activity of HDL is believed to reside in 
its enzymes, particularly arylesterase. Several reports indicated that HDL-associated 
arylesterase enzyme protects against LDL oxidative modification. The arylesterase 
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TABLE 14 
IMPACT OF TOCOMIN PRETREATMENT ON PLASMA, LDL 
PHOSPHOLIPIDS AND LDL-LYSOPHOSPHATIDYLCHOLINE CONTENT IN 



























































Values are mean (mg/dl) 1 SD from pooled plasma of 5 hamsters in each group 
except L-T2 (n=3). 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; N-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
saline injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, 
fed 10 mg Tocomin/hamster /day, 10 days before and 12 h after LPS injection; L-T2, 
administered LPS and 5 mg Tocomin/hamsters simultaneously, 12 h prior to 
killing; T-T, Z-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
turpentine or zymosan injection. 
Significantly different from N-C at V< 0.001 and ^ not significant. 
Significantly different from L-C at ''p< 0.001 and ^not significant. 
Significantly different from T-C at ''p< 0.001 and 'not significant. 
Significantly different from Z-C at ''p< 0.001. 
Results 
activity was shown to be regulated both genetically and by diet, indicating that adequate 
dietary intake of antioxidants such as vitamin E is essential. Therefore, we have also 
investigated the antioxidative impact of Tocomin on enzymatic activity of arylesterase 
in plasma and isolated HDL fraction of LPS, turpentine or zymosan stressed hamsters. 
As shown in Table 15, arylesterase activity of normal hamsters (N-C) was reduced from 
a value of 705 units in plasma to 517 units (27 %) in HDL fraction, isolated from 
plasma of N-C hamsters by dextran sulfate precipitation method. This decrease in HDL-
-associated arylesterase activity may be apparently due to decrease in percent recovery 
(73 %) of HDL particles, during their fractionation from plasma. Arylesterase activity in 
plasma and HDL of LPS stressed hamsters was significantly reduced from 705 and 517 
units in N-C to 468 (34 %) and 320 units (38 %) in L-C. Treatment of LPS stressed 
hamsters (L-Ti) with Tocomin for 10 days before and 12 h after LPS injection 
significantly blocked the decrease in plasma and HDL arylesterase activity and 
increased them by 30 % and 31 %, respectively, when compared to corresponding L-C 
values. Consistent with above results, the ratio of LDL-C: plasma arylesterase activity 
in L-C hamsters was significantly increased by 157 %, when compared to ratio in N-C. 
Pretreatment with Tocomin (L-Ti) mediated a significant decreased of 48 % in LDL-C: 
plasma arylesterase activity ratio. After 24 h of turpentine injection to hamsters in T-C 
group, a significant decrease of 22 % and 23 % in plasma and HDL arylesterase activity 
was observed, when compared to corresponding N-C values. Pretreatment of Tocomin 
to turpentine stressed hamsters (T-T) elevated the arylesterase activity in plasma and 
HDL by 22 % and 26 %, respectively. The ratio of LDL-C: plasma arylesterase activity 
in T-C hamsters was significantly increased from a ratio value of 1.235 x 10"'^  in N-C to 
ratio value of 2.20 x 10'^  in T-C. This increase in ratio of LDL-C: plasma arylesterase 
activity was significantly reduced to a value of 1.443 x lO''^  (34 %) in T-T hamsters. 
Similarly, in Z-C, plasma and HDL arylesterase activity was significantly reduced by 
28 % and 32 %, respectively, when compared to corresponding values in N-C. 
Pretreatment of zymosan stressed hamsters with Tocomin (Z-T) increased the enzyme 
activity of arylesterase in plasma and HDL by 24 % and 33 %, respectively, when 
compared to corresponding values in Z-C. A substantial increase of 102 % was 
observed in the ratio of LDL-C to plasma arylesterase activity in Z-C, which was 
significantly reduced by 37 % in Z-T hamsters. These results indicate that due to an 
increase in oxidafive stress, arylesterase activity in plasma and HDL fraction was 
significantly reduced. Pretreatment of stressed hamsters with Tocomin significantly 
prevented this decrease in arylesterase activity and restored to a level 81 % to 97 % of 
normal control values in N-C group. 
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TABLE 15 
EFFECT OF TOCOMIN PRETREATMENT ON PLASMA, HDL 
ARYLESTERASE ACTIVITY AND LDL-C: PLASMA ARYLESTERASE 
ACTIVITY RATIO IN THREE GROUPS OF STRESSED HAMSTERS 




3 , n ^TO-. in-5 jvj.C 705.3+3.177 517.2±4.62 1.235x10 •'±0.378x10 
L-C 467.7±5.64 319.9+1.27 




L-Ti 609.6±4.97 418.6±3.05 (daiT'o/^b 
(+30.33 %)' (+30.85 %f ^"'* '^^ ^ "^ ^ 
T-C 548.8+8.28* 398.3±2.86 
(-22.18 %)" (-22.97 %)" 
T-T 671.4±3.07* 500.3+0.618 
(+22.33 %)" (+25.60 %)" 
2.200 xlO-^+0.41 xlO-^  
(+78.13 %)" 
1.443x10"^ ±0.189x10"^ 
(-34.40 %) ' 
2.500x10^+0.896x10"^ Z-C 505.5±2.52 352.0±5.51 MMAO/X 
(-28.32 Vof (-31.94 %)" ^^"^•'* ^"^ 
Z-T 627.4+10.12* 466.5±1.30 '•'"' fS^'-'^S''''" 
(+24.11 %)'• (+32.52%)" (-36.68/0) 
^LDL-C (mg/ml) values are taken from Table 4. 
Values are mean ± SD from pooled plasma of 5 hamsters in each group. 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; N-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after 
saline injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, 
fed 10 mg Tocomin/hamster /day, 10 days before and 12 h after LPS injection;T-T, 
Z-T, fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after turpentine or 
zymosan injection. 
Significantly different from N-C at ''p<0.001 and ''p<0.05. 
Significantly different from L-C at ''p<0.001 and ^p<0.05. 
Significantly different from T-C at ''p<0.001 and ''p<0.05. 
Significantly different from Z-C at ''p<0.001 and ''p<0.05. 
Results 
3.5 Effect of Tocomin Pretreatment on Plasma, Liver and Kidney Xanthine 
Oxidase Activity in LPS, Turpentine or Zymosan Stressed Hamsters 
Xanthine oxidase is known to be an important biological source of free radicals. 
There is overwhelming evidence to suggest that serum xanthine oxidase activity is 
significantly increased in various pathological disorders, like hepatitis, inflammatory 
diseases, hypercholesterolemia, atherosclerosis, ischemia-reperfusion, carcinogenesis, 
aging and diabetes and that tree radicals generated in the enzymatic processes are 
involved in oxidative damage. Thus, it may be possible that the inhibition of this 
enzymatic pathway by the compounds that have both antiradical and xanthine oxidase 
inhibitory properties may have additional therapeutic importance in the treatment of the 
above diseases. Therefore, we have investigated the possible inhibitory effect of 
Tocomin on plasma, liver and kidney xanthine oxidase activity in LPS, turpentine or 
zymosan stressed hamsters. As seen in Table 16, plasma xanthine oxidase activity was 
significantly increased from 7.82 units in N-C to 10.91 units/ml (40 %) in LPS stressed 
hamsters, whereas, an increase of 25 % in liver and a substantial increase of 68 % in 
kidney xanthine oxidase activity was seen. Tocomin had a positive effect in preventing 
this increase in xanthine oxidase activity of plasma, liver and kidney and decreased 
them by 19 %, 13 % and 33 %, respectively, in L-Ti, when compared to corresponding 
values in L-C. After 24 h of turpentine injection, xanthine oxidase activity in plasma, 
liver and kidney were significantly increased by 25 %, 17 % and 33 %, respectively. 
Pretreatment with Tocomin (T-T) prevented the increase in plasma, liver and kidney 
xanthine oxidase activity and decreased them by 13 %, 7 % and 11 %, respectively, 
when compared to corresponding T-C values. An increase of 31 %, 16 % and 33 % was 
observed in plasma, liver and kidney xanthine oxidase activity, respectively, of 
zymosan stressed hamsters (Z-C), in comparison to corresponding N-C values. 
Pretreatment of these hamsters with Tocomin mediated a decline of 10 %, 7 % and 12 
% in plasma, liver and kidney xanthine oxidase activity, respectively, when compared 
to corresponding values in Z-C. These results demonstrate that Tocomin in addition to 
their potent antioxidant activity also significantly inhibited the elevated levels of 
xanthine oxidase associated with plasma, liver and kidney of LPS, turpentine or 
zymosan stressed hamsters, indicating a dual therapeutic benefit in the treatment of 
these disorders. 
3.6 Regulatory Effect of Tocomin Pretreatment on Antioxidant Defense System in 
LPS, Turpentine or Zymosan Stressed Hamsters 
Infection and inflammatory diseases are associated with oxidative stress due to a 
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TABLE 16 
TOCOMIN MEDIATED IMPACT ON PLASMA, LIVER AND KIDNEY 
XANTHINE OXIDASE ACTIVITY IN THREE GROUPS OF STRESSED 
HAMSTERS 
Group 
Xanthine oxidase activity 
Plasma 
(U/ml) 
r Liver r Kidney r 





(+39.51 % ) " 
0.6028±0.025 
0.752710.024 
(+24.86 % ) " 
0.3001±0.027 
0.5053±0.127 
(+68.37 % ) " 
L-T, 8.7911.76 
(-19.43 % ) " 
0.6515+0.032 




(+25.00 % ) " 
0.702710.031 
(+16.57 % ) " 
0.398110.025 


















'One unit of enzyme activity is defined as nmole of uric acid formed/min/ml. 
'^ One unit of enzyme activity is defined as nmole of uric acid formed/min/mg 
protein. 
Values are mean 1 SD from pooled plasma or homogenate from pooled liver or 
kidney of 5 hamsters in each group. 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, fed 10 
mg Tocomin/hamster/day, 10 days before and 12 h after LPS injection; T-T, 2^T, 
fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after turpentine or 
zymosan injection. 
Significantly different from N-C at ''p< 0.001. 
Significantly different from L-C at ''p< 0.001. 
Significantly different from T-C at ''p< 0.001. 
Significantly different from Z-C at ''p< 0.001. 
Results 
higher production of reactive oxygen species (ROS), such as superoxide radical, 
hydroxyl radical, hydrogen peroxide and/or deficiency in the antioxidant defense 
systems. An impaired radical scavenger function has been linked to the decreased 
activity of enzymatic and nonenzymatic scavengers of free radicals. Therefore, the 
status of antioxidant enzymes, such as catalase, superoxide dismutase (SOD), 
glutathione peroxidase (Gpx), glutathione-S-transferase (GST) and glutathione 
reductase (Gred) including reduced glutathione (GSH) concentrations in erythrocytes, 
liver and kidney of LPS, turpentine or zymosan stressed hamsters are highly important. 
3.6.1 Impact on erythrocytes catalase and superoxide dismutase activities 
As seen in Table 17, the erythrocytes catalase and SOD activities in LPS stressed 
hamsters (L-C) was significantly decreased by 41 % and 25 %, respectively, in 
comparison to corresponding N-C values. Feeding of Tocomin for 10 days before, and 
12 h after LPS injection significantly prevented this decrease in catalase and SOD 
activities and increased them by 33 % and 23 %, respectively, when compared to 
corresponding normal values in L-C. After 24 h of turpentine injection (T-C), a 
significant reduction of 12 % in both the catalase and SOD activities was seen, when 
compared to corresponding N-C values. Treatment with Tocomin for 10 days before and 
24 h after turpentine injection blocked this decrease and increased both the catalase and 
SOD activities by 8 %, in comparison to corresponding T-C values. Similarly, in 
zymosan stressed hamsters (Z-C), catalase and SOD activities were significantly 
decreased by 18 % and 7 %, respectively, in comparison to corresponding N-C values. 
Pretreatment of these hamsters with Tocomin (Z-T) prevented this decrease and elevated 
these enzyme levels by 14 % and 3 %, respectively. 
3.6.2 Effect on erythrocytes glutathione peroxidase, glutathione reductase activities 
and reduced glutathione content 
The data summarized in Table 18 showed a significant increase of 48 %, 40 % 
and 36 % in the Gpx activity of LPS (L-C), turpentine (T-C) or zymosan (Z-C) stressed 
hamsters, respectively, in comparison to normal control value. Tocomin pretreatment to 
LPS (L-Ti), turpentine (T-T) or zymosan (Z-T) stressed hamsters was associated with a 
significant reduction in Gpx activity by 18 %, 20 % and 18 %, respectively. On the 
other hand, Gred activity and GSH content in L-C hamsters were significantly 
decreased by 46 % and 67 %, respectively. Pretreatment with Tocomin (L-T]) 
significantly prevented this decrease in erythrocytes Gred activity and GSH content and 
increased these values by 66 % and 54 %, respectively, when compared to 
corresponding values in L-C. Consistent with the decrease in Gred activity and GSH 
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TABLE 17 
EFFECT OF TOCOMIN PRETREATMENT ON ERYTHROCYTES CATALASE 

















"One unit of enzyme activity is defined as the p,moles of H2O2 decomposed/min/g 
Hb. 
^One unit of enzyme activity is defined as the amount of enzyme required to inhibit 
O.D. at 560 nm of chromogen production by 50 % in one minute. 
Values are mean ± SD from pooled erythrocytes hemolysate of 5 hamsters in each 
group. 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, fed 10 
mg Tocomin/hamster /day, 10 days before and 12 h after LPS injection; T-T, Z-T, 
fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after turpentine or 
zymosan injection. 
Significantly different from N-C at ''p< 0.001. 
Significantly different from L-C at ''p< 0.001. 
Significantly different from T-C at ''p< 0.001. 





















(-18.18 % ) ' 
355.30±3.88* 
(+14.09 % ) ' 
TABLE 18 
IMPACT OF TOCOMIN PRETREATMENT ON ERYTHROCYTES 
GLUTATHIONE PEROXIDASE, GLUTATHIONE REDUCTASE ACTIVITIES 




















(- 20.37 % ) ' 
1.106±0.009* 






























(-40.15 %)' ' 
0.84910.086 
(+35.62 Vof 
^One unit of enzyme activity is defined as the ^moles of oxidized glutathione 
formed/min/g Hb. 
^One unit of enzyme activity is defined as the jiimoles of NADPH oxidized/min/g Hb. 
Values are mean 1 SD from pooled erythrocytes hemolysate of 5 hamsters in each 
group. 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, fed 10 
mg Tocomin/hamster /day, 10 days before and 12 h after LPS injection; T-T, Z-T, 
fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after turpentine or 
zymosan injection. 
Significantly different from N-C at 'p< 0.001 and ''p< 0.05. 
Significantly different from L-C at 'p< 0.001 and ''p< 0,05. 
Significantly different from T-C at ''p< 0.001 and ''p< 0.05. 
Significantly different from Z-C at ''p< 0.001 and ''p< 0.05. 
Results 
content in L-C, a reduction of 23 % and 48 % in Gred activity and GSH content was 
observed in T-C hamsters. Tocomin pretreatment to tliese hamsters (T-T) blocked this 
decrease and restored Gred activity and GSH concentration in erythrocytes by 21 % and 
45 %, respectively, in comparison to corresponding values in T-C hamsters. In 
comparison to corresponding normal control values, Gred activity and GSH content in 
Z-C hamsters were decreased by 38 % and 40 %, respectively. Pretreatment of these 
hamsters with Tocomin (Z-T) prevented this decrease in Gred activity and GSH content 
and increases them by 41 % and 36 %, respectively, in comparison to corresponding 
values in Z-C. These results indicate that the erythrocytes catalase, SOD, Gred activities 
and GSH content was significantly decreased, whereas, Gpx activity was significantly 
increased in LPS, turpentine or zymosan stressed hamsters. Furthermore, dietary 
tocotrienols being a potent antioxidant, prevented this decrease or increase in enzyme 
activities as well as GSH content. 
3.6.3 Impact on liver and kidney catalase and superoxide dismutase activities 
Consistent with the decline in the enzymatic activities of erythrocytes catalase 
and SOD in LPS, turpentine or zymosan stressed hamsters; liver and kidney catalase 
and SOD activities were also decreased in these hamsters (Table 19). After 12 h of LPS 
administration to hamsters (L-C), a significant decrease of 32 % and 51 % in catalase 
and SOD activities of liver were seen, whereas, kidney catalase and SOD activities were 
significantly decreased by 50 % and 59 %, respectively, when compared to 
corresponding tissue values in N-C. Administration of Tocomin to LPS stressed 
hamsters (L-Ti) for 10 days before and 12 h after LPS injection significantly prevented 
this decrease in hepatic catalase and SOD activities and partially restored these values 
by 30 % and 48 %, respectively. Similarly, kidney catalase and SOD activities in L-Ti 
hamsters were significantly increased by 33 % and 51 %, respectively. In turpentine 
stressed hamsters (T-C), hepatic catalase and SOD activities were significantly 
decreased from 5.958 units and 0.8309 units in N-C to 4.526 units (24 %) and 0.603 
units (27 %) in T-C hamsters. Similarly, a significant decrease of 33 % and 38 % in 
kidney catalase and SOD activities were observed, when compared to corresponding 
values in N-C. Pretreatment of turpentine stressed hamsters with Tocomin (T-T) 
significantly blocked this decrease and showed an increase of 22 % and 17 % in hepatic 
catalase and SOD activities, respectively, whereas, in kidney, an increase of 26 % and 
34 % was observed. After 24 h of zymosan injection (Z-C), the decrease in liver 
catalase and SOD activities was 25 % and 28 %, respectively, whereas, a significant 
decrease of 33 % and 39 % in kidney catalase and SOD activities was seen, when 
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TABLE 19 
IMPACT OF TOCOMIN PRETREATMENT ON LIVER AND KIDNEY 
CATALASE AND SUPEROXIDE DISMUTASE ACTIVITIES IN THREE 





































































^One unit of enzyme activity is defined as the ^moles of H2O2 decomposed/min/mg 
protein. 
^One unit of enzyme activity is defined as the amount of enzyme required to inhibit 
O.D. at 560 nm of chromogen production by 50 % in one minute. 
Values are mean (U/mg protein) ± SD from PMS fraction of pooled liver or pooled 
kidney of 5 hamsters in each group. 
N-C, fed 0.5 ml palmvitae oil/hamster/day, 10 days before and 24 h after saline 
injection; L-C, T-C, Z-C, LPS, turpentine or zymosan stressed control; L-Ti, fed 10 
mg Tocomin/hamster/day, 10 days before and 12 h after LPS injection; T-T, Z-T, 
fed 10 mg Tocomin/hamster/day, 10 days before and 24 h after turpentine or 
zymosan injection. 
Significantly different from N-C at ''p< 0.001. 
Significantly different from L-C at ''p< 0.001. 
Significantly different from T-C at ''p< 0.001. 
Significantly different from Z-C at *p< 0.001. 
Results 
compared to corresponding tissue values in N-C group. Administration of Tocomin to 
zymosan stressed hamsters (Z-T) for 10 days before and 24 h after zymosan injection 
was associated with a significant increase in hepatic catalase and SOD activities by 21 
% and 17 %, respectively. In kidney, these enzyme activities were significantly 
increased by 25 % and 35 %, respectively. 
3.6.4 Impact on the regulation of liver and kidney glutathione peroxidase, 
glutathione reductase and glutathione-S-transferase activities 
Table 20 summarizes the results of Gpx, Gred and GST activities in liver and 
kidney of LPS, turpentine or zymosan stressed hamsters without and with Tocomin 
treatment. In LPS stressed hamsters (L-C), the enzymatic activities of Gpx, Gred and 
GST in liver were significantly decreased from the values of 64.2, 10.31 and 151.9 
U/mg protein in N-C to 25 (61 %), 5.99 (42 %) and 69.9 (54 %) U/mg protein, 
respectively, whereas, in kidney, a significant decrease of 61 %, 66 % and 50 % was 
observed in Gpx, Gred and GST activities, respectively. As evident, pretreatment of 
LPS stressed hamsters with Tocomin (L-T|) resulted in a significant increase of 81 %,' 
35 % and 57 % in liver and 88 %, 103 % and 50 % in kidney Gpx, Gred and GST 
activities, respectively, when compared to corresponding tissue values in L-C group. In 
T-C hamsters, a significant decline in hepatic Gpx (45 %), Gred (22 %) and GST 
(41 %) activities were observed, whereas, kidney Gpx, Gred and GST activities were 
reduced by 34 %, 33 % and 25 %, respectively, in comparison to corresponding tissue 
values in N-C. Pretreatment with Tocomin (T-T) mediated a significant decline of 
43 %, 12 % and 34 % in liver and 27 %, 25 % and 11 % in kidney Gpx, Gred and GST 
activities, respectively, when compared to corresponding tissue values in T-C. After 
24 h of zymosan injection (Z-C), hepatic Gpx, Gred and GST activities were 
significantly decreased by 45 %, 22 % and 41 %, whereas, kidney Gpx, Gred and GST 
activities were also significantly decreased by 34 %, 34 % and 25 %, respectively. 
Pretreatment of zymosan stressed hamsters with Tocomin (Z-T) resulted in a significant 
increase of 42 %, 11 % and 18 % in liver Gpx, Gred and GST activities, respecfively. 
Similarly, an increase of 26 %, 25 % and 10 % in kidney Gpx, Gred and GST activities, 
respectively, was seen, when compared to corresponding values in Z-C. 
In summary liver and kidney catalase, SOD, Gpx, Gred and GST enzymes, 
which constitute a mutually supportive team of defense against ROS, are significantly 
decreased in LPS, turpentine or zymosan stressed hamsters. In addifion, feeding of 
dietary tocotrienols (Tocomin) for 10 days before and 12 h after LPS or 24 h after 
turpentine or zymosan injection substantially quenches these free radicals (ROS), thus 
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Results 
3.6.5 Impact on liver and kidney total, free and protein-bound-sulfhydryl contents of 
glutathione 
Reduced glutathione, a major non-protein thiol plays a crucial role in 
coordinating the body's antioxidant defense processes. Perturbation of GSH status of a 
biological system can lead to serious consequences. As evident from Table 21, hepatic 
total, free and protein-bound-SH contents of glutathione in L-C hamsters were 
significantly reduced by 56 %, 33 % and 60 %, respectively, when compared to 
corresponding N-C values. Similarly, a significant decrease of 49 %, 63 % and 45 % in 
kidney total, free and protein-bound-SH glutathione concentrations was observed. 
Pretreatment of LPS stressed hamsters with Tocomin (L-Ti), blocked this decrease and 
showed an increase in the levels of hepatic total (39 %), free (30 %) and protein-bound-
SH (42 %) glutathione, when compared to corresponding values in L-C hamsters. 
Whereas, kidney total, free and protein-bound-SH contents of glutathione were 
significantly increased by 50 %, 66 % and 48 %, respectively, in L-Ti, when compared 
to corresponding values in L-C. After 24 h of turpentine injection (T-C), the decrease 
in hepatic total, free and protein-bound-SH contents of glutathione were 45 %, 20 % 
and 49 %, respectively, whereas, in kidney, total, free and protein-bound-SH levels of 
glutathione were significantly decreased by 36 %, 26 % and 39 %, respectively, when 
compared to corresponding tissue values in N-C. Tocomin pretreatment to stressed 
hamsters (T-T) prevented this decrease and exhibited a significant increase in hepatic 
total (20 %), free (8 %) and protein-bound-SH (24 %) levels of glutathione, whereas, 
total, free and protein-bound-SH contents of glutathione in kidney were increased by 
21 %, 18 % and 22 %, respectively, when compared to corresponding tissue values in 
T-C. Consistent with T-C hamsters, zymosan stressed hamsters (Z-C) also showed a 
significant reduction of 44 %, 20 % and 49 % in hepatic total, free and protein-bound-
SH concentrations of glutathione, when compared to corresponding values in N-C. 
Similarly, total, free and protein-bound-SH contents of glutathione in kidney were 
reduced by 35 %, 26 % and 37 %, respectively. Pretreatment with Tocomin (Z-T) 
mediated an increase in liver total, free and protein-bound-SH levels of glutathione by 
20 %, 8 % and 23 %, respectively. Similarly, in kidney, a 15 %, 18 % and 15 % 
increase in total, free and protein-bound-SH contents of glutathione were observed in 
Z-T hamsters, when compared to corresponding values in Z-C. These results indicate 
that the decline in liver and kidney GSH content of LPS, turpentine or zymosan stressed 
hamsters was significantly blocked after Tocomin pretreatment, indicating an 
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TABLE 22 
AVERAGE AGE, BODY WEIGHT, HEIGHT AND BODY MASS INDEX (BMI) OF 
NORMOLIPIDEMIC AND TYPE 2 DIABETIC-HYPERCHOLESTEROLEMIC 
SUBJECTS 
Group Age Body weight Height BMI 
(yr) (kg) (cm) (kg/m') 
N-C 48.07+1.32 61.52+0.411 155.6210.478 25.40±0.268 
45.73±2.37 59.60±2.90 160.31±3.20 23.2411.18 
B 46.1517.92 61.36+1.63 161.1615.47 23.6911.52 
53.61112.22 61.40+2.90 157.5114.58 24.7411.40 
D 61.4415.41 63.0011.63 158.9811.77 24.9210.724 
E 50.30110.50 59.3013.50 157.2511.25 25.0611.74 
Values are mean 1 SD from 4,17,10,14,10 and 7 subjects in group N-C, A, B, 
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Results 
3.7 Serum Triglyceride, Total Cholesterol, VLDL-C, LDL-C, LDL-ApoB, and 
HDL-C Levels in Normolipidemic and Five Groups of Type 2 Diabetic-
Hypercholesterolemic Subjects 
As shown in Table 24, serum TG, TC, VLDL-C, LDL-C, LDL-apoB, HDL-C 
and non-HDL-C levels in normolipidemic subjects were 90, 141, 18, 86, 151, 36 and 104 
mg/dl, respectively. As described in Methods (Table 23), based on their individual TC, 
LDL-C and sd-LDL-C values and duration of treatment with atorvastatin plus 
fenofibrate, 58 type 2 diabetic subjects were divided into five groups (A-E). Serum TG, 
TC, VLDL-C, LDL-C, LDL-apoB, HDL-C and non-HDL-C values of patients in group 
A were 54, 98, 11, 65, 109, 26 and 72 mg/dl, respectively. Whereas, in group B, the 
levels of TG, TC, VLDL-C, LDL-C, LDL-apoB, HDL-C and non-HDL-C were 55, 136, 
11, 99, 157, 32 and 105 mg/dl, respectively. TG, TC, VLDL-C, LDL-C, LDL-apoB, 
HDL-C and non-HDL-C values of diabetic- hypercholesterolemic subjects included in 
group C were 70, 181, 14, 127, 205, 39 and 142 mg/dl, respectively. On the other hand, 
these lipid levels in group D subjects were 100, 253, 20, 177, 271, 60 and 197 mg/dl, 
respectively. Whereas, diabetic- hypercholesterolemic subjects in group E exhibited a 
TG, TC, VLDL-C, LDL-C, LDL-apoB, HDL-C and non-HDL-C value of 150, 339, 30, 
241, 357, 77 and 263 mg/dl, respectively. These results indicate substantially higher 
levels of serum and lipoprotein lipids in group E, when compared to corresponding 
values in other groups. This is apparently due to treatment of type 2 diabetic-
hypercholesterolemic subjects in group E with lipid lowering drugs (atorvastatin plus 
fenofibrate) for only 5.3 weeks, in comparison to diabetics in group A, B, C and D, 
treated for 98, 47.3, 39.3 and 15 weeks, respectively. Based on these results it can be 
concluded that degree of hypercholesterolemia in type 2 diabetic patients is directly 
related to the duration of treatment with hypolipidemic drugs in each group. 
3.8 Cholesterol and ApoB Concentrations of LDL, Sd-LDL and Lb-LDL Isolated 
from Pooled Serum of Normolipidemic and Five Groups of Type 2 Diabetic-
Hypercholesterolemic Subjects 
It is well known that compared with large buoyant (lb-) LDL, small dense (sd-) 
LDL is considered to be more atherogenic. Several studies have reported that not only 
the prevalence of sd-LDL but also its concentration was substantially increased in 
patients with diabetes, CHD or diabetes with CHD. Quebec cardiovascular study has 
confirmed that predominance of sd-LDL is a strong and independent predictor of CHD 
in the first seven years of follow up. Recently, it has been reported that progression of 
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sd-LDL. In the present study, we have determined the clinical significance of serum 
cholesterol and apoB concentrations of sd-LDL in five groups of type 2 diabetics with 
varying degree of hypercholesterolemia and compared them with cholesterol and apoB 
contents associated with Ib-LDL, as well as LDL. Table 25 shows that in 
normolipidemic subjects, cholesterol and apoB concentrations of LDL were 86 and 151 
mg/dl, respectively. The cholesterol and apoB contents of sd-LDL fraction were 25 and 
46 mg/dl, respectively, whereas, cholesterol and apoB concentration associated with 
Ib-LDL were 60 and 101 rag/dl, respectively. In normolipidemic subjects, the percent 
wise distribution of cholesterol and apoB from LDL particle to sd-LDL and Ib-LDL 
fractions were 29 %, 30 %, 70 % and 67 %, respectively. LDL-C and LDL-apoB 
concentrations of diabetic- hypercholesterolemic subjects in group A were 65 and 109 
mg/dl, respectively. Sd-LDL-C and Ib-LDL-C levels in group A were 20 and 40 mg/dl, 
respectively, which was 31 % and 61 % of total LDL-C. Similarly, sd-LDL-apoB and 
Ib-LDL-apoB contents were 30 and 77 mg/dl, respectively, which was 28 % and 71 % of 
total LDL-apoB. In group B, LDL-C and LDL-apoB levels were 99 and 157 mg/dl, 
respectively. Sd-LDL-C and sd-LDL-apoB contents of group B subjects were 33 and 50 
mg/dl, respectively. In addition, the percent wise distribution of cholesterol and apoB 
from LDL to sd-LDL and Ib-LDL were 32 %, 32 %, 59 % and 64 %, respectively, in 
diabetic subjects of group B. LDL-C levels of diabetics included in group C, D and E 
were 127, 177 and 241 mg/dl, respectively, whereas, LDL-apoB values were 205, 271, 
and 357 mg/dl, respectively. Cholesterol levels of sd-LDL in these groups were 50, 104 
and 159 mg/dl, respectively, whereas, their apoB contents were 81, 151 and 238 mg/dl, 
respectively. In addition, cholesterol and apoB concentrations associated with Ib-LDL in 
these groups were 72, 71, 77 mg/dl and 120, 113 and 114 mg/dl, respectively. In group 
C, D and E, 40 %, 59 % and 66 % of LDL-C were recovered in the sd-LDL fractions, 
respectively. Similarly, sd-LDL-apoB levels in group C, D and E were 40 %, 56 % and 
67 %, respectively, of LDL-apoB. The percent Ib-LDL-C, in group C, D and E were 57 
%, 40 % and 32 %, respectively, of LDL-C. Similarly, in group C, D and E, the percent 
share of LDL-apoB were 59 %, 42 % and 32 %, respectively, of Ib-LDL-apoB. These 
results indicate that a homogenous preparation of sd-LDL and Ib-LDL can be obtained 
from purified plasma LDL by using heparin-Mg"^ "^  precipitation as described in 
"Methods". The results also established that, relative to Ib-LDL as well as LDL, the 
prevalence and concentration of highly atherogenic sd-LDL were substantially 
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Results 
3.9 Ex Vivo and Cu^^-Mediated In Vitro Susceptibility to LDL, Sd-LDL and 
Lb-LDL Oxidation in Normolipidemic and Five Groups of Type 2 Diabetic-
Hypercholesterolemic Subjects 
Several lines of research indicate that in comparison to Ib-LDL, sd-LDL is 
considered to be more atherogenic as a result of their lower resistance to oxidative stress 
and reduced content of antioxidants and free cholesterol, better penetration into the 
arterial wall, lower binding affinity for LDL-receptor, prolonged plasma half life and are 
enriched with poly unsaturated fatty acids and hydroperoxides. Therefore, we have 
determined the differential ex vivo and in vitro oxidative susceptibility of sd-LDL and 
Ib-LDL as well as LDL, isolated from serum of normolipidemic and diabetic-
hypercholesterolemic subjects included in five groups (A-E). Data summarized in Table 
26 shows that the ex vivo base line diene conjugation (BDC) levels of LDL in group A, 
B, C, D and E diabetic subjects were increased from 241 nmole/mg protein in N-C to 
400 (66 %), 384 (59 %), 389 (61 %), 399 (66 %) and 409 (70 %) nmole/mg protein, 
respecfively. Similarly, in sd-LDL-C, BDC levels were increased by 33 %, 37 %, 44 %, 
48 % and 48 %, whereas, no increase, 32 %, 36 %, 39 % and 41 % in BDC levels of 
Ib-LDL-C were observed in group A, B, C, D and E, respectively, when compared to 
corresponding values in N-C. Maximal formation of conjugated diene and MDA during 
in vitro Cu'^-mediated oxidation of LDL and Ib-LDL were achieved after 12 h of 
incubation, whereas for sd-LDL these values were obtained after 30 min of oxidation. 
The maximal conjugated diene values of LDL, sd-LDL and Ib-LDL in N-C group were 
increased by 188 %, 180 % and 131 %, respectively, when compared to corresponding 
basal values in N-C. In comparison to maximal value in N-C, LDL, sd-LDL and Ib-LDL 
associated maximal conjugated diene values of patients included in group A, B, C, D and 
E were significantly increased by 44 % to 49 %, 40 % to 48 % and 38 % to 46 %, 
respectively. As expected, the lag phase time of LDL was reduced from 82 min in N-C to 
80, 80, 50, 44 and 30 min in group A, B, C, D and E diabetic subjects, respectively. 
When compared to the lag phase time of N-C, no change was seen in the lag phase time 
of Ib-LDL in group A, B and C, whereas, in group D and E these values of Ib-LDL were 
decreased by 25 % and 70 %, respectively. In contrast, sd-LDL oxidation resulted in a 
substantially lower lag phase time of only 12 min in N-C, which is 3.3- and 6.8-fold 
lower than Ib-LDL and LDL, respectively. The lag phase time of sd-LDL in diabetic-
hyperlipidemic patients included in group A, B, C, D and E, were reduced to 6.?>, 6.0, 
4.0, 2.0 and 2.0 min, respectively, from a 12 min value in N-C. These results indicate a 
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As seen in Table 27, consistent with basal and maximal conjugated diene levels, 
the ex vivo basal level of MDA in LDL were increased from a value of 3.87 rmiole/mg 
protein in N-C to 4.60 (19 %), 5.09 (32 %), 5.18 (34 %), 5.43 (40 %) and 6.01 (56 %) 
nmole/mg protein in group A, B, C, D and E, respectively. The maximal MDA of LDL 
in N-C group was substantially increased by 485 %, in comparison to basal value in 
N-C, whereas, maximal MDA of LDL in group A, B, C, D and E were increased by 13 
%, 40 %, 44 %, 45 % and 59 %, respectively. Relative to Ib-LDL or LDL, the basal 
MDA in sd-LDL were significantly increased by 26 %, 140 %, 175 %, 177 % and 180 
% in group A, B, C, D and E, respectively, when compared to N-C value. In N-C group, 
the formation of maximal MDA in sd-LDL was substantially increased by 563 %, when 
compared to basal value in N-C. In comparison to maximal MDA in N-C, MDA in 
sd-LDL of group A, B, C, D and E were significantly increased by 50 %, 58 %, 70 %, 
75 % and 76 %, respectively. Similarly, the basal MDA in Ib-LDL were significantly 
increased by 7 %, 96 %, 107 %, 107 % and 110 % in group A, B, C, D and E, 
respectively, when compared to N-C value. The maximal MDA associated with Ib-LDL 
in N-C group was substantially increased from basal value of 2.87 nmole/mg protein to 
maximal value of 16.85 nmole/mg protein. In comparison to a maximal value in N-C, 
maximal MDA of Ib-LDL in group A, B, C, D and E were significantly increased by 34 
%, 35 %, 55 %, 70 % and 73 %, respectively. The combined results demonstrate a 
markedly enhanced oxidizability of sd-LDL, in comparison to Ib-LDL, which may 
contribute to the increased risk associated with atherogenesis. These results also indicate 
that ex vivo and in vitro levels of conjugated diene and MDA in sd-LDL and Ib-LDL as 
well as LDL were significantly and proportionally increased in different groups of 
diabefics, with varying degree of hypercholesterolemia. 
3.10 Time Course Study of Conjugated diene, Lipid hydroperoxide, 
Malondialdehyde and Electrophoretic Mobility of LDL, Sd-LDL and Lb-LDL 
Isolated from Serum of Normolipidemic and Five Groups of Type 2 Diabetic-
Hypercholesterolemic Subjects 
Based on the above results, relative electrophoretic mobility of LDL, sd-LDL and 
Ib-LDL samples in each group were determined before and after Cu"^ "^ -induced oxidation 
for different time intervals (Table 26 and 27). At indicated time points of oxidation, 
formation of conjugated diene, lipid hydroperoxide and MDA in LDL, sd-LDL and 
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3.10.1 Levels of ex vivo basal and Cu^-induced in vitro formation of conjugated diene, 
lipid hydroperoxide, MDA and electrophoretic mobility in LDL, sd-LDL and Ib-
LDL from pooled serum samples of normolipidemic subjects at indicated time 
points of oxidation 
As shown in Fig. 3.2, conjugated diene levels of LDL from normolipidemic 
subjects was progressively and significantly increased from the basal value of 259 units 
to a value of 354 (37 %), 477 (84 %), 585 (126 %), 719 (178 %), 735 (184 %), 747 
(188 %), 767 (196 %), 781 (202 %) and 788 (204 %) units, after 30, 60, 90, 120, 180, 
240, 360, 480 and 720 min of oxidation, respectively. Similarly, the lipid hydroperoxide 
levels of LDL at these time points were significantly increased by 13 %, 38 %, 66 %, 
106 %, 109 %, 112%, 115 %, 116 % and 117 %, respectively, in comparison to basal 
value of 4.1 units. At indicated time points of LDL oxidation, MDA were also increased 
from a basal value of 3.78 units to 92 %, 218 %, 285 %, 470 %, 494 %, 521 %, 540 %, 
582 % and 596 %, respectively. Consistent with the time dependent increase in the 
formation of conjugated diene, lipid hydroperoxide and MDA during Cu"^-induced 
oxidation, the electrophoretic mobility of native LDL was increased from 1.0 mm to 
1.1 mm, 1.1 mm and 2.5 mm, after 60, 120 and 720 min of in vitro oxidation, 
respectively. 
On the other hand (Fig. 3.3), sd-LDL subpopulation, known to be more prone to in 
vivo and in vitro oxidative modification, resulted in an increased formation of 
conjugated diene from a basal value of 236 units to 9 %, 42 %, 49 %, 56 %, 143 %, 248 
%, 256 % and 255 %, after Cu^Mnduced oxidation for 4, 8, 12, 14, 16, 30, 60 and 120 
min, respectively. At these time points, lipid hydroperoxide level associated with 
sd-LDL was significantly increased by 55-, 115-, 187-, 199-, 202-, 209-, 214- and 
214-fold, respectively, in comparison to a basal value of 2.09 units. Compared to basal 
MDA value of 3.92 units in sd-LDL, concentration of MDA at the above indicated 
points, were significantly increased by 25 %, 43 %, 79 %, 315 %, 489 %, 541 %, 552 % 
and 556 %, respectively. Consistent with these results, the electrophoretic mobility of 
native sd-LDL was 1.4 mm, which was increased to 1.8, 1.8, 2.1 and 2.1 mm, after 4, 8, 
12 and 30 min of oxidafion, respectively. 
Conjugated diene levels of Ib-LDL from normolipidemic subjects (Fig. 3.4) was 
significantly increased from a basal value of 165 units to a value of 187 (13 %), 248 
(50 %), 310 (88 %), 370 (124 %), 475 (187 %), 501 (203 %), 516 (212 %), 531 (221 %) 
and 547 (232 %) units, at 30, 60, 90, 120, 180, 240, 360, 480 and 720 min of oxidation, 
respectively. Whereas, the lipid hydroperoxide levels associated with Ib-LDL at these 
120 
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time points were increased by 12 %, 36 %, 62 %, 89 %, 92 %, 96 %, 97 %, 102 % and 
104 %, respectively, in comparison to basal value of 4.14 units. Similarly, MDA in 
Ib-LDL shows an increase of 80 %, 180 %, 334 %, 591 %, 672 %, 713 %, 754 %, 790 
% and 813 %, respectively, at above indicated time points, when compared to basal 
MDA of 2.46 units. Similarly, electrophoretic mobility of Ib-LDL was also increased 
from a migration value of 1.1 mm in native to 1.3 mm, 1.3 mm and 2.1 mm, oxidized for 
60, 120 and 720 min, respectively. 
3.10.2 Levels of ex vivo basal and Cu^-induced in vitro formation of conjugated 
diene, lipid hydroperoxide and electrophoretic mobility in LDL, sd-LDL and Ib-
LDL from pooled serum samples of diabetic-hypercholesterolemic subjects in 
group A and B at indicated time points of oxidation 
As depicted in Fig. 3.5 & 3.8, conjugated diene level of LDL from diabetic-
hyperlipidemic subjects included in group A was significantly increased from a basal 
value of 375 units to maximal value of 906 units (141 %), obtained after 720 min of 
oxidation. Similarly, lipid hydroperoxide levels of LDL from diabetics in group A and B 
were significantly increased from a basal value of 5.11 and 8.26 units to a maximal 
value of 494 (96-fold) and 544 (66-foId) units, respectively, after 720 min of oxidation. 
Consistent with these results, compared with the electrophoretic mobility of native LDL 
in N-C, mobility of native LDL from both group A and B was increased to 1.1 mm, 
which was further increased to 2.1mm and 2.0 mm, after 720 min of oxidation. 
After 120 min of oxidation, conjugated diene levels of sd-LDL from group A (Fig. 
3.6 & 3.8) was significantly increased from a basal value of 308 units to 960 (212 %) 
units. At this time point of oxidation, lipid hydroperoxide level associated with sd-LDL 
of group A and B were significantly increased by 120- and 102-fold, respectively, when 
compared to corresponding basal value of 3.72 and 4.64 units. Similarly, the 
electrophoretic mobility of sd-LDL from both group A and B was increased to 1.5 mm, 
when compared to native sd-LDL mobility of 1.4 mm from N-C. Whereas, after 30 min 
of sd-LDL oxidafion, the mobility in agarose gel was increased to 2.1 mm and 1.9 mm 
in group A and B, respectively. 
Compared to basal conjugated diene value of 228 units in Ib-LDL of group A, 
maxima] conjugated diene level was significantly increased to 709 units (211 %), after 
720 min of oxidation (Fig. 3.7 & 3.8). Similarly, lipid hydroperoxide levels of Ib-LDL 
from group A and B diabetic-hyperlipidemic subjects were significantly increased from 
a basal value of 5.11 and 5.46 units to a maximal value of 392 (77-fold) and 461 
(84-fold) units, respectively. Compared with the electrophoretic mobility of native Ib-
121 
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LDL in N-C, mobility of native Ib-LDL from serum of both group A and B subjects 
were increased to 1.1 mm, which was further increased to 2.1mm and 2.0 mm, 
respectively, after 720 min of oxidation. 
3.10.3 Levels of ex vivo basal and Cu^-induced in vitro formation of conjugated 
diene, lipid hydroperoxide, MDA and electrophoretic mobility in LDL, sd-LDL 
and Ib-LDL from pooled serum samples of diabetic-hypercholesterolemic 
subjects in group C, D and E at indicated time points of oxidation 
As shown in Fig. 3.9 & 3.12, conjugated diene levels of LDL in group C and D 
were significantly increased from a basal value of 381 and 405 units to 582 (53 %), 816 
(114 %), 975 (160 %) units and 597 (48 %), 794 (96 %), 1005 (149 %) units, 
respectively, after 60, 120 and 720 min of Cu'*"^ -induced oxidation. Similarly, in group E 
(Fig. 3.15), an increase of 3 %, 13 % and 154 % was observed in conjugated diene 
levels, after 10, 30 and 720 min of LDL oxidation, when compared to a basal value of 
410 units. Lipid hydroperoxide levels of LDL from group C and D (Fig. 3.9 & 3.12) 
were substantially increased by 25-, 30-, 66-fold and 29-, 33-, 63-fold, respectively, 
after 60, 120 and 720 min of oxidation, when compared to respective basal value of 8.53 
and 9.06 units. In addition, at indicated time points, concentration of lipid 
hydroperoxide in group E was increased by 10-, 24- and 57-fold, respectively, in 
comparison to a basal value of 10.14 units (Fig. 3.15). Similarly, MDA associated with 
LDL of group C and D (Fig. 3.9 & 3.12) were significantly increased by 206 %, 389 %, 
634 % and 202 %, 485 %, 598 %, respectively, in comparison to corresponding basal 
value of 4.98 and 5.3 units. Whereas, compared to basal MDA value of 5.89 units in 
group E, an increase of 16 %, 68 % and 592 % was observed, after 10, 30 and 720 min 
of oxidation (Fig. 3.15). Consistent with the time dependent increase in the formation of 
conjugated diene, lipid hydroperoxide and MDA during in vitro oxidation, the 
electrophoretic mobility of native LDL samples from group C, D and E (Fig. 3.9, 3.12 & 
3.15) were increased to 1.1 mm, fi-om a common mobility value of 1.0 mm for native 
LDL of N-C. After 60, 120 and 720 min of LDL oxidation from group C, its 
electrophoretic mobility was increased to 1.6 mm, 2.0 mm and 2.4 mm, respectively, 
whereas, in group D, it was increased to 1.8 mm, 2.0 mm and 2.4 mm, respectively, 
after 60, 120 and 720 min of oxidation. Similarly, in group E, after 10, 30 and 720 min 
of LDL oxidation, the electrophoretic mobility was increased to 1.6, 2.0 mm and 2.4 
mm, respectively. 
As shown in Fig. 3.10, levels of conjugated diene formation in sd-LDL of group 
C were progressively and significantly increased by 8 %, 14 %, 71 %, respectively after 
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2, 4 and 12 min of sd-LDL oxidation, wliereas, after 4, 8 and 12 min of sd-LDL 
oxidation, an increase of 9 %, 15 %, 61 %, respectively, was observed from group D 
diabetic subjects (Fig. 3.13), in comparison to corresponding basal value of 317 and 336 
units. In addition, conjugated diene level associated with sd-LDL of group E (Fig. 3.16), 
was increased from a basal value of 339 units to 345 (2 %), 371 (9 %) and 552 (63 %) 
units, after 2, 4 and 12 min of oxidation, respectively. Similarly, after 2, 4 and 12 min of 
sd-LDL oxidation from group C (Fig. 3.10), lipid hydroperoxide level was increased by 
21-, 37-, 82-fold, respectively, when compared to a basa value of 5.98 units, whereas, in 
group D (Fig. 3.13), it was increased by 36-, 38-, 79-fold, respectively, after 4, 8 and 12 
min of sd-LDL oxidation, in comparison to a basal value of 6.5 units. In group E (Fig. 
3.16), after 2, 4 and 12 min of sd-LDL oxidation, lipid hydroperoxide level was 
significantly increased fi-om a basal value of 6.79 units to 126 (19-fold), 244 (37-fold) 
and 535 (79-fold) units, respectively. Similarly, MDA of sd-LDL from group C and D 
(Fig. 3.10 & 3.13) patients was also increased by 22 %, 26 %, 216 % and 29 %, 79 %, 
266 %, in comparison to a basal value of 10.1 and 10.67 units, respectively. MDA of sd-
LDL from group E (Fig. 3.16) subjects was significantly increased by 22 %, 39 % and 
262 %, after 2, 4 and 12 min of oxidation, respectively, when compared fi-om a basal 
value of 10.76 units. Consistent with a time dependent increase in the formation of 
conjugated diene, lipid hydroperoxide and MDA after oxidation of sd-LDL fi-om group 
C, D and E, the electrophoretic mobility of unoxidized native sd-LDL in these groups 
(Fig. 3.10, 3.13 & 3.16) were increased to 1.5 mm, 1.5 mm and 1.6 mm, respectively, 
which was higher than the mobility value of 1.4 mm of unoxidized native sd-LDL from 
normal subjects in N-C group. The electrophoretic mobility of sd-LDL from group C 
were increased to 1.9 mm, 2.3 mm and 2.3 mm, respectively, after 2, 4 and 12 min of 
oxidation, whereas, in group D, it was increased to 2.3 mm, 2.4 mm and 2.4 mm, 
respectively, after 4, 8 and 12 min of oxidation. Similarly, after 2, 4 and 12 min of sd-
LDL oxidation firom diabetic subjects included in group E, the electrophoretic mobility 
was increased to 1.9,2.3 mm and 2.4 mm, respectively. 
Figure 3.11 & 3.14 shows that the conjugated diene levels of Ib-LDL in group C 
and D were significantly increased from a basal value of 251 and 300 units to 391 (56 
%), 731 (191 %), 745 (197 %) and 397 (32 %), 735 (145 %), 751 (150 %), respectively, 
after 60, 120 and 720 min of Cu'^-induced oxidation. Similarly, an increase of 4 %, 8 % 
and 157 % was observed in conjugated diene level of group E (Fig. 3.17), after 10, 30 
and 720 min of oxidation, when compared to basal value of 302 imits. Lipid 
hydroperoxide levels of Ib-LDL from group C and D (Fig. 3.11 & 3.14) were 
substantially increased by 59-, 62-, 78-fold and 54-, 58-, 72-fold, respectively, after 60, 
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120 and 720 min of oxidation, when compared to respective basal value of 6.14 and 
6.79 units. In addition, at indicated time points, concentration of lipid hydroperoxide in 
group E (Fig. 3.17) was increased by 25-, 58- and 75-fold, respectively, in comparison 
to a basal value of 6.94 units. Similarly, MDA associated with Ib-LDL of group C and D 
(Fig. 3.11 & 3.14) were increased by 119 %, 497 %, 483 % and 146 %, 488 %, 507 %, 
respectively, in comparison to corresponding basal value of 5.12 and 5.27 units. 
Whereas, compared to basal MDA value of 5.49 units in group E, an increase of 5 %, 27 
% and 545 % was observed, after 10, 30 and 720 min of oxidation (Fig. 3.17). 
Consistent with the time dependent increase in the formation of conjugated diene, lipid 
hydroperoxide and MDA during in vitro oxidation, the electrophoretic mobility of 
native Ib-LDL samples from group C, D and E (Fig. 3.11, 3.14 & 3.17) were increased 
to 1.2 mm, 1.3 mm and 1.3 mm, respectively, from a common mobility value of 1.1 mm 
for native Ib-LDL of N-C. After 60, 120 and 720 min of Ib-LDL oxidation from group 
C, its electrophoretic mobility was increased to 1.5 mm, 1.9 mm and 2.0 mm, 
respectively, whereas, in group D, it was increased to 1.5 mm, 1.8 mm and 2.0 mm, 
respectively, after 60, 120 and 720 min of oxidation. Similarly, in group E, after 10, 30 
and 720 min of Ib-LDL oxidation, the electrophoretic mobility was increased to 1.4, 1.9 
mm and 2.0 mm, respectively. 
These results demonstrate the ex vivo basal, and Cu**-mediated in vitro time 
dependent increase in the formation of conjugated diene, lipid hydroperoxide, MDA and 
electrophoretic mobility of LDL, sd-LDL and Ib-LDL samples from normolipidemic 
and five groups of diabetic-hypercholesterolemic subjects. The maximal Cu'^-induced 
formation of conjugated diene, lipid hydroperoxide and MDA in LDL and Ib-LDL of 
each group was achieved after 12 h of oxidation, while for sd-LDL, maximal value of 
each oxidation product was obtained after 30 min in N-C, A and B group, and after 12 
min in group C, D and E. The electrophoretic mobility of native LDL (1.1 mm), sd-LDL 
(1.5-1.6 mm) and Ib-LDL (1.2-1.3 mm) samples in each diabetic group (A-E) was 
increased as compared to the mobility value of corresponding native LDL (1.0 mm), sd-
LDL (1.4 mm) and Ib-LDL (1.1 mm) samples in normal control group, indicating a 
further differential increase in the in vivo oxidative modification of the LDL density 
subfractions. In addition, in vitro oxidation of LDL, sd-LDL and Ib-LDL for indicated 
time periods was associated with a progressive increase in the levels of above lipid 
peroxidation products and their electrophoretic mobility. Both the formation of maximal 
oxidation products in LDL, sd-LDL and Ib-LDL and their electrophoretic mobility, in 
turn, are dependent on degree of hypercholesterolemia in diabetic-hypercholesterolemic 
subjects in each group. 
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3.11 Serum Levels of Total antioxidants, Arylesterase Activity and Ratio of 
LDL- C: Serum Arylesterase Activity in Normolipidemic and Type 2 Diabetic-
Hypercholesterolemic Subjects 
Arylesterase or paraoxonase (PON) is a serum enzyme with an antioxidant 
function. Several in vitro and in vivo studies have provided support for the contention 
that this enzyme protects LDL from oxidative modifications. The enzyme arylesterase 
has been identified as an independent genetic risk factor for vascular disease particularly 
in type 2 diabetic patients. It has been reported that type 1 and type 2 diabetic patients 
and STZ-induced diabetic rats, have lower PON activity and concentration, higher 
LDL: PON concentration ratio and a reduced capacity to LDL oxidation. Antioxidant 
supplements may be expected to influence PON activity by altering oxidative stress. 
Inactivation of PON by oxidized LDL can be inhibited by antioxidants. Therefore, we 
have measured the serum total antioxidant concentration and enzymatic activity of 
arylesterase from serum of normolipidemic and type 2 diabetic-hypercholesterolemic 
subjects. Table 28 shows that in diabetic-hypercholesterolemic subjects, total antioxidant 
levels were significantly reduced from a control value of 696 nmole/ml in N-C to 204 
(71 %), 135 (81 %), 118 (83 %), and 84 (88 %) nmole/ml, in diabetic-
hypercholesterolemic patients included in group A, C, D and E, respectively. Consistent 
with the decline in serum total antioxidant concentration, serum arylesterase activity was 
significantly reduced from 675 units in N-C to 645 (4 %), 590 (13 %), 354 (47 %), 230 
(66 %) and 170 (75 %) units in group A, B, C, D and E diabetic subjects, respectively. 
Based on above result, the ratio of LDL-C: serum arylesterase activity in group A was 
decreased by 19 %, in comparison to a ratio value of 0.125 in N-C. On the other hand, 
when compared with normal control value, the ratio of LDL-C: serum arylesterase 
activity was significantly increased by 34 %, 183 %, 512 % and 1035 % in group B, C, 
D and E diabetic subjects, respectively. These results indicate that total antioxidant 
concentration and arylesterase activity in serum samples of each diabetic-
hypercholesterolemic group was significantly decreased in comparison to 
normolipidemic subjects, which is due to an increase in oxidative stress in different 
diabetic groups (A-E) with varying degree of hypercholesterolemia. 
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TABLE 28 
SERUM LEVELS OF TOTAL ANTIOXIDANTS, ARYLESTERASE ACTIVITY 
AND THE RATIO OF LDL- C: SERUM ARYLESTERASE ACTIVITY IN 
NORMOLIPIDEMIC AND FIVE GROUPS OF TYPE 2 DIABETIC-
HYPERCHOLESTEROLEMIC SUBJECTS 
Group Total antioxidants Arylesterase activity LDL-C^: serum arylesterase activity 
(nmole/min/ml) (jimole/min/ml) 
N-C 695.72+1.11 675.04+7.22 0.125 x 10"^±0.001 
A^ 203.76±1.26* 645.013.18 0.101 x 10"^±0.003 
(-70.71 %)" (-4.45 %)" (-19.34 % ) ' 
B^ 589.05+1.47 0.168 x 10'^+0.009 
(-12.73 %)" (+33.99 %)" 
C^ 134.76+1.06* 354.53+2.91 0.356 x 10'^±0.005 
(-80.63 %)" (-47.48 % ) ' (+183.83 %)" 
D^ 117.80±0.982* 230.45±1.43 0.768x10-^10.004 
(-83.06 %)" (-65.86 % ) ' (+512.18 %f 
E^ 83.9411.76* 169.2111.16 1.42x10-^10.010 
(-87.93 %)" (-74.93 %) (+1035.82 %)" 
^LDL-C (mg/ml) values are taken from Table 24. 
*Values are mean 1 SD from pooled serum of 4, 17, 10, 14, 10 and 7 subjects in 
group N-C, A, B, C, D and E, respectively 
Significantly different from N-C at''p<0.001. 
^Group A, B, C, D and E were previously treated with atorvastatin plus fenofibrate 
for 98, 47.3,39.3,15 and 5.3 weeks, respectively. 
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Fig. 33. Panel (a): Levels of ex vivo basal and Cu^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in sd-LDL of normolipidemic 
subjects. Basal values of conjugated diene, hydroperoxide and MDA represent 
the status of oxidized sd-LDL in vivo. Concentrations of conjugated diene, 
hydroperoxide and MDA are shown after different periods of sd-LDL oxidation. 
Values are mean of triplicate determinations from pooled samples, and are 
statistically significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of sd-LDL after different periods 























Fig. 3.4. Panel (a): Leveb of ex vivo basal and Cu^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in Ib-LDL of normolipidemic 
subjects. Basal values of conjugated diene, hydroperoxide and MDA represent 
the status of oxidized Ib-LDL in vivo. Concentrations of conjugated diene, 
hydroperoxide and MDA are shown after different periods of Ib-LDL oxidation. 
Values are mean of triplicate determinations from pooled samples, and are 
statistically significant with respect to corresponding basal value, except MDA 
value at 30,60,90 and 120 min which are insignificant. 
Panel (b): Agarose gel electrophoresis of Ib-LDL after different periods 
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Fig. 3.7. Panel (a): Levels of ex vivo basal and Cu^4nduced in vitro formation of 
conjugated diene and hydroperoxide in Ib-LDL of group A diabetic-
hyperchofesterofemic subjects. Basal values of conjugated diene and 
hydroperoxide represent the status of oxidized Ib-LDL in \ivo. Concentrations of 
conjugated diene and hydroperoxide are shown after 720 min of Ib-LDL 
oxidation. Values are mean of triplicate determinations from pooled samples, 
and are statistically significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of Ib-LDL after 720 min of 
oxidation: 1- unoxidized native Ib-LDL of N-C; 2- unoxidized native Ib-LDL of 
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Fig. 3.8. Panel (a): Levels of tx vivo basal and Cu^-induced in vitro formation of 
hydroperoxide in LDL, sd-LDL and Ib-LDL of group B diabetic-
hypercholesterolemic subjects. Basal values of hydroperoxide represent the status 
of oxidized LDL, sd-LDL and Ib-LDL in vivo. Concentrations of hydroperoxide 
are shown after different periods of LDL, sd-LDL and Ib-LDL oxidation. Values 
are mean of triplicate determinations from pooled samples, and are statistically 
significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of LDL, sd-LDL and Ib-LDL after 
different periods of oxidation: (i) 1- unoxidized native LDL of N-C; 2- unoxidized 
native LDL of group B; 3-12 h (ii) 1- native sd-LDL of N-C; 2- native sd-LDL of 
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Fig. 3.9. Panel (a): Levels of cr vrw basal and Cu^-indoced in vitro formation of 
conjugated dlene, hydroperoxide and MDA in LDL of group C diabetic subjects. 
Basal values of conjugated diene, hydroperoxide and MDA represent the status 
of oxidized LDL in vivo. Concentrations of conjugated diene, hydroperoxide and 
MDA are shown after different periods of LDL oxidation. Values are mean of 
triplicate determinations from pooled samples, and are statistically significant 
with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of LDL after different periods of 
oxidation: 1- unoxidized native LDL of N-C; 2- unoxidized native LDL of group 
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Fig. 3.10. Panel (a): Levek of tx vivo basal and Cu^-induced in ntro formation of 
conjugated diene, hydroperoxide and MDA in sd-LDL of group C diabetics. 
Basal values of conjugated diene, hydroperoxide and MDA represent the status 
of oxidized sd-LDL in vivo. Concentrations of conjugated diene, hydroperoxide 
and MDA are shown after different periods of sd-LDL oxidation. Values are 
mean of triplicate determinations from pooled samples, which are statistically 
significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of sd-LDL after different 
periods of oxidation: 1- unoxidized native sd-LDL of N-C; 2- unoxidized native 
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Rg. 3.11. Panel (a): Levels of tx vivo basal and Cu^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in Ib-LDL of group C diabetic 
subjects. Basal values of conjugated diene, hydroperoxide and MDA represent 
the status of oxidized Ib-LDL in vivo. Concentrations of conjugated diene, 
hydroperoxide and MDA are shown after different periods of Ib-LDL oxidation. 
Values are mean of triplicate determinations from pooled samples, and are 
statistically significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of Ib-LDL after different 
periods of oxidation: 1- unoxidized native Ib-LDL of N-C; 2- unoxidized native 
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Fig. 3.12. Panel (a): Levels of ex vivo basal and Cu -induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in LDL of group D diabetic subjects. 
Basal values of conjugated diene, hydroperoxide and MDA represent the status 
of oxidized LDL in vivo. Concentrations of conjugated diene, hydroperoxide and 
MDA are shown after different periods of LDL oxidation. Values are mean of 
triplicate determinations from pooled samples, and are statistically significant 
with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of LDL after different periods 
of oxidation: 1- unoxidized native LDL of N-C; 2- unoxidized native LDL of 





















Fig. 3.13. Panel (a): Levels of ex vivo basal and Cu^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in sd-LDL of group D diabetics. 
Basal values of conjugated diene, hydroperoxide and MDA represent the status 
of oxidized sd-LDL in vn'o. Concentrations of conjugated diene, hydroperoxide 
and MDA are shown after different periods of sd-LDL oxidation. Values are 
mean of triplicate determinations from pooled samples, which are statistically 
signiflcant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of sd-LDL after different 
periods of oxidation: 1- unoxidized native sd-LDL of N-C; 2- unoxidized native 
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Fig. 3.14. Panel (a): Levels of ejc vivo basal and Cu"^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA In Ib-LDL of group D diabetic 
subjects. Basal values of conjugated diene, hydroperoxide and MDA represent 
the status of oxidized Ib-LDL in vivo. Concentrations of conjugated diene, 
hydroperoxide and MDA are shown after different periods of Ib-LDL oxidation. 
Values are mean of triplicate determinations from pooled samples, and are 
statistically significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of Ib-LDL after different 
periods of oxidation: 1- unoxidized native Ib-LDL of N-C; 2- unoxidized native 
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Fig. 3.15. Panel (a): Levels of ex vivo basal and Cu^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in LDL of group E diabetic subjects. 
Basal values of conjugated diene, hydroperoxide and MDA represent the status 
of oxidized LDL in vivo. Concentrations of conjugated diene, hydroperoxide and 
MDA are shown after different periods of LDL oxidation. Values are mean of 
triplicate determinations from pooled samples, and are statistically significant 
with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of LDL after different periods 
of oxidation: 1- unoxidized native LDL of N-C; 2- unoxidized native LDL of 
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Fig. 3.16. Panel (a); Levels of ex vivo basal and Cu^-induced in vitro formation of 
conjugated diene, hydroperoxide and MDA in sd-LDL of group E diabetics. 
Basal values of conjugated diene, hydroperoxide and MDA represent the status 
of oxidized sd-LDL in vivo. Concentrations of conjugated diene, hydroperoxide 
and MDA are shown after different periods of sd-LDL oxidation. Values are 
mean of triplicate determinations from pooled samples, and are statistically 
significant with respect to corresponding basal value. 
Panel (b): Agarose gel electrophoresis of sd-LDL after different 
periods of oxidation: 1- unoxidized native sd-LDL of N-C; 2- unoxidized native 
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Rg. 3.17. Panel (a): Levels of ex vivo basal and Cu -induced in vitro formation of 
conjugated dienc, hydroperoxide and MDA in Ib-LDL of group E diabetic-
hypercholesterolemic subjects. Basal values of conjugated dlene, hydroperoxide 
and MDA represent the status of oxidized Ib-LDL in vivo. Concentrations of 
conjugated diene, hydroperoxide and MDA are shown after different periods of 
Ib-LDL oxidation. Values are mean of triplicate determinations from pooled 
samples, and are statistically significant with respect to corresponding basai 
value. 
Panel (b): Agarose gel electrophoresis Ib-LDL different periods of 
oxidation: 1- unoxidized native Ib-LDL of N-C; 2- unoxidized native Ib-LDL of 
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The present study demonstrates the extensive proatherogenic changes, that 
occurred as a part of the host response to hpopolysaccharide (LPS, acute systemic 
infection), zymosan (acute noninfectious systemic inflammation), or turpentine (acute 
localized sterile inflammation) administration, on a variety of parameters, like, plasma 
and lipoprotein lipids including apoB content of LDL and its subpopulation, small dense 
(sd)-LDL and large buoyant (Ib)-LDL, plasma, liver and kidney lipid peroxidation 
products, ex vivo and in vitro oxidizability of LDL, sd-LDL and Ib-LDL, including 
lysophosphatidylcholine (LPC) content of LDL, erythrocytes MDA release; erythrocytes, 
liver and kidney enzymatic and nonenzymatic antioxidants including plasma total 
antioxidants and arylesterase activity. Pretreatment of stressed hamsters with dietary 
tocotrienols (Tocomin) significantly reduced the overall oxidative burden and effectively 
ameliorated the above altered parameters, thus, indicating a potent atheroprotective effect 
of Tocomin. 
For many years, a-tocopherol (a-T) was generally considered the most potent 
chain breaking antioxidant in the vitamin E family (Burton et al, 1983). However, 
several reports have shown tocotrienols (T3S) to be more potent than tocopherols (Suama 
et al, 1993; Kamat and Devasagayan, 1995; Kamat et ah, 1997). Tocotrienols have been 
shown to exhibit greater free radical scavenging properties as cell membrane constituents 
than tocopherols (Yamaoka and Carrillo, 1990; Serbinova et al, 1991). They quench free 
radicals in cell membranes and protect them against lipid peroxidation. The higher 
antioxidant potency of a-Ts as compared to a-T is attributed to the combined effects of 
three properties: it's higher recycling efficiency from chromanoxyl radical, its more 
uniform distribution in membrane bilayer, and its stronger disordering of membrane 
lipids which makes interaction of chromanols with lipid radicals more efficient. Since, 
Tocomin used in the present study is a mixture of a-Ts, y-Ts, 6-T3 and a-T; we have 
examined the efficacy of individual T3S, a-T and Tocomin as a scavenger of peroxyl 
radical. Our result showed that by using DPPH, the order of antiradical activity or 
hydrogen donating ability, expressed in terms of half quenching concentration (IC50) was 
5-T3>a-T3>y-T3>Tocomin>a-T. Our results are in agreement with earlier reports 
(Qureshi et al, 2000) indicating that in intact membranes, including LDL particles, 
tocotrienols may have a significantly greater antioxidant effect than a-T and they may 
provide greater protection against CAD. The possible mechanism for this superior 
efficacy of tocotrienols compared to a-T has been reported elsewhere (Packer, 1995). 
The reduction in the free radical quenching efficiency of Tocomin (50.3 ^M) in 
comparison to 8-T3, a-T3, y-Ts is apparently due to the presence of 23 % a-T, which has 
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a lowest peroxyl radical scavenging efficiency of 70.8 jiM. These results are consistent 
with a previous report indicating the presence of higher percentage (20 %) of a-T in 
TRF, reduces the antioxidant activity (Qureshi et al, 2000). 
Several epidemiological studies suggest a link between infection/inflammation 
and atherosclerosis. During the acute phase response (APR) to infection and 
inflammation, cytokines induce tissue and plasma events that lead to a wide variety of 
changes in the plasma concentrations of lipids and lipoproteins. Because these changes in 
lipids and lipoproteins are similar to those proposed to promote atherogenesis, they may 
initiate or aggravate atherosclerosis if the course of infection or inflammation is 
prolonged (Khovidhunkit et al, 2000; Khovidhunkit et al, 2004). Atherosclerosis is a 
complex process, and atherosclerotic lesions in the arterial wall are characterized by lipid 
accumulation in macrophages, resulting in foam cell formation (Brown and Goldstein, 
1983). The development of lipid-filled foam cells is primarily regulated by two major 
determinants: lipid uptake and lipid removal. In epidemiological studies, several risk 
factors for atherosclerosis have been identified. Hypercholesterolemia, especially 
elevated levels of LDL-C, is one major risk factor for CAD, and therapeutic reductions 
of total cholesterol (TC) and LDL-C levels result in a decrease in cardiovascular 
morbidity and mortality (Scandinavian simvastatin survival study, 1994; Shepherd et al, 
1995; Sacks et al, 1996; Downs et al, 1998). Hypertriglyceridemia and elevated levels 
of TG rich VLDL have recently reemerged as risk factors for atherosclerosis (Austin et 
al, 1998; Stampfer et al, 1996). On the other hand, plasma HDL-C levels are inversely 
correlated with the risk of atherosclerosis (Gordon et al, 1989). In agreement with these 
concepts, therapies that raise HDL and decrease triglyceride reduce the morbidity and 
mortality from CAD (Gordon et al, 1989; Frick et al, 1987). These intervention trials 
support the concept that LDL and possibly VLDL play a pivotal role in lipid uptake and 
that HDL is a key lipoprotein in lipid removal from macrophage foam cells in the arterial 
wall. 
Our results demonstrate a significant increase in plasma total lipid, TG and free 
fatty acid (FFA) in LPS (L-C), turpentine (T-C) or zymosan (Z-C) stressed hamsters. A 
similar increase in serum TG and FFA in LPS treated hamsters or rats were previously 
reported (Feingold et al, 1992a; Kawakami et al, 1986; Ly et al, 1995). In another 
report an increase in plasma TG level was seen during inflammation, induced by 
turpentine oil in pigs (Navarro et al, 2005). The increase in plasma TG levels is 
apparently due to an increase in VLDL which can be the result of either increased VLDL 
production or decreased VLDL clearance. These results are consistent with the finding 
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that low doses of LPS stimulate VLDL production, whereas high doses of LPS inhibit 
VLDL clearance in rats (Feingold et ah, 1992a). In addition, experiments in rats and 
mice showed that low doses of LPS rapidly stimulate VLDL production by increasing 
adipose tissue lipolysis, increasing hepatic de novo fatty acid synthesis, and decreasing 
hepatic fatty acid oxidation, all of which provide fatty acid substrate for esterification 
into TG and assembly into VLDL particles in the liver as well as increase in plasma FFA 
(Memon et al., 1992b; Memon et al, 1993). A significant increase in plasma TC of L-C, 
T-C or Z-C stressed hamsters was observed, which is in agreement with other reports, 
indicating an increase in serum TC level in LPS treated rodents, as well as in turpentine 
treated pigs (Feingold et al, 1993a; Khovidhunkit et al, 2004; Navarro et al, 2005). The 
results also show that in comparison to plasma esterified cholesterol, a substantial 
increase in free cholesterol of L-C (151 %), T-C (53 %) and Z-C (94 %) hamsters were 
observed, indicating a reduction in the esterification of free cholesterol, which is 
consistent with a reduced plasma LCAT activity. Similar results indicating an increase in 
plasma TC and free cholesterol (93 %) fraction and decreased plasma LCAT activity in 
LPS treated hamsters has been reported by Ly et al. (1995). Reduced plasma LCAT 
activity was also observed in LPS treated monkeys (Auerbach and Park, 1989). Similar 
to plasma lipids, VLDL-C, LDL-C and atherogenic non-HDL-C levels were also 
increased in 3 distinct models of stressed hamsters, indicating that the increase in plasma 
TC is apparently due to increase in VLDL-C and LDL-C concentrations. An increase in 
VLDL-C and LDL-C levels has previously been reported in LPS treated rodents 
(Feingold et al., 1993a; Hardardottir et al., 1994a) and in turpentine treated pigs 
(Navarro et al, 2005). On the other hand, a low decrease of 6 %, 3 % and 17 % in 
plasma antiatherogenic HDL-C level of L-C, T-C or Z-C hamsters, respectively, was 
seen, which is not comparable to a much higher decrease of 25 % and 45 % in HDL-C of 
LPS treated hamsters and turpentine treated pigs, respectively (Feingold et al., 1993a; 
Navarro et al., 2005). As indicated above, substantial increase in plasma free cholesterol 
and a significant decrease in LCAT activity during infection and inflammation could 
potentially impair cholesterol removal, because free cholesterol gradient is not efficiently 
maintained for diffusion to occur. In addition, LCAT is required for the conversion of 
free cholesterol into cholesteryl ester so that cholesteryl ester can move into the core of 
HDL particles, resulting in a larger a-HDL. Cholesteryl ester in HDL can be transported 
to the liver for elimination via several routes (Khovidhunkit et al, 2000). Similar to 
plasma TG, TC and FFA, liver and kidney TG, TC and FFA levels were also 
significantly increased in L-C, T-C or Z-C hamsters. The therapeutic effect of dietary 
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tocotrienols (Tocomin) in the amelioration of all the above altered parameters in 3 
distinct models of infection and inflammation represents an initial demonstration. 
Low density lipoproteins are composed of distinct subclasses that differ in size, 
density, chemical composition, and their association with cardiovascular disease 
(Gardner et al, 1996; Griffin et al, 1994; Lamarche et ah, 1997). Lipoprotein profiles 
that are relatively rich in sd-LDL particles are associated with up to a 3-fold greater risk 
of myocardial infarction than those mainly consist of Ib-LDL particles (Austin et al, 
1988; Austin et al, 1990; Stampfer et al, 1996). Furthermore, sd-LDL has poorer 
binding affinity to the LDL receptor, resulting in increased plasma half-life in the 
circulafion and decreased clearance (Nigon et al., 1991). In addition, because of the 
smaller size, sd-LDL can efficiently penetrate the endothelial barrier into the arterial 
intima and interact with intima proteoglycans, leading to retention in the arterial wall 
(Hurt-Camejo et al, 1990). Therefore, sd-LDL are considered more proatherogenic. It 
has been shown that not only the prevalence of sd-LDL but its concentration was 
significantly increased in healthy subjects with various types of hyperlipidemia such as 
hyperLDLcholesterolemia, hypertriglyceridemia, combined hyperlipidemia and 
chylomicronemia, hyperlipidemia with CHD, and type 2 diabetic patients with CHD 
(Hirano et al, 2004). Several studies have reported a 2- to 3-fold increase in CHD risk 
among patients with a predominance of sd-LDL particles (Austin et al, 1988; Austin et 
al, 1990; Ausfin et al, 1994). Similarly, Quebec cardiovascular study has confirmed that 
a predominance of sd-LDL is a strong and independent predictor of CHD in the first 
seven years of follow-up (St-Pierre et al, 2005). Recently, Koba et al. (2006) have 
reported that the progression of CHD was closely linked not to the LDL particle size, but 
to the concentration of sd-LDL. Therefore, sd-LDL has been highlighted as a new 
powerfiil and better marker for the risk of CHD (Austin et al, 1995; Hirano et al., 2004; 
Koba et al., 2006). Our results demonstrate that as a part of host response to infection 
and inflammation, relative to Ib-LDL, the concentration of more atherogenic sd-LDL 
was substanfially increased. An average increase > 59 %, >38 % or > 48 % of LDL-C 
and LDL-apoB were recognized in sd-LDL subpopulation of L-C, T-C or Z-C stressed 
hamsters, respectively. Pretreatment of these hamsters with Tocomin significantly 
reduced the cholesterol and apoB content of sd-LDL as well as their percent share of 
LDL close to corresponding normal control values, indicating a strong antiatherogenic 
effect of Tocomin. It is interesting to mention that Tocomin mediated reduction in sd-
LDL-C levels was proportionally and preferentially greater than that of LDL-C levels, 
with a maximum effect in L-Ti (55 % vs. 32 % in LDL-C) hamsters. In addition, both 
cholesterol and apoB content of LDL density subfractions have always increased or 
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decreased in tandem, indicating that each particle is homogeneous. The substantial and 
preferential increase in cholesterol and apoB content of sd-LDL in 3 models of stressed 
hamsters is consistent with a previous finding indicating that sd-LDL particles have 
poorer binding affinity to the LDL receptor, resulting in increased plasma half life in the 
circulation and decreased clearance (Nigon et al, 1991). Our results are consistent with a 
recent report (Tokuno et al, 2007), where administration of 1 mg pitavastatin to type 2 
diabetic-hyperlipidemic patients for 3 months significantly reduced both LDL and sd-
LDL. Mechanism wise, similar to pitavastatin (Saito et al, 2001; Sone et al, 2002), 
induction of LDL receptors by dietary tocotrienols may stimulate the uptake the LDL 
and sd-LDL particles with a minimum effect on Ib-LDL particle. Alternatively, similar to 
potent induction of LDL receptors by 2 mg pitavastatin, high dose of tocotrienols may 
preferentially facilitate the removal of sd-LDL particles (Sone et al., 2002). The efficient 
and preferential removal of sd-LDL than Ib-LDL in Tocomin treated stressed hamsters 
may also be related to precursor-product relationship. In humans, TG rich large VLDL 
(VLDLl) is proposed to be a precursor of sd-LDL, while smaller VLDL (VLDL2) is 
proposed to be a precursor of Ib-LDL (Packard and Shepherd, 1997; Tribble et al, 
2001). As shown for fibrate (Milosavljevic et al, 2001), dietary tocotrienols may also 
reduce sd-LDL particles by suppressing the production of VLDLl and sfimulating the 
transfer from VLDLl to VLDL2 via the activation of lipoprotein lipase. Consistent with 
these reports, our results show a concomitant decline of both plasma TG and sd-LDL 
levels in 3 groups of stressed hamsters pretreated with 10 mg Tocomin/day for 10 days 
before and 12 h after LPS (L-Ti), or 24 h after turpentine or zymosan injection. Thus, the 
specific decrease in sd-LDL-C implied significant increases in LDL buoyancy. Based on 
our results, the primary target of therapy in hyperlipidemic subjects with and without 
CHD should be the preferential lowering of highly atherogenic sd-LDL subpopulation 
along with LDL. 
It has been established that LDL-C/HDL-C and HDL-C/TC ratios are good 
predictors for the presence and severity of CAD (Drexel et al, 1992). Consistent with the 
known similarities of lipoprotein metabolism in hamsters with humans (Spady et al, 
1988), a LDL-C/HDL-C ratio of 2.49 in normal hamsters was obtained, which is lower 
than the normal range of 3.2-3.6 or preferably lower reported for humans. This normal 
rafio of 2.49 was increased to a ratio value of 4.53, 3.56 or 4.33 in L-C, T-C or Z-C 
hamsters, respecfively. Pretreatment of these hamsters with Tocomin significantly 
reduced these rafios to 2.9, 2.56 or 3.08, respectively, which are close to normal ratio 
value. Similarly, in normal hamsters, HDL-C/TC ratio of 0. 220 was observed, which is 
similar to a reported ratio of 0.20 or preferably higher in humans. This ratio of 0.220 in 
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N-C was significantly reduced to a ratio value of 0.135 in L-C, 0.166 in T-C or 0.138 in 
Z-C hamsters, which were significantly increased and restored (76 % to 97 %) to near 
normal ratio value in Tocomin pretreated hamsters. Consistent with the above results, we 
have initially included sd-LDL-C/HDL-C ratio, which was substantially increased from a 
ratio of 0.75 in N-C to a ratio value of 2.69, 1.43 or 2.16 in L-C, T-C or Z-C hamsters, 
respectively, while pretreatment of stressed hamsters with dietary Tocomin reduced these 
ratios to near normal value. These results, which represent an initial demonstration, 
indicate that pretreatment of stressed hamsters with tocotrienols effectively ameliorated 
all the lipid parameters including highly atherogenic sd-LDL. This Tocomin mediated 
decrease of substantially elevated sd-LDL in stressed hamsters could have major clinical 
implications because of known quantitative changes in LDL profile are associated with 
an improvement of prognosis of CAD patients. 
The significant increase in plasma and lipoprotein lipid levels in 3 models of 
infection and inflammation is consistent with a significant increase of 55 %, 41 % or 47 
% in hepatic HMG-CoA reductase activity of L-C, T-C or Z-C hamsters, respectively. It 
is possible that this increase in hepatic HMG-CoA reductase activity, in response to 
APR, provide cholesterol that allows for the increased production of lipoproteins and 
elevations in serum lipid levels that may be beneficial to the body's host defense. 
Feingold et al. (1993a) have previously reported that LPS administration to hamsters 
increased hepatic cholesterol synthesis by increasing the HMG-CoA reductase activity 
which can be accounted for by an increase in HMG-CoA reductase mRNA levels. In our 
study, similar mechanism for the increased production of cholesterol may be involved in 
turpentine and zymosan stressed hamsters. Pretreatment of stressed hamsters with dietary 
Tocomin was associated with a significant reduction of 67 % to 72 %, in hepatic 
HMG-CoA reductase activity, which is apparently responsible for the reduction in lipid 
levels. Therefore, Tocomin enriched in tocotrienols may exert their hypochlolesterolemic 
effect in LPS, turpentine or zymosan stressed hamsters in a similar manner as previously 
reported for hyperlipidemic animals (Minhajuddin et al, 1999; Qureshi et al, 2001b; 
Beg et al, 2000a) and humans (Qureshi et al, 1991a; Qureshi et al, 1997; Qureshi et al, 
1995). Mechanism wise, as previously shown in HepG2 cells, as well as in 
normolipidemic and hyperlipidemic rats, tocotrienols reduce cholesterol synthesis by 
suppressing HMG-CoA reductase activity, which in turn is reduced by a decline in its 
protein mass (Minhajuddin et al, 1999; Parker et al, 1993). The decline in protein mass 
may be achieved by inhibition of HMG-CoA reductase synthesis and/or enhanced 
degradation. Consistent with in vivo results in rats (Minhajuddin et al, 1999), 
y-tocotrienol has been shown to mediate the suppression of enzymatic activity and 
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protein mass of HMG-CoA reductase in HepG2 cells through decreased synthesis (57 % 
of control) and enhanced degradation (2.4-fold versus control) of the enzyme (Parker et 
ai, 1993). In addition, y-tocotrienol was shown to upregulate LDL receptor in 
mammalian cells and may be implicated in part for the reduction of apoB-lipoprotein 
in vivo (Parker et al, 1993). Thus, tocotrienols reduce cholesterol formation in 
mammalian cells by suppressing HMG-CoA reductase activity through two actions: 
decreasing the efficiency of translation of HMG-CoA reductase mRNA and increasing 
the controlled degradation of HMG-CoA reductase protein, posttranscriptionally (Parker 
et al., 1993). In addition, another report indicates that y-tocotrienol influences apoB 
secretion by both cotranslational and posttranslational processes involving a decreased 
rate of apoB translocation and accelerated degradation of apoB in HepG2 cells. This 
activity correlated with a decrease in free and esterified cholesterol (Theriault et al, 
1999a). Together, the information indicates an association between the suppression of 
hepatic cholesterol synthesis and apoB secretion, and the observed lowering of apoB and 
LDL-C levels in animal and human models (Theriault et al., 1999a). However, 
elucidation of precise in vivo mechanism(s) of Tocomin-mediated inhibition of HMG-
-CoA reductase at molecular level remains to be investigated. Our results indicating a 
lowering of apoB and cholesterol content of LDL and highly atherogenic sd-LDL in 3 
models of stressed hamsters treated with tocotrienols may involve similar mechanisms as 
described above (Minhajuddin et al, 1999; Parker et al, 1993; Theriault et al., 1999a). 
Oxidative modification of lipoproteins is believed to play a central role in the 
pathogenesis of atherosclerosis (Berliner and Heinecke, 1996; Steinberg, 1997). Because 
plasma contains several antioxidants (Frei, 1995) and lipoproteins with oxidative damage 
have been isolated from atherosclerotic lesions (Berliner and Heinecke, 1996; Steinberg, 
1997), lipoprotein oxidation generally is considered to occur in the vessel wall. Although 
lipid oxidation in the vessel wall is thought to occur as a result of a local deficiency of 
endogenous antioxidants or an excess of free metal ions, only limited data support these 
hypotheses. Research has shown that human atherosclerotic plaques contain massive 
amounts of lipid peroxidation products, despite the presence of large quantities of 
a-tocopherol (vitamin E) and ascorbate (Suama, 1995). Therefore, it is unclear whether 
oxidized lipoproteins originate in the arterial wall or are produced in the circulation and 
then enter the intimal space. Our data show that systemic oxidation of lipid/lipoprotein 
particles occurs as a part of the host response to infection and inflammation. Conjugated 
diene (which measure the initial phase of lipid peroxidation), lipid hydroperoxide 
(intermediate product of lipid peroxidation) and MDA (which measure the degradation 
phase of lipid peroxidation) in plasma, erythrocytes, liver and kidney are significantly 
149 
Discussion 
increased in hamsters after LPS, turpentine or zymosan administration. A similar 
increase in serum conjugated diene and MDA has been reported in 3 models of stressed 
hamsters. However, protective effect of antioxidant vitamins or lipid lowering agents 
with antioxidant property, such as statins, was not investigated (Memon et ah, 2000). 
The increase in plasma lipid peroxidation products is associated with a significant 
decline in total antioxidants capacity of plasma. The former suggests increased 
production of oxidants while the latter indicates diminished antioxidant defense. Both the 
changes indicate an existence of profound oxidative stress. These resuhs are in 
concordant with well known prooxidant properties of LPS, turpentine and zymosan. 
Administration of LPS (acute systemic infection), zymosan (acute noninfectious 
systemic inflammation), and turpentine (acute localized sterile inflammation) generally 
leads to fulminant release of reactive oxygen species (ROS) (Gabay and Kushner, 1999; 
Mehta et ah, 1998). Acute infection and inflammation results in an increase in plasma 
TNF-a and NO levels, suggestive of activation of the inflammatory response and thus an 
increase in lipid peroxidation related to reactive nitrogen species (RNS) as well as ROS 
(Sung et ai, 2005; Tsao et al., 2003; Mehta et al, 1998). Our results indicate a 
significant decrease in plasma lipid peroxidation products with a concomitant and 
significant increase in plasma total antioxidants in 3 groups of stressed hamsters 
pretreated with 10 mg Tocomin/day for 10 days before and 12 h after LPS (L-Ti), or 24 
h after turpentine or zymosan injection. However, simultaneous administration of LPS 
and 5 mg Tocomin to hamsters (L-T2), 12 h prior to killing, the increase in plasma total 
antioxidants was significantly lower (19 % in L-T2 vs. 106 % in L-Ti) with no decrease 
in the levels of conjugated diene and lipid hydroperoxide except a decline of only 11 % 
in MDA, indicating that pretreatment of hamsters with dietary tocotrienols, 10 days prior 
to LPS administration is essential. Therefore, LPS-, turpentine- or zymosan-induced 
oxidative stress was not only attenuated but significantly reversed/restored in hamsters 
pretreated with Tocomin. These results are in agreement with an earlier report (Skibska 
et al, 2006) indicating an increase in plasma MDA and a decrease in total antioxidants 
capacity in LPS treated rats, which were reversed by subsequent lipoic acid treatment, a 
known nonenzymatic antioxidant. Similar to plasma, MDA content of erythrocytes in 
LPS, turpenfine or zymosan stressed hamsters were significantly increased by 52 %, 
26 % or 30 %, respectively. The intact erythrocytes isolated from 3 groups of stressed 
hamsters exhibited a further increase (>4-fold) in susceptibility to hydrogen peroxide 
induced MDA release, as compared to the respective basal MDA content. Pretreatment 
of stressed hamsters with Tocomin significantly blocked the in vivo as well as in vitro 
susceptibility of erythrocytes to lipid peroxidation and reversed the MDA levels close to 
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normal control values. Based on our results, its seems plausible that oxygen radicals 
formed over and above the detoxifying capacity of erythrocytes can cause peroxidative 
breakdown of phospholipid fatty acids and accumulation of MDA, which may enhance 
membrane damage. Our study suggests that due to constant availability of antioxidants, 
tocotrienols, in the body of treated hamsters, the integrity of erythrocytes membrane is 
significantly improved as shown by substantial protection against in vivo and in vitro 
H2O2 induced lipid peroxidation. An increase in erythrocytes MDA concentration was 
previously reported in LPS treated rats, which were significantly reduced following 
treatment with vitamin A, C, E or EGB761 (Kanter et al, 2005; Coskun et al, 2005). 
Consistent with the increased lipid peroxidation in plasma and erythrocytes, the 
conjugated diene, lipid hydroperoxide and MDA in liver and kidney of 3 groups of 
stressed hamsters were also significantly increased. However, their degree of increase 
was significantly lower than plasma and erythrocytes lipid peroxidation products. Similar 
to erythrocytes, free radical mediated enhanced peroxidation of tissue membrane fatty 
acids is significantly blocked in stressed hamsters pretreated with Tocomin. A similar 
increase in MDA level in kidney (Coskun et al, 2005) and liver (Kaur et al, 2006; 
Vimal and Devaki, 2004) in LPS treated rats have been reported earlier, which were 
significantly declined after vitamin E or EGB761, allicin and hespiridin treatment. 
Zymosan treated rats (Deitch et al, 1992) and turpentine treated rabbits (Proulx and Du 
Souich, 1995) also exhibited an increase in hepatic conjugated diene or MDA formation. 
However, in these studies antioxidant supplementation was not used. 
Although LDL is a major risk factor for CAD, experiments have shown that 
incubation of macrophages with native LDL does not result in foam cell formation, a 
characteristic feature of atheromatous lesions (Brown and Goldstein, 1983). However, 
after chemical modification of LDL, rapid uptake occurs, leading to cholesterol 
accumulation in the macrophage with subsequent foam cell formation, which suggests 
that LDL modification is a necessary step in atherogenesis. Oxidized LDL can induce 
foam cell formation, and oxidative modification of LDL is now recognized as an 
important process that occurs in vivo (Steinberg et al., 1989). Different subclasses of 
LDL have been isolated based on size or density. As discussed earlier (page no. 146), 
besides increase in the circulating levels of LDL during infection and inflammation in 
hamsters, there is an appearance of high concentrations of sd-LDL subpopulation, which 
is shown to be more atherogenic than LDL. An enhanced susceptibility to oxidative 
modification could contribute to the greater atherogenecity of small, dense LDL (De 
Graaf er al, 1991; Tribble et al, 1992; Dejager et al, 1993; Chait et al, 1993; Tribble et 
al, 1994; Tribble et al, 1995; Tribble et al, 2001). In contrast to native LDL, oxidized 
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LDL particles initiate a series of events, including vascular inflammation and 
macrophage foam cell formation that are central to the atherogenic process (Tribble, 
1999). LDL particles with a greater tendency to become oxidized might thus be more 
likely to participate in proatherogenic events. There is only one published report (Memon 
et ai, 2000) demonstrating a significant increase in conjugated diene and lipid 
hydroperoxide levels in LDL fraction from LPS or zymosan treated hamsters. Moreover, 
LDL isolated from LPS treated hamsters was significantly more susceptible to in vitro 
oxidation with Cu"*""^  resulting in a 3-fold decrease in lag phase (Memon et ai, 2000). No 
one to date has studied the protective effect of dietary tocotrienols, a known 
hypolipidemic agent with a strong antioxidant property, on the ex vivo and in vitro Cu^ "^ -
induced oxidizability of more atherogenic sd-LDL and less atherogenic Ib-LDL as well 
as LDL isolated from normal and LPS, turpentine or zymosan treated hamsters. Our 
results show that in normal hamsters, relative to Ib-LDL, sd-LDL susceptibility to in vivo 
oxidation, measured as ex vivo base line diene conjugation (BDC), was increased, 
whereas, in comparison to a lag phase value of 90 min and 60 min for LDL and Ib-LDL, 
the lag time of sd-LDL was markedly reduced to 18 min, indicating a 3- to 5-fold 
shortening in the lag phase of sd-LDL oxidation. This substantial difference in the 
oxidative susceptibility between sd-LDL and Ib-LDL of normal hamsters is consistent 
with the previous reports indicating an inherently reduced content of antioxidant and free 
cholesterol, increased amount of more oxidizable polyunsaturated fatty acids and 
preformed hydroperoxide in sd-LDL particles (De Graaf et ai, 1991; Thomas et al., 
1994; Sevanian et al., 1996; Tribble et al., 2001). During acute infection and 
inflammation in L-C, T-C and Z-C, due to exaggerated oxidative stress and depletion of 
plasma antioxidants, the ex vivo BDC level of sd-LDL, in comparison to Ib-LDL, was 
further increased by an average value of ~1.9-fold, indicating an enhanced in vivo 
oxidative susceptibility of sd-LDL. The Cu '^^ -catalyzed oxidizability of sd-LDL from 
stressed hamsters was further reduced fi-om a lag time of 18 min in N-C to 8 min, 14 min 
and 12 min in L-C, T-C and Z-C, while in Ib-LDL, lag time was reduced to 30 min in L-
C and 40 min in both T-C and Z-C from a N-C lag time value of 60 min. Consistent with 
these results, maximal conjugated diene as well as MDA formation in LDL and Ib-LDL 
was achieved after 12 h of oxidation, while for sd-LDL only 30 min was needed, 
indicating a substantially enhanced oxidative susceptibility of sd-LDL as compared to Ib-
LDL or LDL. Tocomin supplementation partially blocked the in vivo and in vitro LDL, 
sd-LDL and Ib-LDL oxidizability as seen by a decrease in ex vivo BDC levels and an 
increase in their lag phase values. Similarly, ex vivo basal and Cu'^ '^ -induced maximal 
formation of lipid hydroperoxide and MDA were markedly increased in circulating LDL, 
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sd-LDL and Ib-LDL from animals treated with LPS, turpentine or zymosan. The 
significant increase in conjugated diene, lipid hydroperoxide and MDA in LDL and sd-
LDL persists when expressed as nanomoles per milligram protein or cholesterol, which 
suggests that increased oxidation of LDL density subfractions was not merely a result of 
change in the composition of LDL and sd-LDL during APR. Relative to Ib-LDL, a 
markedly increased in vivo and in vitro oxidizability of sd-LDL subpopulation during 
APR suggests that it may be more prone to further oxidation in the vessel wall of humans 
during infection and inflammation, as reported for atherogenic lipoprotein phenotype 
pattern B subjects by Chait et al. (1993). Pretreatment of stressed hamsters with Tocomin 
caused a significant decrease and partially normalized both the basal and maximal levels 
of lipid hydroperoxide and MDA in LDL, sd-LDL and Ib-LDL. Our results demonstrate 
that plasma and LDL associated phospholipids were also increased during APR, which 
were significantly decreased in Tocomin pretreated hamsters. In comparison to plasma 
and LDL phospholipids, lysophosphatidylcholine content (LPC) of LDL, which is 
known to exert several proatherogenic effect and is a marker for oxidative modification 
of LDL (Steinberg, 1997), was substantially increased (4- to 8-fold) in circulating LDL 
after LPS, turpentine or zymosan treatment, which indicates that lipoprotein 
phospholipids are oxidized in vivo during APR. A similar increase in LDL associated 
LPC content in LPS treated hamsters was previously reported by Memon et al. (2000). 
Feeding of dietary tocotrienols for 10 days before and 12 h after LPS or 24 h after 
turpentine or zymosan administration, significantly blocked the increase in LPC levels of 
LDL and reduced them by 1.3- to 1.6-fold, indicating a potent hypolipidemic and 
antioxidant property of Tocomin. Together, these results indicate that LDL isolated from 
LPS, turpentine or zymosan treated hamsters was more susceptible to in vitro Cu"^-
catalyzed oxidation, which suggests that acute phase LDL may alone be more susceptible 
to fiirther oxidation in the vessel wall. 
Several mechanisms could contribute to increased oxidative modification of 
LDL, sd-LDL and Ib-LDL dtiring APR. Paraoxonase (PON)/arylesterase are HDL-
-associated enzyme that protects LDL and HDL from oxidative stress (Mackness et al., 
1991; Watson et al, 1995). This enzyme destroys oxidized phospholipids that are 
biologically active and thereby prevents the toxic proatherogenic effects induced by 
oxidized LDL (Watson et al, 1995) and preserves HDL modification by lipid peroxides 
(Shih et al, 1998; Oda et al, 2002). Van Lenten et al. (1995) have previously reported 
that PON activity in HDL decreased in rabbits following injection of croton oil and in 
humans postoperatively. Recently, Asian et al. (2008) have demonstrated that senun 
PON and arylesterase activities were significantly decreased in H. pylori infected 
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subjects. Our results demonstrate that plasma and HDL arylesterase activity significantly 
decreases (22 % to 38 %), whereas, LDL-C/arylesterase activity ratio was significantly 
increased following LPS, turpentine or zymosan administration. This reduction in 
arylesterase activity with a concomitant increase in LDL-C/arylesterase activity ratio is 
consistent with earlier reports in LPS treated hamsters (Feingold et al., 1998) or in 
H. pylori infected subjects (Asian et al., 2008). However, in those studies protective 
effect of any antioxidants or a hypolipidemic drug with antioxidant property was not 
investigated. In our study, pretreatment with Tocomin significantly prevented both the 
decrease in arylesterase activity as well as increase in LDL-C/arylesterase activity ratio, 
and reversed these levels close to normal control values. It has previously been shown 
that depletion of PON results in the loss of the antioxidant function of HDL, and addition 
of PON to HDL restores the protective function of HDL (Castellani et al, 1997). In 
addition, Aviram et al. (1998) also reported that purified PON is a potent inhibitor of 
in vitro LDL and HDL oxidation. Additionally, lipoproteins isolated from PON knockout 
mice were more susceptible to oxidation than lipoprotein isolated from their wild-type 
littermates (Shih et al., 1998), and PON knock out mice on a high fat-high cholesterol 
diet are more susceptible to atherosclerosis (Shih et al, 1998). These studies strongly 
suggest an important role for PON in preventing the oxidation of both LDL and HDL, 
and hence in the protection of atherosclerosis. Our results indicating a markedly 
enhanced in vivo as well as in vitro oxidizability of more atherogenic sd-LDL than 
Ib-LDL in conjunction with a decreased plasma and HDL arylesterase activity during 
APR is likely to be a potential mechanism for the increased oxidation of circulating LDL 
density subfractions. A decrease in arylesterase activity during acute phase response 
could therefore be another factor linking the APR with increased atherogenesis. 
Xanthine oxidase (XO) and xanthine dehydrogenase (XD) are interconvertible 
forms of the same enzyme, known as xanthine oxidoreductase (XOR) (Borges et al, 
2002). In purine catabolism, XOR catalyzes the oxidative hydroxylation of hypoxanthine 
to xanthine and subsequently of xanthine to uric acid. Uric acid acts as a potent 
antioxidant and free radical scavenger. Xanthine oxidoreductase has, therefore, important 
functions as a cellular defense enzyme against oxidative stress. With both XO and XD 
forms, but particularly with the XO form, numerous ROS and RNS are synthesized 
(Vorbach et al, 2003). Thus, the synthesis of both an antioxidant (uric acid) and 
numerous free radicals (ROS and RNS) makes XOR an important protective regulator of 
the cellular redox potential. Xanthine oxidase generates Or' by catalyzing hypoxanthine 
and xanthine to uric acid. Under pathophysiologic conditions, this is another major 
source of vascular oxidative stress (Droge, 2002). Xanthine oxidase exists in plasma. 
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liver, kidney and endothelial cells but not in smooth muscle cells (Harrison et ai, 2003). 
There is overwhelming evidence that serum XO levels are significantly increased in 
various pathological states (Borges, et al., 2002). The role of XO in the vascular 
dysfunction that occurs in the atherosclerosis was reported by White et al. (1996). Based 
on the above information, it may be possible that the inhibition of this enzymatic 
pathway by compounds that have both antiradical as well as XO inhibitory properties 
could provide additional therapeutic benefit. It has been reported that some flavonoids 
and structurally related antioxidants inhibit XO activity (Nagao et al., 1999; Khan and 
Sultana, 2004). Increased XO activity in plasma, liver and kidney of different animal 
models has been reported during LPS, E. coli infection or turpentine and zymosan 
induced inflammation (Celik et al., 2007; Kahl et al., 2004; Kurosaki et al., 1995; Deitch 
et al., 1992; Proulx and Du Souich, 1995). Our results show a significant increase in 
plasma, liver and kidney XO activity in LPS, turpentine or zymosan stressed hamsters. 
Pretreatment of these hamsters with Tocomin significantly blocked this increase in XO 
activity to a level close to corresponding normal control values. These results show that 
dietary tocotrienols, in addition to their potent hypolipidemic and antioxidant activity, 
has the ability to inhibit XO activity in plasma, liver and kidney, indicating an additional 
therapeutic benefit in the prevention and treatment of infection and inflammation 
induced atherosclerosis. 
The acute phase response represents the initial line of defense against injury as 
well as bacterial and parasitic infections. Lipopolysaccharide, turpentine or zymosan, 
which elicits the APR, has been shown to reduce the expression of certain conjugation 
enzymes as well as antioxidant enzymes. Cytokines, secreted from macrophages in 
response to infection and inflammation, have been implicated in the suppression of 
activity of these enzymes in addition to their role in oxidative stress. These enzymes are 
important in defending the body against free radicals as well as toxic substances by 
converting them to a form that can be readily excreted. Therefore, any changes in these 
enzymes could be potentially detrimental to the host by altering these defense 
mechanisms. Normal cellular metabolism involves the production of ROS (McCord, 
1993), low levels of ROS are vital for proper cell functioning, while excessive in vivo 
generation of these products can adversely affect cell functioning (Gregorevic et al., 
2001; Fattman et ai, 2003). Malondialdehyde (MDA) is one of the final products of lipid 
peroxidation in human cells, and an increase in ROS causes overproduction of MDA, 
which is considered a surrogate marker of oxidative stress (Nielsen et al., 1997; Draper 
et ai, 1990). Increased MDA production in erythrocytes is known to cause a decrease in 
the membrane fluidity of the membrane lipid bilayer and increased osmotic stability of 
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cells (Raccah et al., 1996). The major intracellular antioxidant enzyme, superoxide 
dismutase (SOD), specifically converts superoxide radicals to hydrogen peroxide, 
(Andersen et al, 1997) and catalase (CAT) as well as glutathione peroxidase (Gpx) 
detoxifies hydrogen peroxide to water (Inoue et al., 1994). Glutathione peroxidase 
protects against free radical injury by reducing the peroxide concentration via a 
glutathione dependent reduction process, thereby reducing the amount of peroxides 
available to produce cellular damage. Reduced glutathione is a major intracellular 
nonenzymatic antioxidant. It has many biological functions, including maintenance of 
membrane protein and lipoprotein SH groups in the reduced form, the oxidation of which 
can otherwise cause altered cellular structure and function. Glutathione cycle operates in 
the erythrocytes for the disposal of H2O2 generated in the cell supplementing the function 
of catalase. Glutathione (GSH) and H2O2 are twin substrates for Gpx. Glutathione is 
formed from its oxidized form, GSSG by the enzyme glutathione reductase (Gred), 
which requires NADPH as a cofactor (Meister, 1992; Meister and Anderson, 1983). 
Therefore, as the balance between free radical production and antioxidant defenses is 
lost, the resultant oxidative stress through a series of events deregulates the cellular 
functions leading to various pathological conditions. An antioxidant compound might 
contribute partial or total alleviation of such damage. An impaired ROS scavenging 
function has been linked to the decreased activity of enzymatic and nonenzymatic 
scavengers of free radicals. Our results demonstrate a significantly lower CAT and SOD 
activities in erythrocytes from LPS, turpentine or zymosan treated hamsters, while MDA 
levels in plasma, erythrocytes or H2O2 induced MDA release in intact erythrocytes were 
significantly increased. In addition, the activity of Gred and intracellular GSH content in 
erythrocytes was also significantly reduced, while Gpx activity was significantly 
increased. This decrease in GSH level during APR may be due to the combined effect of 
inhibited Gred and reduced NADPH supply. Our result showing an increased 
erythrocytes Gpx activity in stressed hamsters apparently further reduces the GSH 
content. In addition, the increased Gpx activity represents a compensatory mechanism to 
degrade H2O2. These results are consistent with the findings of Yerer et al. (2006) 
showing a decrease in CAT activity and an increase in Gpx activity in LPS treated rats. 
Dietary Tocomin given 10 days before the onset of infection and inflammation 
significantly improved the integrity of erythrocytes membrane as shown by improved 
protection against lipid peroxidation as well as reversal of SOD, CAT, Gpx, and Gred 
including GSH content to near normal level. 
As discussed above, oxidative stress causes impairment in enzymatic and 
nonenzymatic defense system that may lead to cellular damage because of their 
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decreased capacity to remove the generated free radicals. In addition, changes in some 
conjugative enzymes, such as glutathione-S-transferase (GST) have been reported 
following endotoxin treatment that could alter an animal's response to drugs or other 
compounds that are metabolized by these enzymes. Glutathione-S-transferase is an 
important enzyme involved in conjugation reaction catalyzing the detoxification of a 
variety of endogenous and exogenous compounds. Glutathione-S-transferase provides 
protection to tissues by the conjugation of xenobiotics to GSH. The conjugation reaction 
removes some of the intracellular GSH that may enhance oxidant injury because the 
level of GSH is low and is not available for antioxidant enzymes such as Gpx. Our 
results show a significant decrease in the activities of antiperoxidative enzymes, CAT, 
SOD, Gpx, Gred and GST in liver and kidney during APR, induced by the administration 
of LPS, turpentine or zymosan to hamsters. In principle, the decreases observed in the 
activities of the above antioxidant enzymes in liver and kidney are consistent with 
several scattered reports, where only one of the three above APR inducers was used in 
the rat, rabbit or mice model. A decrease in the hepatic SOD, CAT, Gpx and GST 
activities in LPS treated rats has previously been reported (Macdonald et ah, 2003; 
Watson et al., 1999; Payabvash et ai, 2006; Vimal and Devaki, 2004). In zymosan 
treated mice, a decrease in liver CAT activity was previously reported by Deitch et al. 
(1992), while a significant decrease in hepatic CAT, SOD and Gpx activities in 
turpentine treated rabbits has been reported by Proulx and Du Souich (1995). A couple of 
reports show a decrease in kidney SOD, CAT and Gpx activities in LPS treated rats 
(Kanter et al., 2005; Coskun et al., 2005). In addition, vitamin E treatment decreased 
lipid peroxidation, increased enzymatic antioxidant activities and also prevented the 
renal tissue damage in LPS treated rats (Coskun et al., 2005). 
Glutathione is found in relatively high concentrations in liver and is usually the 
most abundant intracellular thiol. Glutathione protects against oxidative damage in 
systems that scavenge radicals, eliminate lipid peroxidation products, preserve 
thiol-disulfide status of proteins, and repair oxidant damage (Shan et al., 1990). 
Maintenance of normal cellular GSH levels is crucial for a variety of cellular functions, 
and oxidative stress has been associated with a decrease in these levels (Okabe et ai, 
1994). In this study, total, free and protein bound-SH contents of glutathione in liver and 
kidney were decreased following LPS, turpentine or zymosan exposures, suggesting an 
increased utilization of glutathione during the removal of free radicals and peroxides. 
This decrease in hepatic and kidney GSH levels in stressed hamsters may be due to the 
effect of inhibited Gred activity and also apparently due to reduced supply of NADPH. 
In addition, since GSH also acts as substrate and cosubstrate in essential enzymatic 
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reactions of Gpx and GST, inhibition of their activities may also be due to decreased 
levels of GSH during APR in liver and kidney. Support to these results is obtained by the 
finding of Portoles et al. (1996) where endotoxin exposure to rats caused a significant 
decrease in total glutathione with significant increase in GSSG levels, an indicator of 
increased oxidative stress. Because the ability of cells to withstand oxidative stress is 
partially mediated by glutathione, changes in glutathione levels may predispose the 
animal to oxidative injury. Other studies have shown that GSH depletion intracellularly, 
by binding GSH (Nathan et al, 1981) or decreasing GSH synthesis (Arrick et al, 1982), 
predisposes the cell to oxidative injury. Our results are consistent with other reports 
indicating a reduction in levels of hepatic GSH in LPS treated rats (Watson et al., 1999; 
Payabvash et al, 2006; Portoles et al, 1996; Vimal and Devaki, 2004; Kaur et al, 2006) 
and in turpentine treated rats (Belmonte et al, 2007) and rabbits (Proulx and Du Souich, 
1995). Tocomin administration to hamsters, 10 days before the onset of infection and 
inflammation significantly blocked the oxidative stress, as evidenced by a significant 
increase in hepatic and kidney SOD, CAT, Gpx, Gred and GST activities including GSH 
content and restored these levels close to corresponding normal control values. 
Restoration of overall antioxidant defense system by Tocomin may also be beneficial in 
preventing LPS, turpentine or zymosan induced oxidative hepatic and renal tissue 
damage. 
Our results indicating strong antioxidant impacts of Tocomin in LPS, turpentine 
or zymosan stressed hamsters are in agreement with earlier findings of our laboratory in 
normolipidemic and hyperlipidemic rats as well as hyperlipidemic/atherosclerotic rabbits 
(Beg et al, 2000a; Beg et al, 2000b; Beg and Zainuddin, 2003), and other reports 
indicating an inhibition in the formation of conjugated dienes and MDA by Tocotrienol 
rich fraction (TRF) or individual tocotrienols and tocopherols when fed to rats along with 
an atherogenic diet. These results also indicate that y-tocotrienol exerts a significantly 
more potent impact as compared to a-tocopherol (Watkins et al, 1993). Support to our 
results is also obtained from another study where feeding of a mixttire of tocotrienols 
along with an atherogenic diet to rabbits was associated with a significant reduction in 
the formation of serum lipid peroxides (Teoh et al, 1994). Tocotrienol rich fi-action 
treatment of patients with hyperlipidemia and carotid stenosis caused a significant 
decrease in MDA, an ex vivo indicator of maximal platelet peroxidation (Tomeo et al, 
1995; Theriault et al, 1999b). The antioxidant activity of the a-tocotrienol (T3) 
homologue has been shown to be more than 3-fold greater than that of a-tocopherol (T) 
(Packer, 1995). Using an in vitro liposome system, antioxidant activities for several 
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tocotrienols were 4- to 33-fold higher than that for a-T. The order of activity was 
didesmethyl tocotrienols (d-P25-T3)> desmethyl (d-P21-T3)>TRF25 >8-T3 >y-T3>a-
T3>a-T (Qureshi et al., 2000). These results indicate that in intact membranes, including 
LDL particles, tocotrienols may have a significantly greater antioxidant effect than 
tocopherols and they may provide greater protection against CAD. Didesmethyl 
tocotrienols (d-P25-T3) is the most potent homologue of all natural forms of unsaturated 
(T3) and saturated (T) vitamin E tested. These findings were further confirmed by 
determining the antioxidant activities involving coupled autooxidation of P-carotene and 
linoleic acid. The antioxidant activities of known a-, y- and 5-tocotrienols and TRF25 
(prepared from stabilized and heated rice bran with 6 % a-T) were 22 %, 27 %, 32 % 
and 24 % better than a-T, respectively (Qureshi et al, 2000). The possible mechanism 
for this superior efficacy of tocotrienols compared to tocopherols has been reported 
elsewhere (Packer, 1995). Comparative protective effects of TRF (75 % tocotrienols and 
25 % a-tocopherol) and a-tocopherol on copper-induced oxidation of plasma LDL and 
indices of lipid peroxidation in human umbilical vein endothelial cells revealed that TRF 
is a more (2.5-fold) potent antioxidant than a-tocopherol (Mutalib et al., 2003). 
Differences in the transport and tissue uptake of the saturated (T) and unsaturated (T3) 
tocols have been reported by other investigators (Kayden and Traber, 1993; Hayes et al, 
1993; Pearson and Barnes, 1970). A hepatic binding protein with high specificity for a-T 
in the liver results in the subsequent enrichment of this tocol in the VLDL moiety and as 
a consequence, the LDL moiety. The tocotrienols on the other hand are transported non-
-specifically like other lipid soluble compounds (Kayden and Traber, 1993; Pearson and 
Barnes, 1970; Suama et al, 1993). Thus, although tocotrienols was found to be more 
potent in vitro, the poor absorption of these compounds in the intestine is suggested to 
significantly affect their efficacy in vivo. It has been previously reported that treatment of 
hypercholesterolemic humans with TRF25 resulted in substantial increases in the levels 
of LDL-bound antioxidants, especially tocotrienols, which are known to have 
significantly greater antioxidant activity than tocopherols (Qureshi et al, 1997). 
Therefore, it appears that tocotrienols as TRF or Tocomin exert their antioxidant effect 
on plasma LDL oxidation while being attached to LDL particle. 
Based on our combined results and other scattered reports, it is evident that 
infection and inflammation induce the APR, leading to multiple alterations in lipid and 
lipoprotein metabolisms aimed at decreasing the toxicity of a variety of harmful agents 
and fissue repair by redistributing nutrients to cells involved in host defense 
(Khovidhunkit et al, 2004). Acute phase response, mediated by cytokines, preserves the 
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host from acute injury. The activation of the inflammatory cascade will induce an 
increase in plasma TG levels, which increases from increased VLDL secretion as a result 
of adipose tissue lipolysis, increased de novo hepatic fatty acid synthesis, and 
suppression of fatty acid oxidation. With more severe infection, VLDL clearance 
decreases secondary to decreased lipoprotein lipase and apolipoprotein E in VLDL 
(Khovidhunkit et al., 2004). In rodents, hypercholesterolemia is attributable to increased 
hepatic cholesterol synthesis and decreased LDL clearance, conversion of cholesterol to 
bile acids, and secretion of cholesterol into the bile. LDL levels increased during 
infection and inflammation while in humans LDL levels decreased but there is an 
increase in more atherogenic sd-LDL particles (Khovidhunkit et al, 2004). Acute phase 
response increases the serum cholesterol levels by increasing hepatic cholesterol 
synthesis which is due to an increase in the transcription rate, mRNA expression, protein 
mass, and activity of HMG-CoA reductase, the rate-limiting enzyme in the biosynthetic 
pathway of cholesterol in liver (Feingold et al, 1993a). On the other hand, LPS 
administration decreases apoE mRNA levels in the liver while having no effect on apoAI 
mRNA levels. These findings suggest that HMG-CoA reductase is member of group of 
hepatic proteins that are positively regulated by inflammatory stimuli (acute phase 
proteins) while apoE can be considered a negative acute phase protein in hamsters. 
Therefore, it is possible that increase in hepatic HMG-CoA reductase provide cholesterol 
that allows for the increased production of VLDL and LDL and elevations in serum lipid 
levels that may be beneficial to the body's host defense (Feingold et al, 1993a). 
Infection and inflammation leads to a reduction in HDL levels with marked 
changes in HDL structure and metabolism (Khovidhunkit et al, 2004). Many of the 
enzymes and transfer proteins that are responsible for the remodeling of HDL, including 
LCAT, hepatic lipase, CETP, and PLTP, decrease while sPLA2 increases during 
inflammation (Khovidhunkit et al, 2004; Ly et al, 1995). Inflammatory HDL particles 
are increased in size with decreases in cholesterol ester and increases in free cholesterol, 
TG, and FFA. There are also marked changes in the protein composition of HDL. 
ApoAI, apoAII, apoM and paraoxonase I levels decrease while SAA, lipopolysaccharide 
binding protein, apoJ, apoE, apoAIV, and apoAV increase (Khovidhunkit et al, 2004; 
Feingold et al, 2008; Auerbach and Park, 1989; Feingold et al, 1998; Hardardottir et al, 
1994c). In addition to these structural changes induced during infection and 
inflammation there are marked changes in the function of HDL. While normal HDL 
protects LDL from oxidation, HDL isolated during inflammation promotes LDL 
oxidation (Van Lenten et al, 1995). Finally, HDL isolated during inflammation does not 
facilitate the movement of cholesterol from macrophages to lipoprotein particles as 
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effectively as normal HDL (Khovidhunkit et al, 2001). Thus, the changes in HDL that 
occur during infection and inflammation could facilitate the development of 
atherosclerosis. 
Reactive oxygen species and free radicals are part of local host defense 
mechanisms, because they play a role in killing invading microorganisms and are 
induced by the same stimuli that induce APR. Due to the presence of persistence 
inflammation and oxidative stress, lipid peroxidation in plasma, erythrocytes, liver and 
kidney were increased with a concomitant decline in plasma total antioxidants, which is 
apparently responsible for cell membrane destruction and cell damage. Similarly, 
lipoproteins may scavenge these free radicals to prevent systemic toxicity and membrane 
damage. However, in doing so, lipoproteins may get oxidized. One of the major enzymes 
that play a key role in microbial killing, myeloperoxidase, is acutely released by 
activated neutrophils and monocytes in response to LPS and other inflammatory stimuli 
(Grisham, 1988). Myeloperoxidase also plays an important role in the oxidation of 
protein and lipid components of LDL and is expressed in atherosclerotic lesions 
(Heinecke, 1997). Moreover, LPS acutely induces the expression of lipoxygenases 
(Schade, 1986) to increase the synthesis of prostaglandins and leukotrienes during the 
inflammatory response. Lipoxygenases also participate in LDL oxidation by oxidizing 
fatty acids, cholesteryl esters, and phospholipids (Folcik, 1995). Because the activation 
of myeloperoxidase and lipoxygenases after LPS administration or other inflammatory 
stimuli occurs rapidly (Grisham, 1988; Schade, 1986) compared with LDL oxidation, 
which takes about 24 hours (Memon et al, 2000), it is unclear whether these enzymes 
participate in LDL oxidation during APR. Early activation of myeloperoxidase or 
lipoxygenase may initiate the oxidative process, which then accelerates after the 
depletion of paraoxonase/arylesterase or transferrin or after the upregulation of 
ceruloplasmin. Further research is warranted to understand fully the metabolic changes 
that occur during APR and contribute to lipoprotein oxidation. Infection and 
inflammation, which elicits the APR, has been shown to reduce the expression of certain 
conjugation enzymes as well as antioxidant enzymes. Cytokines, secreted from 
macrophages in response to endotoxin, have been implicated in the suppression of 
activity of these enzymes in addition to their role in oxidative stress. These enzymes are 
important in defending the body against free radicals as well as toxic substances by 
converting them to a form that can be readily excreted. Therefore, any changes in these 




The above results, which represent an initial demonstration, indicate that the host 
response to infection and inflammation induces several changes: hyperlipidemia, 
enhanced lipid peroxidation in plasma and tissues, with depletion in plasma total 
antioxidants, increased in vivo oxidizability of highly atherogenic sd-LDL, relative to Ib-
LDL and LDL, and overall weakening of antioxidant defense system. Moreover, in vitro 
oxidation of sd-LDL resulted in an approximately 3-fold shorter lag time than Ib-LDL. 
Therefore, LDL particles with a greater tendency to become oxidized might thus be more 
likely to participate in proatherogenic events. Increased oxidation of LDL density 
subfractions that occurs during infection and inflammation could be one of the 
mechanisms that may promote atherosclerosis in patients with chronic infection and 
inflammatory diseases. Oral pretreatment of hamsters with dietary tocotrienols for 10 
days significantly prevented the above LPS, turpentine or zymosan induced adverse 
effects and ameliorated the levels of all the evaluated parameters. Our results strongly 
suggest that the alleviation of inflammatory conditions is due to potent lipid lowering 
and free radical scavenging properties of dietary Tocomin and, thus, can be useful in the 
therapy of systemic inflammatory process which might induce atherosclerosis. In 
conclusion, considering the strong hypolipidemic/antiatherogenic and antioxidant actions 
of Tocomin, daily intake of tocotrienols as dietary supplement may be useful in the 
prevention and treatment of infection/inflammation induced dyslipidemia/hyperlipidemia 
as well as atherosclerosis in dyslipidemic patients with chronic infection. 
As discussed on page 146, Hirano et al. (2004) have shown that not only the 
prevalence of sd-LDL but also its concentration was significantly increased in subjects 
with various types of hyperlipidemia, hyperlipidemia with CHD and in type 2 diabetic-
hyperlipidemic patients with CHD. Similarly, Quebec cardiovascular study has 
confirmed that a predominance of sd-LDL is a strong and independent predictor of CHD 
in the first seven years of follow-up (St-Pierre et al., 2005). Recently, Koba et al. (2006) 
have reported that the progression of CHD was closely linked not to the LDL particle 
size, but to the concentration of sd-LDL. Thus, sd-LDL has been highlighted as a new 
powerful and better marker for the risk of diabetes with CHD and CHD alone (Austin et 
al, 1995; Austin et al, 1994). The data presented in this part of the thesis demonstrates 
the association between the distribution of cholesterol and apoB concentrations in sd-
LDL and Ib-LDL as well as their percent share of LDL in five groups of type diabetic 
subjects with varying degree of hypercholesterolemia. In addition, this study is the first 
to examine the in vivo and in vitro Cu"'"'-catalyzed oxidizability of more atherogenic sd-
LDL, less atherogenic Ib-LDL as well as LDL from normolipidemic and five groups of 
type 2 diabetic-hypercholesterolemic subjects. Thus, we have initially determined the 
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relationship between several indices of oxidation such as conjugated diene, lipid 
hydroperoxide, MDA and lag time of LDL, sd-LDL and Ib-LDL with their 
concentrations and degree of hypercholesterolemia in type 2 diabetic subjects. As 
described on page 51, based on serum TC, LDL-C and sd-LDL-C, 58 type 2 diabetic 
subjects with varying degree of hypercholesterolemia were categorized into five groups 
(Table 23 and 24). Due to prior treatment of diabetic subjects in group A and B with 
atorvastatin and fenofibrate for 98 and 47.3 weeks, their lipid parameters were 
normalized to a level similar to normal control values. However, since diabetic subjects 
in group C, D and E were on lipid lowering drugs for 39.3, 15 and 5.3 weeks, 
respectively, their degree of hypercholesterolemia, particularly increased LDL particles, 
in each group was higher in the order C<D<E. In the present study, mean cholesterol 
and apoB content of sd-LDL in normolipidemic subjects was 29 % and 30 % of total 
LDL-C or LDL-apoB, while for Ib-LDL it was 70 % and 67 % of LDL-C or LDL-apoB. 
It is interesting to mention that a similar distribution pattern in cholesterol and apoB 
concentrations of sd-LDL-C and Ib-LDL-C was observed in normolipidemic hamsters 
(Table 4, present study), rats (Ali, 2007) and humans (Hirano et al., 2004). As expected, 
a substantial increase of 101 %, 317 % and 539 % in sd-LDL-C of diabetic-
hyperlipidemic subjects in group C, D and E was seen, while a little increase (18 %-
30 %) in Ib-LDL-C levels had occurred. Thus, a majority of LDL-C (36 %, 103 % or 
128 %) was recovered in more atherogenic sd-LDL subpopulation of diabetic subjects in 
group C, D and E, while a decrease of 19 %, 43 % or 54 % of LDL-C was recognized in 
less atherogenic Ib-LDL, indicating a shift of cholesterol from Ib-LDL to more 
atherogenic sd-LDL subspecies. Our data consistently demonstrates that increase in the 
sd-LDL concentration is directly linked to the increase in LDL particles and severity of 
hypercholesterolemia, which in turn is responsible for the degree of alteration in the LDL 
size profile, with a shift fi^om less atherogenic Ib-LDL to more atherogenic sd-LDL. 
Although sd-LDL particles are cholesterol depleted (McNamara et al., 1996), our results 
show that both cholesterol and apoB content of sd-LDL and its percent share of total 
LDL-C and total LDL-apoB always increased in tandem, indicating a strong relationship 
between sd-LDL-C and sd-LDL-apoB values. These results suggests that quantification 
of cholesterol is sufficient to evaluate the sd-LDL mass and that apoB measurement is 
not essential. These results are fiilly consistent with the contention that cholesterol and 
apoB of each particle in LDL density subfractions is homogeneous. The above results 
indicating a marked increase in the levels of sd-LDL-C and sd-LDL-apoB and their 
percent share of total LDL-C or LDL-apoB in diabetic patients with varying degree of 
hypercholesterolemia are similar to the data in stressed hamsters, presented in the 
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preceding pages (Table 4). Some aspect of our results is in agreement with a previous 
report in diabetic patients with CHD, hyperLDLcholesterolemia, and 
hypercholesterolemia with CHD (Hirano et al, 2004). However, in that study, sd-LDL-C 
was measured and Ib-LDL-C was estimated as a difference between LDL-C and 
sd-LDL-C, while apoB levels associated with sd-LDL and Ib-LDL were not reported 
(Hirano et al., 2004). Small dense LDL is known to be generated from large triglyceride-
rich VLDLl particle, production of which is enhanced by insulin resistance during 
diabetes, thus resulting in an increased prevalence of sd-LDL subpopulation (Packard 
and Shephered, 1997; Tribble et al, 2001; Bemeis and Krauss, 2002). Our results are 
consistent with these findings, showing a significant increase in plasma TG, VLDL-C 
and sd-LDL-C levels in diabetic patients in group C, D and E. Thus, the greater 
atherogenic potential of sd-LDL relative to Ib-LDL may explain the higher incidence of 
CHD in diabetic patients than in isolated hypercholesterolemia (Hirano et al, 2004). In 
addition, because of greater preponderance of sd-LDL, a moderately high LDL-C 
(between 130 and 160 mg/dl) in a type 2 diabetic patient is equivalent to a much higher 
LDL-C in terms of CHD risk for a nondiabetic subject (Grundy et al, 1999; Haffher et 
al, 1998; NCEP Expert Panel, 1993). Based on our results, the primary target of therapy 
in type 2 diabetic patients with and without CHD should be aggressive lowering of 
highly atherogenic sd-LDL subspecies along with LDL-C to a level <100 mg/dl as 
suggested by NCEP Expert Panel for patients with preexisting CHD (NCEP Expert 
Panel, 1993). 
An increasing number of studies have pointed out a possible role of LDL 
peroxidation in the occurrence of atherogenic lesions, which are one of the most frequent 
complications of diabetes (Deckert et al, 1978; Stout, 1979; Colwell et al, 1981). The 
involvement of increased oxidative stress in diabetes is supported by several data such as 
increased concentrations of lipid peroxidation products, namely, conjugated diene, 
hydroperoxide and MDA as well as decreased plasma levels of antioxidants in diabetic 
patients (Sato et al, 1979; Karpen et al, 1984; Wolf, 1987). This study is the first to 
examine the ex vivo and in vitro Cu^" -^catalyzed oxidizability of LDL, more atherogenic 
sd-LDL and less atherogenic Ib-LDL from normolipidemic and diabetic subjects with 
varying degree of hypercholesterolemia i.e. hyperLDLcholesterolemia. In normal 
subjects, LDL, sd-LDL and Ib-LDL susceptibility to in vivo oxidation, measured as ex 
vivo baseline diene conjugation (BDC) was similar, while in diabetic subjects of each 
group, BDC formation was higher in the order LDL>sd-LDL>lb-LDL. In normal 
subjects, relative to Ib-LDL and LDL, the lag time required for Cu"^ "^ -catalyzed 
conjugated diene formation in sd-LDL was markedly shortened by >3-fold and >6-fold 
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respectively, indicating a substantially higher oxidative susceptibility of sd-LDL. This 
enormous difference in the oxidizability between sd-LDL, Ib-LDL or LDL of 
normolipidemic humans is consistent with the previous reports indicating an inherently 
reduced content of antioxidants, and free cholesterol, increased amount of more 
oxidizable polyunsaturated fatty acids and preformed hydroperoxide in sd-LDL 
(De Graaf e^  al., 1991; Thomas et al., 1994; Sevanian et al, 1996; Tribble et al, 2001). 
During prolonged diabetes coupled with hypercholesterolemia/hyperLDL 
cholesterolemia, due to sustained oxidative stress and increasing depletion of serum 
endogenous antioxidants in group A-E (-70 % to -88 % vs. N-C value; Table 29), the 
oxidizability of sd-LDL was further increased and its lag phase value of 12.0 min in N-C 
was reduced to 6.8 min in group A, 6.0 min in group B, 4.0 min in Group C, 2.0 min in 
group D and E, which is 6- to 15-fold or 12- to 20-fold lower than corresponding lag 
phase values in Ib-LDL or LDL. In contrast, considering the significantly increased 
buoyancy in Ib-LDL particles, its lag phase value of 40 min in N-C was not fiirther 
reduced in group A, B and C, while it was reduced to 30 min in group D and 12 min in 
group E, indicating a substantially lower susceptibility to Cu"^ "^ -catalyzed oxidation than 
sd-LDL. Maximal formation of conjugated diene and MDA during in vitro 
Cu'^-catalyzed oxidation of LDL and Ib-LDL was achieved after 12 h of incubation, 
whereas, for sd-LDL, these maximal values were obtained after 30 min of oxidation, 
indicating a markedly enhanced in vitro oxidizability of sd-LDL. 
Figure 3.2-3.17 demonstrates the ex vivo basal and Cu'*~ -^catalyzed in vitro time 
dependent increase in the generation of conjugated diene, lipid hydroperoxide, MDA and 
electrophoretic mobility of LDL, sd-LDL and Ib-LDL samples from normolipidemic and 
five groups of diabetic-hypercholesterolemic subjects. Consistent with the preferentially 
enhanced ex vivo oxidizability of sd-LDL subspecies in normal subjects, its 
electrophoretic mobility of 1.4 mm was also higher than 1.1 mm for Ib-LDL or 1.0 mm 
for LDL. As expected, in each group of diabetic-hypercholesterolemic subjects, the 
electrophoretic mobility of native sd-LDL, Ib-LDL and LDL was increased to a maximal 
value of 1.6 mm, 1.3 mm and 1.1 mm respectively, indicating a fiirther differential 
increase in the in vivo oxidative modification of the LDL density subfractions, which is 
apparently due to varying degree of increases in oxidative stress in these diabetic-
hypercholesterolemic subjects. In addition, in vitro Cu"^ "^ -catalyzed oxidation of LDL, 
sd-LDL and Ib-LDL in each group for indicated time periods, revealed a close 
association between progressive increase in the levels of three lipid peroxidation 
products and their electrophoretic mobility, indicating an overall oxidative modification 
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of lipid moieties including apoproteinB-100 contained in LDL and its density 
subfractions. A maximal electrophoretic mobility of 1.9 mm to 2.1 mm in LDL, sd-LDL 
and Ib-LDL from normal control and diabetic subjects of group A and B was obtained, 
which is consistent with the normalization of serum and lipoprotein lipid levels in group 
A and B (Table 23 and 24). Consistent with increasing hypersd-LDLcholesterolemia 
(100-540 % vs. N-C value; Table 25) in diabetic subjects of group C, D and E, the 
electrophoretic mobility of sd-LDL after only 4 min of oxidation was increased to a 
common mobility value of 2.3 mm from their corresponding native sd-LDL mobility 
value of 1.5 mm, 1.5 mm or 1.6 mm, respectively. In contrast, for less atherogenic Ib-
LDL, the electrophoretic mobility was increased from native Ib-LDL value of 1.2 mm 
and 1.3 mm to 1.9 mm and 1.8 mm in group C and D, respectively, after 120 min of 
oxidation, while in group E its electrophoretic mobility was increased to 1.9 mm from a 
native value of 1.3 mm, after 30 min of oxidation. Consistent with above resuhs, 
describing a significantly enhanced oxidizability of more atherogenic sd-LDL, its 
electrophoretic mobility was also substantially increased than less atherogenic Ib-LDL, 
indicating an enormous acceleration in Cu^^-catalyzed oxidation of sd-LDL. 
It is well known that diabetes may enhance oxidative stress not only through the 
increased production of ROS but also through weakening the antioxidant defense system. 
In this context, the antioxidant role of serum HDL-complexed arylesterase/paraoxonase 
(PON) enzyme in the protection of LDL as well as HDL from oxidative modification is 
important. In diabetic subjects, a lower PON/arylesterase activity and concentration, 
higher LDL-C: PON concentration ratio and a reduced capacity to prevent LDL 
oxidation have been reported (Boemi et ah, 2001; Patel et ah, 1990). Our results also 
show an increasing reduction in serum arylesterase activity (-5 % to -75 % vs. N-C 
value) and increasing elevation in LDL-C: arylesterase activity ratio (+34 % to +1036 % 
vs. N-C value; Table 29) in diabetic subjects of group A-E with increasing 
hyperLDLchoIesterolemia. Together, these results indicating an enhanced ex vivo and in 
vitro oxidizability of LDL and more atherogenic sd-LDL in conjunction with a decreased 
serum arylesterase activity and increased LDL-C: arylesterase activity ratio in diabetic 
subjects with varying degree of hyperLDLchoIesterolemia is likely to be a potential 
mechanism for the increased oxidation of circulating LDL density subfractions. 
Based on our combined results presented in this section of the thesis, it can be 
concluded that increasing severity of oxidative stress evoked in diabetic subjects is 
closely related to increasing degree of hypercholesterolemia, particularly 
hyperLDLchoIesterolemia and hypersd-LDLcholesterolemia, in the order C<D<E. This 
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differential effect was fully reflected in decreasing levels of serum total antioxidants and 
arylesterase activity as well as in several indices of oxidative stress, such as substantial 
shift from less atherogenic Ib-LDL to more atherogenic sd-LDL, differential in vivo and 
in vitro oxidizability of LDL, sd-LDL and Ib-LDL, as indicated by their ex vivo levels of 
conjugated diene, lag time and MDA. Taken together, the ex vivo and Cu'*" -^catalyzed in 
vitro oxidation of LDL, sd-LDL and Ib-LDL in each group for indicated time periods, 
revealed a close association between progressive increase in the levels of conjugated 
diene, lipid hydroperoxide and MDA and their electrophoretic mobility, which in turn 
ftilly correlated with increasing degree of hypercholesterolemia. 
It is interesting to mention that similar to diabetic-hypercholesterolemic patients 
in group C, D and E, different degree of hypercholesterolemia and oxidative stress 
induced in LPS (non-HDL-C +71 %, sd-LDL-C +238 % vs. N-C), turpentine 
(non-HDL-C +39 %, sd-LDL-C +84 %) and zymosan (non-HDL-C +47 %, sd-LDL-C 
+140 %) stressed hamsters also exhibited a similar corelationship between various 
parameters. These include hypercholesterolemia, particularly hyperLDLcholesterolemia 
and hypersd-LDLchoIesterolemia, in the order LPS<zymosan<turpentine stressed 
hamsters. This differential effect was fully correlated with decreasing levels of plasma 
total antioxidants and arylesterase activity as well as in several indices of oxidative 
stress, such as substantial shift from less atherogenic Ib-LDL to more atherogenic 
sd-LDL, and differential in vivo and in vitro oxidizability of LDL, sd-LDL and Ib-LDL. 
Based on the combined results presented in the thesis, it can be concluded that the 
increased prevalence and concentration of sd-LDL in dyslipidemic patients with either 
chronic infection and inflammation or diabetes might contribute to their increased CHD 
risk. Quantification of sd-LDL-C by a simple and rapid preciphation method involving 
fractionation of purified precipitated LDL (see "Methods", page 55) is useftil to evaluate 
atherogenic risks in various types of hyperlipidemia/hypercholesterolemias, including 
diabetieslinked dyslipidemia as well as infection and inflammation induced dyslipidemia. 
Thus, sd-LDL, being a better and integral marker for CHD risks, than LDL, is applicable 
to routine clinical use and allows the rapid analysis of large number of samples. Finally, 
considering the strong hypolipidemic/antiatherogenic and antioxidant actions of 
Tocomin, daily supplementation of dietary tocotrienols may be useful in the prevention 
and treatment of infection/inflammation and diabetes induced 
dyslipidemia/hyperlipidemia and atherosclerosis. Furthermore, daily intake of dietary 
Tocomin will be highly efficacious, cost effective as well as good source of vitamin E. 
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Results presented in the first part of the thesis demonstrate that hamsters, 12 h 
after lipopolysaccharide (LPS, acute systemic infection), or 24 h after zymosan (acute 
noninfectious systemic inflammation), or turpentine (acute localized sterile 
inflammation) administration, which are well characterized inducers of acute phase 
response (APR), became substantially hyperlipidemic. This hyperlipidemia in 3 distinct 
models of stressed hamsters was associated with significant increases in plasma total 
lipid, TG, FFA, TC, VLDL-C and LDL-C, with a minimum decrease (3 % to 17 %) in 
HDL-C. The results show that relative to esterified cholesterol, the increase in free 
cholesterol was substantially higher in L-C (151 %), T-C (53 %) and Z-C (94 %) 
hamsters, indicating a reduction in the esterification of free cholesterol, which is 
consistent with a reduced plasma LCAT activity. Feeding of dietary tocotrienols 
(Tocomin) for 10 days before and 12 h after LPS, or 24 h after turpentine or zymosan 
administration, significantly ameliorated all the above parameters. Consistent with 
plasma, liver and kidney TG, FFA and TC levels, which were increased in stressed 
hamsters, were significantly reduced to near normal value in Tocomin pretreated groups. 
Concordant with published reports that relative to large buoyant (lb-) LDL, the 
concentration of small dense (sd-) LDL was substantially increased in patients with 
hyperLDLcholesterolemia, hypertriglyceridemia, combined hyperlipidemia, and 
hyperlipidemia with CHD; our results demonstrate a substantial increase in more 
atherogenic sd-LDL. An average increase >59 %, >38 % or >48 % of LDL-C and 
LDL-apoB were recognized in sd-LDL subpopulation of L-C, T-C or Z-C stressed 
hamsters, respectively. Pretreatment of these hamsters with Tocomin significantly 
reduced the cholesterol and apoB content of sd-LDL as well as their percent share of 
LDL close to normal values. It is interesting to mention that Tocomin mediated reduction 
in sd-LDL-C levels was proportionally and preferentially greater than that of LDL-C 
levels. In addition, both cholesterol and apoB content of LDL density subfi-actions have 
always increased or decreased in tandem, indicating that each particle is homogeneous. 
Consistent with the known similarities of lipoprotein metabolism in hamsters 
with htunans, a LDL-C/HDL-C ratio of 2.49 in normal hamsters was obtained, which is 
lower than the normal range of 3.2-3.6 or preferably lower reported for humans. This 
normal ratio of 2.49 was increased to a ratio value of 4.53, 3.56 or 4.33 in L-C, T-C or Z-
C hamsters, respectively. Similarly, in normal hamsters, HDL-C/TC ratio of 0. 220 was 
observed, which is similar to a reported ratio of 0.20 or preferably higher in humans. 
This ratio of 0.220 in N-C was significantly reduced to a ratio value of 0.135 in L-C, 
0.166 in T-C or 0.138 in Z-C hamsters. In addition, we have initially included sd-LDL-
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C/HDL-C ratio, which was substantially increased from a normal ratio value of 0.751 to 
2.69, 1.43 or 2.16 in 3 groups of stressed hamsters. Pretreatment of stressed hamsters 
with dietary Tocomin reversed all the above ratios to near normal levels. These results, 
which represent an initial demonstration, indicate that treatment of stressed hamsters 
with tocotrienols effectively ameliorated all the lipid parameters including highly 
atherogenic sd-LDL. 
The significant increase in plasma and lipoprotein lipid levels in 3 models of 
infection and inflammation is consistent with a significant increase of 55 %, 41 % or 
47 % in hepatic HMG-CoA reductase activity of L-C, T-C or Z-C hamsters, respectively. 
Pretreatment of stressed hamsters with dietary Tocomin was associated with a significant 
reduction of 67 % to 72 %, in hepatic HMG-CoA reductase activity, which is apparently 
responsible for the reduction in lipid levels. Based on these results, it can be concluded 
that cholesterol lowering property of Tocomin in stressed hamsters is due to the 
suppression of enzymatic activity of HMG-CoA reductase, the rate limiting enzyme in 
the biosynthetic pathway of cholesterol. 
As a part of host response to infection and inflammation, plasma, erythrocytes, 
liver and kidney lipid peroxidation products, namely, conjugated diene, lipid 
hydroperoxide and malondialdehyde (MDA), as well as in vitro MDA release from intact 
erythrocytes subjected to hydrogen peroxide-induced lipid peroxidation were 
significantly increased (+54 % to +109 % vs. N-C), while plasma total antioxidants was 
significantly reduced (-33 % to -61 % vs. N-C) in L-C, T-C or Z-C hamsters. Tocomin 
administrafion to stressed hamsters for 10 days before and 12 h after LPS (L-Ti), or 24 h 
after turpentine or zymosan administration, significantly decreased the plasma, liver and 
kidney lipid peroxidation products including the in vitro MDA release from intact 
erythrocytes, with a concomitant and significant increase in plasma total antioxidants. 
However, simultaneous administration of LPS and 5 mg Tocomin to hamsters (L-T2), 12 
h prior to killing, the increase in plasma total antioxidants was significantly lower (18 % 
in L-T2 vs. 106 % in L-Ti) with no decrease in the levels of conjugated diene and lipid 
hydroperoxide except a decline of only 11 % in MDA, indicating that pretreatment of 
hamsters with dietary tocotrienols, 10 days prior to LPS administration is essential. Our 
resuhs show that during acute infection and inflammation in L-C, T-C or Z-C hamsters, 
due to exaggerated oxidative stress and depletion of plasma antioxidants, the ex vivo base 
line diene conjugation (BDC) levels of sd-LDL and Ib-LDL including LDL were 
increased. However, in comparison to Ib-LDL BDC level, sd-LDL BDC value was 
higher by an average value of ~1.9-fold, indicating a markedly enhanced oxidative 
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susceptibility of sd-LDL in vivo. Consistent with ex vivo BDC levels of LDL, sd-LDL, 
and Ib-LDL, susceptibility of these particles to Cu'^ '^ -induced oxidation, as measured by 
their lag time, was decreased in stressed hamsters. It is important to mention that in 
comparison to a lag phase value of 90 min for LDL and 60 min for Ib-LDL, in N-C, the 
lag phase of sd-LDL was only 18.0 min, indicating a substantially increased in vitro 
susceptibility of sd-LDL to oxidation. The Cu'^ '^ -catalyzed oxidizability of sd-LDL from 
stressed hamsters was further reduced from a lag time of 18 min in N-C to 8 min, 14 min 
and 12 min in L-C, T-C and Z-C, while the lag time of Ib-LDL was reduced to 30 min in 
L-C and 40 min in both T-C and Z-C from a N-C lag time value of 60 min. Tocomin 
supplementation partially blocked the in vivo and in vitro LDL, sd-LDL and Ib-LDL 
oxidizability as seen by a decrease in ex vivo BDC levels and an increase in their lag 
phase values. Similarly, Cu"^ -^induced maximal formation of lipid hydroperoxide and 
MDA in LDL and Ib-LDL was achieved after 12 h of oxidation, while for sd-LDL only 
30 min was required. These maximal lipid hydroperoxide and MDA levels were 
significantly decreased in Tocomin pretreated groups. Our results demonstrate that 
plasma and LDL associated phospholipids were also increased during APR, which were 
significantly decreased in Tocomin fed hamsters. In comparison to plasma and LDL 
phospholipids, lysophosphatidylcholine content (LPC) of LDL, which is known to exert 
several proatherogenic effect and is a marker for LDL oxidation, was substantially 
increased (4- to 8-fold) in circulating LDL after LPS, turpentine or zymosan treatment, 
which indicates that lipoprotein phospholipids are oxidized in vivo during APR. 
Pretreatment with dietary tocotrienols significantly blocked the increase in LPC levels of 
LDL and reduced them by 1.3- to 1.6-fold, indicating a potent antioxidant property of 
Tocomin. 
Acute infection and inflammation may enhance oxidative stress not only through 
the increased production of ROS but also through weakening the antioxidant defense 
system. In this context, antioxidant role of serum HDL-complexed paraoxonase 
(PON)/arylesterase enzyme in the protection of LDL as well as HDL from oxidative 
modification is noteworthy. Our results demonstrate that plasma and HDL arylesterase 
activity was significantly decreased (22 % to 38 %), while LDL-C/arylesterase ratio was 
significantly increased following LPS, turpentine or zymosan administration. Tocomin 
pretreatment significantly blocked the reduction in arylesterase activity and decreased the 




In contrast to PON/arylesterase enzyme, xanthine oxidase (XO) is known to be an 
important biological source of free radicals. Xanthine oxidase activity in plasma, liver 
and kidney has been reported to be increased during acute infection and inflammation 
stressed rodents with dyslipidemia and that free radicals generated in the enzymatic 
processes are involved in oxidative damage. Our results show that increased XO activity 
in plasma, liver and kidney of L-C, T-C or Z-C stressed hamsters was significantly 
blocked by Tocomin and reduced to a level close to normal values. These results show 
that dietary tocotrienols, in addition to their potent hypolipidemic and antioxidant 
activity, has the ability to reduce XO activity, indicating its additional therapeutic benefit 
in the prevention and treatment of infection and inflammation induced atherosclerosis. 
It is well known that during acute infection and inflammation in rodents, oxidant 
stress may be increased owing to a higher production of ROS, which are controlled by 
anfioxidant enzymes, SOD, catalase, Gpx, Gred and GSH. An impaired radical 
scavenger function has been linked to decreased activity of enzymatic and nonenzymatic 
antioxidants. Our results show a significant decrease in the activities of antiperoxidafive 
enzymes, CAT, SOD, Gred, GST as well as GSH, in erythrocytes, liver and kidney of 
LPS, turpentine or zymosan stressed hamsters, except Gpx activity which was 
significantly increased in erythrocytes but decreased in liver and kidney. Feeding of 
10 mg Tocomin to stressed hamsters, for 10 days before and 12 h after LPS or 24 h after 
turpentine or zymosan administration was quite effective in reversing/normalizing the 
altered levels of enzymatic and nonenzymatic antioxidants in erythrocytes, liver and 
kidney. 
The combined results, which represent an initial demonstration, strongly suggest 
that dietary tocotrienols, because of their potent hypolipidemic/antiatherogenic and 
antioxidant actions, were able to substantially ameliorate/normalize all the altered 
parameters described in this part of the thesis, and thus, can be useful in the therapy of 
systemic inflammatory process which might induce atherosclerosis. In conclusion, based 
on Tocomin mediated multiple therapeutic benefits, described in the present study, daily 
intake of tocotrienols as a dietary supplement may be useful in the prevenfion and 
treatment of infection/inflammation induced dyslipidemia/hyperlipidemia as well as 
atherosclerosis in dyslipidemic pafients with chronic infection and inflammatory 
diseases. 
Results presented in the second part of the thesis demonstrate a close association 
between the distribution of cholesterol and apoB concentrations in sd-LDL and Ib-LDL 
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as well as their percent share of LDL in five groups of type 2 diabetic subjects with 
varying degree of hypercholesterolemia. In addition, we examined the differential in vivo 
as well as in vitro Cu'^ ^-catalyzed oxidizability of more atherogenic sd-LDL, less 
atherogenic Ib-LDL as well as LDL from normolipidemic and five groups of type 2 
diabefic-hypercholesterolemic subjects. Thus, our data exhibited a strong corelationship 
between several indices of oxidation, i.e. conjugated diene, lipid hydroperoxide, MDA, 
and lag time, as well as electrophoretic mobility of in vivo and in vitro oxidized LDL, sd-
LDL and Ib-LDL, with their concentrations in plasma and severity of 
hypercholesterolemia in five groups of type 2 diabetic subjects. 
Due to prior treatment of diabetic subjects in group A and B with atorvastatin and 
fenofibrate for 98 and 47.3 weeks, their lipid parameters were normalized to a level 
similar to normal control values. However, since diabetic subjects in group C, D and E 
were on lipid lowering drugs for 39.3, 15 and 5.3 weeks, respectively, their degree of 
hypercholesterolemia, particularly increased LDL particles, in each group was higher in 
the order C<D<E. Consistent with published reports that relative to Ib-LDL, the 
concentration of more atherogenic sd-LDL was significantly increased in subjects with 
various types of hyperlipidemia, hyperlipidemia with CHD and type 2 diabetic-
hyperlipidemic pafients with CHD, sd-LDL-C levels of diabetic-hypercholesterolemic 
subjects in group C, D and E were increased by 101 %, 317 % and 539 %, respectively, 
in comparison to corresponding values in N-C, while a little increase (18 % to 30 %) in 
Ib-LDL-C levels had occurred. Thus, a majority of LDL-C (36 %, 103 % or 128 %) was 
recovered in more atherogenic sd-LDL subpopulation of diabetic subjects in group C, D 
and E, while a decrease of 19 %, 43 % or 54 % of LDL-C was recognized in less 
atherogenic Ib-LDL, indicating a shift of cholesterol from Ib-LDL to more atherogenic 
sd-LDL subspecies. Our results show that both cholesterol and apoB content of sd-LDL 
and its percent share of LDL-C and LDL-apoB always increased in tandem, indicating 
that each particle in LDL density subfractions is homogeneous. 
During prolonged diabetes coupled with hypercholesterolemia/hyperLDL 
cholesterolemia, due to sustained oxidative stress and increasing depletion of serum 
endogenous antioxidants in group A-E (-70 % to -88 % vs. N-C value; Table 29), the 
oxidizability of sd-LDL was further increased and its lag phase value of 12.0 min in N-C 
was reduced to 6.8 min in group A, 6.0 min in group B, 4.0 min in Group C, 2.0 min in 
group D and E, which is 6- to 15-fold or 12- to 20-fold lower than corresponding lag 
phase values in Ib-LDL or LDL. In contrast, considering a significantly increased 
buoyancy in Ib-LDL particles, its lag phase value of 40 min in N-C was not further 
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reduced in group A, B and C, while it was reduced to 30 min in group D and 12 min in 
group E, indicating a substantially lower susceptibility of Ib-LDL to Cu^^-catalyzed 
oxidation than sd-LDL. Maximal formation of conjugated diene and MDA during in 
vitro Cu"^ "^ -catalyzed oxidation of LDL and Ib-LDL was achieved after 12 h of 
incubation, whereas, for sd-LDL, these maximal values were obtained after only 30 min 
of oxidation, indicating an accelerated in vitro oxidizability of sd-LDL. 
Our results demonstrate that consistent with the preferentially enhanced ex vivo 
oxidizability of sd-LDL subspecies in normal subjects, its electrophoretic mobility of 1.4 
mm was also higher than 1.1 mm for Ib-LDL or 1.0 mm for LDL. As expected, in each 
group of diabetic-hypercholesterolemic subjects, the electrophoretic mobility of native 
sd-LDL, Ib-LDL and LDL was increased to a maximal value of 1.6 mm, 1.3 mm and 1.1 
mm respectively, indicating a further differential increase in the in vivo oxidative 
modification of the LDL density subfractions. In addition, in vitro Cu"^ "^ -catalyzed 
oxidation of LDL, sd-LDL and Ib-LDL in each group for indicated time periods, 
revealed a close association between progressive increase in the levels of three lipid 
peroxidation products and their electrophoretic mobility. Consistent with increasing 
hypersd-LDLcholesterolemia in diabetic subjects of group C, D and E, the 
electrophoretic mobility of sd-LDL after only 4 min of oxidation was increased to a 
common mobility value of 2.3 mm from their corresponding native sd-LDL mobility 
value of 1.5 mm, 1.5 mm or 1.6 mm, respectively. In contrast, for less atherogenic Ib-
LDL, the electrophoretic mobility was increased from native Ib-LDL value of 1.2 mm 
and 1.3 mm to 1.9 mm and 1.8 mm in group C and D, respectively, after 120 min of 
oxidation, while in group E its electrophoretic mobility was increased to 1.9 mm fi^om a 
native value of 1.3 mm, after 30 min of oxidation. Consistent with above results 
describing a significantly enhanced in vivo and in vitro oxidizability of more atherogenic 
sd-LDL, its electrophoretic mobility was also substantially increased than less 
atherogenic Ib-LDL, indicating an enormous acceleration in the Cu'^ '^ -catalyzed oxidation 
of sd-LDL subpopulation. 
It is well known that diabetes may enhance oxidative stress not only through the 
increased production of ROS but also through weakening the antioxidant defense system. 
In this context, the antioxidant role of serum HDL-complexed arylesterase/ paraoxonase 
(PON) enzyme in the protection of LDL as well as HDL from oxidative modification is 
important. Our results show an increasing reduction in serum arylesterase activity and 
increasing elevation in LDL-C: arylesterase activity ratio in diabetic subjects of group 
A-E with increasing hyperLDLcholesterolemia, indicating a reduced capacity of HDL in 
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the protection of LDL oxidation. Together, these resuhs indicating an enhanced ex vivo 
and in vitro oxidizability of LDL and more atherogenic sd-LDL in conjunction with a 
decreased serum arylesterase activity and increased LDL-C: arylesterase activity ratio in 
diabetic subjects with varying degree of hyperLDLcholesterolemia is likely to be a 
potential mechanism for the increased oxidation of circulating LDL density subfractions. 
Based on our combined results presented in this section of the thesis, it can be 
concluded that increasing severity of oxidative stress evoked in diabetic subjects is 
closely related to increasing degree of hypercholesterolemia, particularly 
hyperLDLcholesterolemia and hypersd-LDLcholesterolemia, in the order C<D<E. This 
differential effect was fully reflected in decreasing levels of serum total antioxidants and 
arylesterase activity as well as in several indices of oxidative stress, such as substantial 
shift from less atherogenic Ib-LDL to more atherogenic sd-LDL, and differential in vivo 
and in vitro oxidizability of LDL, sd-LDL and Ib-LDL. In addition, in vivo and Cu"^"*"-
catalyzed in vitro oxidation of LDL, sd-LDL and Ib-LDL in each group for indicated 
time periods, revealed a close association between progressive increase in the levels of 
conjugated diene, lipid hydroperoxide and MDA and their electrophoretic mobility, 
which in turn fully correlated with increasing degree of hypercholesterolemia. 
It is interesting to mention that similar to diabetic-hypercholesterolemic patients 
in group C, D and E, different degree of hypercholesterolemia and oxidative stress 
induced in lipopolysaccharide (non-HDL-C +71 %, sd-LDL-C +238 % vs. N-C), 
turpentine (non-HDL-C +39 %, sd-LDL-C +84 %) and zymosan (non-HDL-C + 47 %, 
sd-LDL-C +140 %) stressed hamsters also exhibited a similar correlationship between 
various parameters. These parameters include hypercholesterolemia, particularly 
hyperLDLcholesterolemia and hypersd-LDLcholesterolemia, in the order 
LPS<zymosan<turpentine stressed hamsters. This differential effect was fully reflected 
in decreasing levels of serum total antioxidants and arylesterase activity as well as in 
several indices of oxidative stress, such as substantial shift from less atherogenic Ib-LDL 
to more atherogenic sd-LDL, and differential in vivo and in vitro oxidizability of LDL, 
sd-LDL and Ib-LDL. 
Based on the combined results presented in the thesis, it can be concluded that the 
increased prevalence and concentration of sd-LDL in dyslipidemic patients with either 
chronic infection and inflammation or diabetes might contribute to their increased CHD 
risk. Quantification of sd-LDL-C by a simple and rapid precipitation method involving 
fractionation of purified precipitated LDL is useful to evaluate atherogenic risks in 
various types of hyperlipidemia/hypercholesterolemias, including diabetic linked 
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dyslipidemia as well as infection and inflammation induced dyslipidemia. Thus, sd-LDL, 
being a better and integral marker for CHD risks, than LDL, is applicable to routine 
clinical use and allows the rapid analysis of large number of samples. Finally, 
considering the strong hypolipidemic/antiatherogenic and antioxidant actions of 
Tocomin, daily supplementation of dietary tocotrienols may be useful in the prevention 
and treatment of infection/inflammation and diabetes induced 
dyslipidemia/hyperlipidemia and atherosclerosis. Therefore, daily use of dietary 
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